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Abstract  
 
Beads loaded with drugs have been shown to be useful for drug delivery, yet only limited research has 
been undertaken on analysing drug-bead interactions and the behaviour of the resultant products. This 
study investigated specific drug-bead physicochemical parameters, such as factors affecting binding 
and subsequent drug release phenomena under conditions mimicking the clinic and the body.  
Isothermal titration calorimetry (ITC) was initially used to investigate interactions between a 
drug, doxorubicin (Dox) and a drug eluting bead (DEB), DC Bead™. Dox was titrated into polymer beads 
at various temperatures, concentrations, volumes, and pH’s of the drug and the polymer considered. 
Furthermore, washing the beads in acid prior to analysis displaced sodium ions which had previously 
interfered with the drug-bead interaction. Similar binding ratios were found with DC Bead™ to that of 
previously reported ultra-violet visible (UV-Vis) spectroscopic analysis of 0.90:1 bead binding sites to 
the drug. The technique was extended to evaluate a range of drugs with DC Bead™ such as 
Mitoxantrone (Mit), Irinotecan (Iri), Topotecan (Top), in addition to other types (DC Bead Lumi™, 
LifePearl™, Tandem™ and HepaSphere™) and sizes of beads (from 60 to 700 nm). The 
thermodynamic information collected suggests that interactions were significantly greater in DC Bead™ 
than the competitor product LifePearl™. Mit-DC Bead™ was the only drug which bound to two bead 
sites per drug molecule, consequently half the concentration of drug was required for bead saturation. 
Alternatively, Iri-DC Bead™ and Top-DC Bead™ involved two drug sites depending on the experimental 
pH, however this encompassed partial binding to each site resulting in ratios similar to that of Dox.  
The open-loop flow-through elution method determined drug elution with different parameters 
such as packing material, flow rate, salt concentration, eluent type and bead volume. Rate of elution 
increased with a decrease in bead size, as a result of a larger surface area to volume ratio. DC Bead™ 
and DC Bead LUMI™ fully eluted Dox at a range of concentrations, however Tandem™ only eluted ~80 
% of the drug, possibly due to drug permanently bound to the beads. Initially DC Bead™ had a higher 
concentration of drug released in comparison to the slower more sustained release of DC Bead LUMI™ 
and Tandem™, and Iri was found to elute much faster than Dox. The method achieved flow rates of 0.1 
mL/min, close to that of an embolised vessel. At these slow flow rates LifePearl™ was found to have 
similar characteristics to DC Bead™, which correlated well with the acquired ITC data.  
xxxvi 
  
Three-dimensional microscopy (3DM) and hot stage microscopy (HSM) supported the view that 
bead swelling effects changed the elution profile. It was also evident that DC Bead™, DC Bead LUMI™ 
and Lifepearl™ homogenously loaded and completely eluted, whereas Tandem™ heterogeneously 
loaded did not fully elute. HepaSphere™ images indicated significant aggregation and fragmentation.  
Investigation of the drug in vitro could be used to predict elution characteristics in vivo, with 
potential implications for product development and quality assurance. In summary, knowledge of the 
drug-bead interactions facilitated a deeper understanding of drug-bead binding to be attained using ITC 
and drug-bead release accomplished with a method of elution. These methods developed will 
undoubtedly assist in developing optimum treatment options.       
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Chapter 1 : Introduction  
 
The term cancer is used to describe cellular modifications that result in uncontrolled cell growth. Trillions 
of cells make up the human body and it takes only one abnormal cell for oncogenesis to occur 1. There 
is evidence to suggest that cancer has existed since 300 BC, despite this cancer treatments have been 
around for less than 100 years 2. Traditionally cancer treatment was based upon location and cell type. 
However, no two cancers are identical, and it is now widely accepted that the cells associated with a 
tumour are diverse and perform different roles during evolution of the tumour. Traditional grouping and 
the accompanying therapies may not lead to effective results. The recent ability to identify genetic and 
biological changes has introduced the world to personalised medicine 1.  
 
1.1. Cancer Prevention, Diagnosis and Therapeutics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Illustration of current cancer therapeutics.  
  
  
 Diagnostics 
 
Radiation Therapy 
 
 
Photodynamic 
Therapy 
 
 
 
Chemotherapy 
Target Therapy 
Surgery 
Theranostics 
Hormonal Therapy 
Hyperthermia 
Therapy 
Immunotherapy 
Gene Therapy 
 
Prophylactics 
Cancer  
Therapeutics 
2 
  
A decline in cancer death rates can be accredited to extensive efforts in the prevention, detection and 
improved therapeutic strategies associated with the categories of Figure 1.1 3.  
Current cancer therapies includes diagnostics; this may show the type, location and rate of 
cancer growth 4. Early diagnosis allows immediate intervention to prevent the further development of 
cancer 5. A biopsy may be required for an accurate diagnosis, wherein a surgeon may remove a portion 
of the suspicious tissue. A pathologist examines cells, tissues and organs for biomarkers, and then 
interprets the laboratory tests to help diagnose the disease and determine the treatment options 6. An 
evaluation can also be done using imaging to visualise the cancer. Methods of imaging include 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), 
single photon emission computed tomography (SPECT), optical imaging, endoscopy, fluoroscopy, 
mammography and ultrasound. The main advantage of imaging is that it is a non-invasive technique, 
however the disadvantage is that it is common to have false negative results, where the image does not 
identify micrometastases and early stages of cancer 7,8.  
Nanoparticles may encapsulate or conjugate to both imaging agents and therapeutic agents. 
This multifunctional product allows diagnosis of the cancer and delivery of the therapy simultaneously, 
alongside real-time monitoring of flow patterns, particle distribution and response to the therapy; this is 
known as a theranostic. More than one imaging particle may be joined to a delivery system, which 
means more than one imaging technique may be used to evaluate a cancer; this may give numerous 
amounts of information and is known as multimodal or multiplexed imaging 5. It is important that the 
delivery system and imaging agent are isobuoyant, so that the device remains in an even suspension 
and does not sediment out during delivery 9. Unfortunately, cancer is usually detected once it has 
reached a visible size or it begins to interfere with a patient’s health. Diagnostics are not only used to 
identify cancer but also have the potential of staging the disease throughout treatment, determining the 
response to therapy and for identifying recurrence 5.  
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1.2. Hepatocellular Carcinoma (HCC) and Colorectal Cancer (CRC)  
According to the International Agency for Research on Cancer, liver cancer is currently the sixth most 
lethal malignancy worldwide and accounts for 9.1 % of all cancer deaths. In 2012 an estimated 782,000 
new cases were diagnosed and more than 746,000 deaths were reported. Prevalence figures in 2012 
suggested 633,000 patients received diagnosis 5 years ago and to be either cured or still living with the 
disease. Hepatocellular carcinoma (HCC) or hepatoma is the primary form of liver cancer, mainly caused 
by the hepatitis B virus (HBV), hepatitis C virus (HCV) and cirrhosis. However, lifestyle factors are also 
related to the risk of developing a tumour. The highest occurrence of the disease is in Asia because of 
HBV and HCV infections. People infected with the virus have a higher risk of developing chronic 
hepatitis, which may lead to cirrhosis of the liver, liver damage, liver cancer, liver failure and ultimately 
fatality. Liver cancer is more likely to affect the elderly and males 10.  
Colorectal cancer (CRC), also known as cholangiocarcinoma or bowel cancer, is the third most 
common cancer in the world with more than 1,361,000 new cases diagnosed and attributed to 694,000 
fatalities in 2012. In 2012 there were 3,544,000 patients alive 5 years after their diagnosis. This cancer 
is also more likely to affect the elderly and the risk is slightly higher in males. In spite of advances in 
diagnosis and treatment in this area, incident rates are highest in Australia and New Zealand. Bowel 
cancer is predominantly associated with lifestyle influences, however some medical conditions and 
hereditary history are also connected to this disease 11.  
Cancers can often spread from the original site and metastasise to lymph nodes, the most 
frequently observed site of extra-lymphatic involvement is the liver 12,13. Secondary malignancies 
account for 95 % of all malignancies, which can lead to hepatic failure and subsequently death 13,14. 
Despite extensive screening and preventative strategies 25 % of colon cancers and 50 – 70 % of rectum 
cancers will spread through the bowel wall, and 50 – 60 % will metastasise to lymph nodes 12,13.  
Patients may be categorised into five groups, referred to as stages 0, A, B, C and D. Stage 0 
patients are those that have been diagnosed very early and are likely to undergo curative treatment 
such as resection of the solid tumour or liver transplant 15. For patients who have been diagnosed at this 
stage five year survival rates are 90 % 12,13. Unfortunately, many patients are not suitable for curative 
treatments and as a result more than three quarters of these must partake in palliative treatment 16,17. 
Patients categorised as stage A (early), B (intermediate) or C (advanced) are candidates for alternative 
palliative therapies. Patients with asymptomatic multinodular HCC stage B are suitable for transarterial 
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chemoembolisation (TACE), whereas stage D (terminal) patients are symptomatically treated 15. Overall 
survival (OS) rates of five years drops to 64 % with progression of the disease 12. The staging system 
can be linked to a treatment schedule created by hepatologist Jordi Bruix; known as the Barcelona-
Clinic Liver Cancer (BCLC) treatment strategy delineated in Figure 1.2. This classification uses pre-
established prognostic variables and allocates therapies according to treatment-related status from very 
early (stage 0) to terminal stage cancer (stage D). Prognosis is defined by tumour status, performance 
status and liver function using the Child-Pugh’s score 18.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: BCLC (Barcelona-Clinic Liver Cancer) algorithm (HCC – hepatocellular carcinoma, PST – performance status, DDLT 
– deceased donor liver transplantation, LDLT – living donor liver transplantation, RF – radiofrequency ablation, PEI – percutaneous 
ethanol injection, TACE – transarterial chemoembolisation, OS – overall survival. N1 and M1 refer to tumour size, number and 
vascular invasion) 18.  
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1.3. Drug Delivery Systems (DDS)   
The first drug delivery system (DDS) was developed in 1952, which was the 12-hour delivery of 
dextroamphetamine (dexedrine) in an oral capsule formulation introduced by Smith Kline & French 19.  
Since then there have been numerous advances in delivery with various formulations of implants, 
ingestible capsules, mucosal inserts and topical patches. Microscopic degradable polymer DDSs 
followed the significant developments in the field, which led to the nanoscopic era 20. Naturally occurring 
and synthetic polymeric materials have played a significant role in the research and development of 
most controlled-release technologies over the last 25 years, shown by an increase in the number of 
publications and patents 21. These DDSs are devices that enable the administration of a therapeutic 
substance into the body controlling elements of release rate, release time and site of drug release into 
the body 22. Currently there are four classified controlled release mechanisms: diffusion-controlled 
(reservoir and matrix), chemically-controlled (pendent chain and biocrodible/biodegradable), solvent-
activated (osmotic and swelling) and magnetically-controlled systems 21.  
Biomaterials can be effective ways to deliver a variety of drugs to the body, and as much as the 
choice of drug varies so can the way in which it is delivered 23. They can be made of a variety of materials 
such as inorganic nanoparticles, liposomes, polymers and viral carriers 24. Effective carriers must be 
stable during delivery, yet still allow the drug to achieve therapeutic action and have minimal side effects 
25. DDSs may be used to deliver substances with difficult physicochemical properties, and so it is 
essential that the device can solubilise and carry hydrophobic drugs 23,25. The design must also contain 
properties that offer protection to the drug, the carrier and the body. The carrier protects the drug from 
various defence mechanisms of the body as proteins can destabilise, inactivate or phagocytise the drug. 
The transporting material reduces cytotoxicity to normal organs, tissues or cells, and preventing 
interactions with cells provides the carrier with more time to circulate in the blood and increases the 
chances of reaching the tumour. It is necessary to maximise the probability of tumour accumulation by 
means of enhanced permeability and retention (EPR) 25.  
The transportation device can also have additional mechanisms for environmental, cellular or 
molecular targets 25. Smart biomaterials can respond to the body environment such as pH, temperature 
and the presence of salt, as well as selectively release a drug at a predetermined site of the body 23. 
The high concentration of metalloproteinases distributed within the tumour has introduced carriers with 
regions cleavable by matrix metalloproteinase-2 (MMP-2) 26. Most tumours have a low pH which 
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provides a means of stimulating trans-activating transcriptional activator (TAT), a cell penetrating 
peptide (CPP) that can facilitate uptake of the drug 27,28. Carriers have been developed to contain 
molecular targets used to bind surface markers overexpressed in certain cancer lines 29. The most 
recent advancement in targeted delivery of drugs is the use of nanotechnology. The practice of 
nanotechnology in this field has had its limitations, but microparticle DDSs have shown their capabilities 
to retain large quantities of drug and deliver these drugs to a targeted area in a controlled and sustained 
manner. Unlike the delivery of nano DDSs, the delivery of micro DDSs often requires surgery under 
general anaesthetic, however the TACE procedure provides a non-invasive means of administering 
drugs for chemotherapy and radiotherapy treatment under local anaesthetic 23.  
The tumour environment often has low partial oxygen pressure (pO2) because of its poorly 
formed vasculature 30. Unfortunately, rather than stunting growth of the tumour through oxygen 
starvation it has been shown to promote metastasis 31,32. Hypoxia also creates an environment where 
the cancer cells are capable of resisting both chemotherapy and radiation, this is because a DDS will 
have difficulties diffusing though the vasculature into the tumour region 32,33. A lack of oxygen will reduce 
proliferation rates in cancer cells, which in turn will decrease the effect of drugs that target mitotic 
mechanisms of fast growing cells. Hypoxia may influence the production of cancer stem cells, possibly 
due to typical stem cells being activated to restore ischemia damaged tissue 31,32. Furthermore, surviving 
cells of chemotherapy and radiation may even project the Darwin theory, whereby remaining cells are 
more aggressive and more resistant after each course of treatment; these are known as multiple drug 
resistant (MDR) cancers 34. The points above are key issues which a DDS may need to address to 
provide effective interventional oncological treatment.  
Tumours frequently have a lower extracellular pH (pHe) in comparison to their intracellular pH 
(pHi). This is caused by a build-up of waste products such as lactic acid from aerobic and anaerobic 
glycolysis, as a result of the dysfunctional vasculature and lymphatic system 33,35,36. Therefore, a DDS 
which releases a therapeutic agent within a low pH could be beneficial. If a low pHe isn’t present one 
can be artificially created by the addition of glucose to non-diabetic patients 37.  
The rate of diffusion across openings between vascular endothelial cells; known as fenestrae, 
can be influenced by certain drug carrier characteristics such as concentration, hydrophilicity, shape, 
size and surface charge, along with properties associated with blood vessels such as the density, 
distribution and size of fenestrae 25. Particles smaller than the distance between the collagen fibrils have 
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greater intratumoural distribution and can cross the extracellular matrix (ECM) 38. However, the 
probability of intratumoural distribution decreases with particles that interact with ECM components and 
non-target cells 25. Distribution may be enhanced by using penetrating peptides, by breaking down ECM 
components with enzymes or by increasing blood perfusion with drugs which increase the diameter of 
blood vessels, before administering the DDS 39–42.  
Targeted delivery can be either active or passive. Active targeting is specific receptor binding, 
ligand binding or other protein interactions, and supports delivery to a specific target cell or molecule. 
Passive targeting is the design of particles that increase the probability of reaching the target. Whichever 
mechanism, the desired result is to increase the therapeutic effect and reduce any side effects. Yet the 
delivery of an arbitrary amount of drug to a designated target is not necessarily targeted drug delivery. 
Many targeted drug transporters hit other locations in addition to the specific target site 25. The theory is 
to target delivery of the drug to terminate only cancer cells like a ‘magic bullet’ 43. Thus far this is 
impossible with current technology, and the reality is that only the immune system comes close to 
achieving Paul Ehrlich’s concept of the magic bullet 44.  
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1.4. Transarterial Chemoembolisation (TACE)  
Conventional TACE (cTACE) has been developed over three decades 45,46. It is used for the treatment 
of inoperable hypervascular tumours (HVTs) and arteriovenous malformations (AVMs) 47. The 
procedure, often delivered sequentially, can be performed with various chemotherapeutics and doses, 
and with or without iodised oil. Embolic materials can be biodegradable or permanent and vary in size, 
hence the procedural techniques are numerous and as a result leads to inconsistent outcomes caused 
by a lack of a standardised method for performing cTACE 16,47–64. Embolic agents prevent blood flow 
through a vessel using biological or physical properties. Biological agents strip the vessel of the 
endothelial lining causing the structure to breakdown and collapse. Mechanical agents occlude the 
lumen of the vessel at either a proximal or distal level. Embolotherapies can be in the form of balloons, 
coils, polymer liquids, particulates and sponges 65. The first particulate embolisation agent was available 
in 1949 and consisted of polyvinyl alcohol (PVA) foam particles 66. This technology was later developed 
into irregular particles which could be assorted into size ranges by sieving particles through 
progressively smaller sized meshes stacked on top of one another. The irregular shape of the particles 
can cause blockages in the catheter and interlocking of the particles causes a more proximal 
aggregation, precluding more distal occlusion. The desire for a more controlled embolic agent led the 
development of tightly calibrated microspheres 9. Microspheres achieve a more distal penetration, 
attributable to their flow-directed nature and more compressible features due to the materials containing 
a large amount of water; terming the formation as hydrogels 67. In the 1970s it was suggested that 
embolic agents have the potential to be combined with chemotherapy in order to occlude vessels and 
deliver a drug in one procedure; this is known as TACE 68. Whilst TACE had a beneficial approach for 
intervention radiologists there was no standardised procedure, which made clinical comparisons 
extremely difficult until the launch of a drug eluting bead (DEB) for TACE; known as DC Bead™ 9,69,70.  
DEBs may be used to deliver chemotherapeutic agents to cancer cells 70. Randomised control 
trials indicated that DEB-TACE provided an improved local response, an enhanced complete response, 
fewer recurrences and a longer time to progression compared with the traditional TACE procedure. 
Although in these studies there was no statistical difference in survival rate, DEB-TACE was better 
tolerated by patients, especially those with advanced HCC disease 71,72. Figure 1.3 frameworks the key 
DEB-TACE benefits. It is possible that once patients are treated with DEB they may be down-staged 
and receive resection or transplantation 73. DEB-TACE is currently being investigated for the treatment 
9 
  
of further malignancies such as gastroenteropancreatic endocrine tumours, intrahepatic 
cholangiocarcinoma and uveal melanoma metastases 74–77.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Outline of the DEB-TACE procedure benefits.  
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1.5. DC Bead™  
DC Bead™ (known as LC Bead™ in the United States of America (USA) 13,49,68,70,78–81) is a 510K FDA 
cleared and CE-Mark approved drug delivery embolisation system (DDES), which provides localised 
controlled sustained delivery of chemotherapeutic agents, as well as embolisation of the tumour feeding 
arteries 47,70,82–86. The device is manufactured by Biocompatibles UK Ltd, which is a part of the BTG plc 
group companies. DC Bead™ was developed in 2002 for the advancement of interventional oncology, 
with a view to standardise the TACE procedure providing handling advantages and patient benefits.  
Regulatory control places immense importance on a distinction between the drug and the 
device. If the device is introduced into the body for purposes other than administration of an active 
ingredient, such as a physical therapeutic effect or a drug to prevent complications from the device, then 
it is strictly regulated as a device rather than a DDS. However, when there is not a clear division of 
characteristics the allocation to either category is decided on a case by case basis 22. DC Bead™ is 
both a device and a DDS, as the product can be administered with and without the drug to deliver the 
therapeutic agent and/or block tumour feeding vessels.  
 
1.5.1. Composition  
The beads consist of a biocompatible PVA hydrogel microsphere, that has been modified with 
hydrophilic 2-acrylamido-2-methylpropane sulfonate sodium salt (AMPS) and is tinted blue to allow 
visualisation of drug loading 47,70,87–89. The basic preparation steps of DC Bead™ can be seen in Figure 
1.4. The negatively charged sulfonate groups enable the bead to complex with positively charged drugs 
14,47,69,88,90. The beads are a non-degradable compressible polymer and are available in a range of sizes 
from 70-700 µm. These are supplied steam sterilised in a 10 mL colour coded glass vial sealed with a 
rubber stopper and aluminium cap, as demonstrated in Table 1.1. Each vial contains 2 mL of beads 
stored in 6 mL of phosphate buffered saline (PBS) and is intended for single patient use. The size of 
bead and the amount of drug is selected according to the pathology of the patient receiving treatment 
by a physician with appropriate interventional occlusion training.  
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PVA + HCl + NAAADA    AMPS + K2S2O8 + CAB + C6H12O2    333 K + TMEDA    H2O, NaCl    Sieve + H2O    (CH3)2CO + 313 K  
Figure 1.4: Preparation of DC Bead™.  
(Monomers: PVA (polyvinyl alcohol) and AMPS (2-acrylamido-2-methylpropanesulfonate sodium salt), catalyst: HCl 
(hydrochloride acid) and NAAADA (N-acryloyl-aminoacetaldehyde dimethylacetal), initiators: K2S2O8 (potassium persulfate) and 
TMEDA (tetramethylethylenediamine), stabilisers: CAB (cellulose acetate butyrate) and C6H12O2 (butyl acetate), washing: H2O 
(water), NaCl (saline), drying: (CH3)2CO (acetone)) 
91  
 
The first size range of DC Bead™ to be used in clinical practice was 500-700 µm, the size was based 
upon the predicate Gelfoam particles that were conventionally in use 92. Gradually, as physicians 
became more confident in its use the preferred size of DEB decreased, as smaller beads are more 
favoured to achieve deeper tumour penetration and increase the delivery of drug as a result of a bead 
surface area to volume ratio 93. This has led to the development of 70-150 µm beads, to meet the desire 
to deliver a large concentration of drug at a greater distal level 94.  
 
Table 1.1: Available DC Bead™, their sizes and label colour 95.  
Bead Reference Bead Size (µm) Label Colour Product Image 
M1 70-150 Black 
 
103 100-300 Yellow 
305 300-500 Blue 
507 500-700 Red 
 
1.5.2. Chemistry  
The selected drug is taken up by the bead through an ion-exchange mechanism 47,88. When mixed with 
certain chromatic drugs the beads change colour, which indicates the drug has been loaded. The beads 
have a high water content of >95 %, which enables the diffusion of molecules into and out of the polymer 
structure 82,96. Elution rate and uptake of the drug is dependent upon bead size, as diffusion is inversely 
proportional to bead diameter, attributed to the increase in surface area to volume ratio 13,47. However, 
it is worth noting that some compounds can have drug-drug interactions, which can affect how the drug 
binds and elutes from the delivery vehicle 89. The beads initially increase in diameter as they are 
reconstituted in water, but then decrease as water is displaced from the bead and the drug is 
sequestered from the solution. As the diameter of the bead decreases the resistance to compression of 
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the bead increases, i.e. they become somewhat stiffer 13,47. The ion-exchange mechanism is a reversible 
interaction, and upon contact with ions contained in blood the drug is released from the bead.  
 
1.5.3. Treatment  
Doxorubicin (Dox) and Irinotecan (Iri) are drugs used in the treatment of various cancers 14,97. Dox is an 
anthracycline, whilst Iri is a semi-synthetic derivative of camptothecin. Both are highly hydrophobic and 
are subsequently formulated with hydrochloric acid (HCl), this increases the solubility for their use in the 
treatment of primary and secondary cancer 4,98,99. DC Bead™ is CE-Mark approved for loading with 
either Dox or Iri, Figure 1.5 and 1.6 indicate the significant colour change upon drug loading.  
 
 
Figure 1.5: DC Bead™ unloaded (A) and DC Bead™ loaded with Dox illustrating the intense colour change from blue to red (B) 
100.  
 
 
Figure 1.6: DC Bead™ unloaded (A) and DC Bead™ loaded with Iri illustrating the intense colour change from blue to turquois 
(B) 101.  
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Figures 1.7 and 1.8 show Dox and Iri loading into DC Bead™, and the subsequent elimination of water.  
 
 
 
 
 
 
   Hydrated DC Bead™        Loaded DC Bead™  
Figure 1.7: DC Bead™ mode of loading with Dox 102.  
 
 
 
 
 
 
 
   Hydrated DC Bead™        Loaded DC Bead™  
Figure 1.8: DC Bead™ mode of loading with Iri 103.  
 
Figures 1.9 and 1.10 display the respective chemical structures of Dox and Iri binding to DC Bead™.  
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     DC Bead™                     Dox HCl 
 
 
 
 
 
 
 
 
 
 
Dox Loaded DC Bead™ 
Figure 1.9: Structural formula of DC Bead™, Dox and the combined product.  
 
∙ HCl 
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     DC Bead™       Iri HCl 
 
 
 
 
 
 
 
 
 
 
Iri Loaded DC Bead™ 
Figure 1.10: Structural formula of DC Bead™, Iri and the combined product.  
 
∙ HCl 
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Chemotherapy has a range of cardiomyocyte effects, this mechanism of chemotherapeutic effect is 
unclear, however it seems that the action through which Dox kills cancer cells or interrupts cell growth 
is derived from the inhibition of topoisomerase II (TOPII), signalling pathway activation, free radical 
generation, deoxyribonucleic acid (DNA) intercalation and binding, as shown in Figure 1.11. TOPII 
simultaneously cuts both strands of the DNA helix in order to manage DNA tangles and supercoils. 
Inhibition of these processes leads to apoptosis and consequently a reduction in tumour burden 104–106. 
Dox penetrates cells, and the intercalation of DNA prevents DNA synthesis and inhibits TOPII. The 
generation of free radicals through interfering with both enzymatic and non-enzymatic pathways leads 
to the accumulation of iron and induced lipid peroxidation, which ultimately results in membrane damage 
104,107–110. Additionally, mitochondrial damage, increased concentration of calcium ions (Ca2+), reduced 
level of K-ATPase (potassium-adenosine triphosphatase), decreased activity of sodium (Na), prevention 
of the sarcoplasmic reticulum function, down regulation of myocardial TNF-α (tumour necrosis factor-
alpha) and Dox binding to bivalent cations of Ca2+, copper (Cu2+), magnesium (Mg2+) and zinc (Zn2+) 
have all been implicated in lethal Dox-induced cardiotoxicity 111–115.  
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Figure 1.11: Dox mode of action (Dox – Doxorubicin, Fe2+ – Iron, β1ADR – β1 adrenergic receptor, mtDNA – Mitochondrial 
deoxyribonucleic acid, MT-CK – Mitochondrial creatine kinase, H2O2 – Hydrogen peroxide, ROS – Reactive oxygen species, HO- 
– Hydrogen monoxide, NO – Nitric oxide, ONOO – Peroxynitrite, MM-CK – Muscular creatine kinase, Ca2+ – Calcium, TOPII – 
Topoisomerase II, Trans reg – Transcriptional regulatory, MLC2 – Myosin light chain, cTn – Cardiac troponin) 116.  
 
Iri belongs to a class of topoisomerase I (TOPI) inhibitors. TOPI is a DNA enzyme responsible for 
controlling and modifying DNA during replication and translation of genetic materials. In Figure 1.12 Iri 
undergoes hydrolysis by carboxylesterases (CES), which is then metabolised to form 7-ethyl-10-
hydroxy-camptothecin (SN-38) in the liver by cytochrome P450 (CYP) isoforms. The pharmacologically 
active compound is transported across cell membranes by adenosine triphosphate (ATP)-binding 
cassette transporters (ABC transporters), SN-38 can then be inactivated through glucuronidation by 
uridine diphosphate glucuronosyltransferase (UGT). Iri and its active metabolite bind to the TOPI-DNA 
complex, preventing religation of the single-strand breaks in the DNA molecule 117,118.  
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Figure 1.12: Iri mode of action. (Iri – Irinotecan. Metabolites (M) of Iri: SN-38 (active glucuronide metabolite), SN-38G (inactive 
glucuronide metabolite), APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-
ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin). ABC (ATP (adenosine triphosphate) – binding cassette transporter 
family), BCHE (butyrylcholinesterase), CES (carboxylesterase), CYP (cytochrome P450 isoform), UGT (uridine diphosphate 
glucuronosyltransferase isoform)) 119.  
 
DC Bead™ loaded with Dox (DEBDOX™) is intended for the treatment of malignant hypervascularised 
tumours such as HCC 120. DC Bead™ can be loaded with a maximum of 37.5 mg Dox/mL of hydrated 
bead. Typically, 2 – 4 mL of beads is administered over a course of treatment with a maximum of 150 
mg of Dox per patient according to systemic dose limits. DC Bead™ loaded with Iri (DEBIRI™) is 
indicated for the treatment of malignant CRC (mCRC) metastasised to the liver. Generally, mCRC 
tumours are diffuse and less vascular than HCC tumours, consequently Iri is the favoured drug for this 
implantation 74,121,122. In this case 50 mg Iri/mL of beads with a recommended dose of up to 4 mL of 
beads is administered, equating to a maximum of 200 mg of Iri per treatment 89.  
The DEB-TACE procedure is minimally invasive and intended to be performed by a physician 
such as an interventional radiologist. Figure 1.13 depicts where a small incision is made, usually in the 
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groin, typically under local anaesthetic and a guide wire is used to position an appropriately sized 
microcatheter into the hepatic branch of the main tumour feeding artery. The tumour is imaged with an 
angiography, the aim is to be as selective as possible and administer the agent deep within the arterial 
tree of the target organ 66. The saline packing solution of the DEBs must be removed before the mixture 
of chemotherapeutic agent (in this case either Dox or Iri) is saturated in the beads along with non-ionic 
contrast media 56,83. The beads are left to sequester the drug, and drug loading time is dependent upon 
bead size and drug concentration 16. Once the beads with medium are in the correct location, this is 
simultaneously administered intravenously into the femoral artery, which is then carried into the tumour 
and surrounding tissue with blood flow 56. The beads compressible nature allows them to traverse the 
arterial network. Eventually the non-degradable beads occlude the vessels, slowing blood flow to the 
target tissue, consequently reducing oxygen and nutrients supplied to the site 123. The use of a 
biomaterial to deliver a drug as well as an imaging agent makes this a theranostic system 124–129. The 
presence of imaging agent allows identification and quantification of a delivery vehicle to a target site 4.  
 
 
Figure 1.13: Administration of DC Bead™ 130.  
 
Hypoxia occurs because cancer cells can grow at a rate that cannot be matched with neovascularisation, 
resulting in insufficient oxygen and nutrients transported to the tumour 1. Hypoxia also triggers the 
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release of growth factors that causes angiogenesis in order to deliver required nutrition and oxygen to 
the tumour 131. When angiogenesis transpires nascent vessels do not mature properly as a result of 
being developed too quickly. These vessels are leaky, which increases the transport of drug carriers 
into the tumour by Brownian motion through endothelial fenestrae, rather than by convective flow 25,132. 
A dysfunctional vasculature and lymphatic system, and compressive stress from excessive cell growth 
leads to high interstitial fluid pressure (IFP). These forces lead to a high net inwards pressure which aids 
the transport of the DDS 133. Defective vasculogenesis also provides a way of diagnosing progression 
of the disease 131. The lymphatics would usually carry the macromolecule away with tissue fluid, however 
retention in the tumour is enhanced because the tumour compresses and damages lymphatics as it 
grows. Embolisation of vessels reduces the wash-out of the chemo-emulsion allowing drug release into 
the plasma over a prolonged period of time, simultaneously inducing ischemia and necrosis, resulting 
in an antineoplastic effect on the cancer cells 16,47,56,134.  
 
1.5.4. Benefits  
The benefits of DEB-TACE are: 1. A reduction in adverse reactions by delivering the active agent directly 
to the target site 70,88. 2. Direct delivery as this increases the duration the tumour is exposed to the drug 
135. Traditional chemotherapy brings systemic distribution of the drug which induces non-specific 
cytotoxicity and increases the risk of side effects, limiting drug concentrations, and therefore reducing 
the levels of drug transported to the solid tumour and surrounding tissue. Systemic therapy can also 
result in the development of drug resistance which represents a growing problem 136. 3. Significantly 
higher concentrations of drug may be delivered with the use of DEB-TACE than can be transported 
systemically in non-toxic doses. This reduces the risk of cancer cells becoming aggressive at sub-lethal 
concentrations 51,123,135. 4. DC Bead™ can either be used as a monotherapy or in an amalgamation of 
therapies, and has been proven to achieve and maintain cytotoxic conditions safely and effectively 
through a combination of Phase I, II and III clinical studies and randomised control trials 72,79,80,137–139. 5. 
Embolisation is possible due to tumours having 95 % of their blood supplied through the hepatic artery, 
whilst the remaining liver parenchyma perfusion receives only 25 % of its blood supply through the 
hepatic artery and the additional 75 % via portal blood flow 83. 6. Finally, as a result of reduced trauma 
patients recover faster with no scaring and minimal risk of infection.  
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DEB-TACE is considered to have an effective EPR, however local delivery of chemotherapeutic 
agent may not be effective against systemic disease and it is becoming increasingly common to combine 
DEB-TACE with systemic therapies. A poor response to DEB-TACE may be due to incomplete or 
ineffective treatment. Incomplete treatment can occur when only a portion of tumour feeding arteries are 
embolised, resulting in an adequate blood supply to the tumour. It could also arise from insufficient 
quantities of DEB delivered to the tumour as a result of aggregation or oversized beads, leaving areas 
under-dosed. Ineffective treatment could transpire because of drug or ischemia resistance 89.  
 
1.5.5. Histology  
There were no adverse reactions associated in the administration of the beads with 150 mg of Dox in a 
porcine model. Electrocardiography, enzyme levels and pathological examination proposed that the 
concentration of Dox released into systemic circulation was below the amount required to induce cardiac 
toxicity. Liver aminotransferase enzymes were initially greater in all treatment groups as a result of 
embolic beads present in the hepatic arteries and the subsequent hepatocyte damage. The increase in 
these enzymes is temporary and levels returned to the original measure within 1 month of the procedure. 
The group embolised with small particles had elevated enzyme levels, as smaller particles produced 
greater tissue necrosis because of the more distal occlusion. Smaller beads with higher Dox loading 
concentrations induced a greater degree of hepatic injury and tissue damage reduced the extent of 
revascularisation. The model demonstrated the combination of Dox and DEBs small in diameter create 
widespread tissue damage 16. Apoptosis under hypoxic conditions caused fibrosis, inflammation and 
necrosis, which radiated out from the centre of DEB clusters 16,82,96. Dox travels further through necrotic 
tissue because it cannot be carried away by the extensive vasculature or metabolised by the vast 
hepatocytes as it has been destroyed. The injured hepatoma activates the inflammatory response to 
stimulate the division of cell and regeneration of damaged tissue, making the organ particularly sensitive 
to chemotherapeutic agents such as Dox since it actively synthesises new DNA. Dox affects all cells, 
but the drug mechanism of action is based upon the sensitivity of rapidly dividing cancerous cells 16.  
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1.6. DC Bead LUMI™  
Biocompatibles UK Ltd have other bead products in development and one type named DC Bead LUMI™ 
was recently launched onto the market. DC Bead LUMI™ builds upon the chemical structure of DC 
Bead™ and was developed to be a radiopaque form. It consists of iodinated polyvinyl alcohol – 
acrylamido methylpropane sulfonate groups, where DC Bead™ comprises polyvinyl alcohol – 
acrylamido methylpropane sulfonates. Simply the addition of iodine is in place of blue dye during the 
manufacturing process. Iodine is consistently and evenly distributed through the bead, it is covalently 
bonded and is therefore a permanent fixture that does not degrade. The radiopaque properties allow for 
visibility of the beads under all standard X-ray imaging modalities such as fluoroscopy, single-shot or 
cone beam CT, during and after the procedure. It was designed to improve the accuracy and control of 
the predicate device with bead location, coverage, targeted embolisation and precise determination of 
the procedural endpoint. It allows for intra-procedural adjustments and post-procedural feedback, and 
Figure 1.14 provides an image of the embolisation ‘footprint’ with DC Bead LUMI™ 140.  
 
 
Figure 1.14: Distinct visualisation of occluded vessels with DC Bead LUMI™, arrow points to occluded vessels 141.  
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As DC Bead™ and DC Bead LUMI™ consist of the same core technology of a sulfonate ion-exchange 
mechanism, drug loading recommendations are the same (37.5 mg Dox/1 mL bead equivalent to 75 mg 
Dox/vial and 50 mg Iri/1 mL bead equivalent to 100 mg Iri/vial). DC Bead LUMI™ is purchased as 2 mL 
of beads suspended in 6 mL of PBS, presented in a sterile 10 mL glass vial. Detailed in Table 1.2 are 
the available sizes, these are identical to the two currently smallest sizes of the well-established DC 
Bead™ model. The only practical difference is that DC Bead™ has a 48-month shelf life compared with 
DC Bead LUMI™ which has a 24-month shelf life, however stability testing to extend the shelf life is 
ongoing. DC Bead LUMI™ is intended as an embolic device with or without the addition of drug for the 
treatment of malignant and non-malignant HVTs and AVMs, indicated for HCC and mCRC patients. It 
is compatible with Dox and Iri, and is stated to have achieved complete and controlled release 140.  
 
Table 1.2: Available DC Bead LUMI™, their sizes and label colour 142.  
 
 
It is important to fully characterise such formulations to optimise their bioavailability for patients. 
Understanding the interaction of drug with the aforementioned polymeric carrier will allow optimisation 
and modification of the design of new types of DDSs for even more effective targeted drug therapy. This 
research project aims to investigate whether the chemical and structural properties of DC Bead LUMI™ 
produce different results to the standard DC Bead™.  
  
Bead Reference Bead Size (µm) Label Colour Product Image 
M1 70-150 Black  
103 100-300 Yellow 
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1.7. LifePearl™  
LifePearl™ is an embolisation microsphere indicated for the treatment of primary HVTs and liver 
metastasis. Like DC Bead™ it is designed to be used bland or for loading with drugs such as Dox or Iri. 
It is manufactured by Terumo Corporation and is the most recently developed DEB, it was released in 
Europe during 2015 but is not yet approved for use in the USA. LifePearl™ is a polyethylene glycol 
(PEG), biocompatible, hydrophilic, compressible, elastic, tightly calibrated and controlled release 
hydrogel. The product boasts enhance suspension characteristics with minimised time to suspension 
and maximised time in suspension. Similar to DC Bead™ drug-bead binding is through a sulfonate site, 
but with the addition of 3-sulfopropyl acetate sodium salt (SPA) rather than AMPS. Presented in Table 
1.3 is the device in a syringe with 2 mL of beads in 4 mL of PBS 143.  
 
Table 1.3: Available LifePearl™, their sizes and label colour 143.  
 
Analysis undertaken by Biocompatibles UK Ltd reported the unpublished data summarised in Table 1.4. 
Using the calculated sulfonate content, the theoretical loading capacity of LifePearl™ is 47.8 mg/mL 
compared with a higher loading capacity of 58.4 mg/mL for DC Bead™. Solid and water content was 
also evaluated in the original bead packaging solution.  
 
Table 1.4: Components of DC Bead™ and LifePearl™.  
  
Bead Reference Bead Size (µm) Label Colour Product Image 
100 100 ± 25 Black  
200 200 ± 50 Yellow 
400 400 ± 50 Blue 
Bead Type Sulfonate Content (mol) Solid Content (%) Water Content (%) 
DC BeadM1™ (70-150 µm) 1.0 x 10-4 6.2 93.8 
LifePearl™ 100 (75-125 µm) 0.83 x 10-4 4.1 95.9 
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1.8. Tandem™  
The main competitor to DC Bead™ is Tandem™ (known as Oncozene™ in the USA) produced by 
Boston Scientific Corporation and launched in 2012. Embozene Tandem™ Microspheres are indicated 
for embolisation and used with 50 mg/mL Dox or Iri, however the biocompatible hydrogel is also capable 
of loading compounds such as epirubicin (Epi) and idarubicin (Ida) 144. Tandem™ is a polymethacrylate 
(PMA) sodium coated with a patented inorganic perfluorinated polymer (Polyzene®-F). It is indicated for 
the treatment of AVMs, HCC, HVTs, uterine fibroids, along with tumour of the head, neck, torso and 
skeletal system, as well as bleeding and trauma, in addition to preoperative reduction of bleeding other 
than the central nervous system 145. The benefits are defined as the smallest size bead with the tightest 
calibration, offering up to 3 mL beads and a 3-year shelf life. The microspheres allow fast drug loading 
time, superior drug loading capacity, precise drug delivery, efficient drug release rates, and a stable size 
during drug loading and storage (<5 % size change) 144.  
The opaque beads are available in various sizes, and in 2 and 3 mL volumes. Displayed in 
Table 1.5 are the beads packaged in 20 mL syringes with colour coded labels and one 3 mL volume of 
Tandem™ is alleged to deliver 150 mg of the loaded drug. The microspheres are stored in a suspension 
of non-pyrogenic sterile solution of physiological saline, the total volume of material and solution inside 
the syringe is approximately 7 mL. This solution is removed before loading the product with the required 
drug. Tandem™ is not to be used with ionic contrast agent as this could lead to microsphere 
deformation. The vascular is evaluated using high resolution imaging and non-ionic contrast agent prior 
to the embolisation procedure. Each package is intended for single patient use, the size and quantity is 
selected by the physician according to the lesion to be treated 145.  
 
Table 1.5: Available Tandem™, their sizes and label colour 146.  
  
Bead Reference Bead Size (µm) Label Colour Product Image 
104 40 ± 10 Black  
107 75 ± 15 Burgundy 
110 100 ± 25 Orange 
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1.9. Hepasphere™  
Another competitor to DC Bead™ is HepaSphere™ (known as QuadraSphere™ in the USA) 
manufactured by Merit Medical Systems, Inc. and launched shortly after DC Bead™ 147–152. 
HepaSphere™ is a PVA acrylic acid superabsorbent copolymer, which has the ability to increase up to 
64 times its original size. It has a similar mechanism to DC Bead™, except the ionic interaction with the 
bead and drug is through carboxylate groups and not sulfate groups. It is suggested that since Dox-
polymer interactions are similar, the elution profile is also akin 148. The hydrophilic microsphere is made 
of two monomer units, vinyl acetate and methyl acrylate, which combine to form sodium acrylate alcohol 
copolymer. HepaSphere™ is indicated for the embolisation of HCC and metastases to the liver when 
loaded with Dox, and mCRC to the liver when loaded with Iri. The advantages are understood to be 
targeted delivery, fast loading, compressibility and an expanding structure 153.  
The product is supplied in a 10 mL glass vial with a crimped cap, and in 25 and 50 mg options. 
The size of sphere in Table 1.6 is selected by the physician according to the size of the target vessel. 
The microspheres are supplied dry and must be reconstituted before use. 75 mg of Dox can be loaded 
into one HepaSphere™ vial and it is intended for practise with non-ionic contrast media 154.  
 
Table 1.6: Available HepaSphere™, their sizes and label colour 155.  
Bead Reference Bead Size (µm) Expanding Size (µm) Label Colour Product Image 
200 30-60 120-240 Orange 
 
300 50-100 200-400 Yellow 
500 100-150 400-600 Blue 
700 150-200 600-800 Red 
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1.10. Experimental Analysis of Drug-Bead Systems  
It is difficult to evaluate drugs and delivery systems in vivo, consequently in vitro methods must also be 
developed to mimic in vivo conditions. In vivo methods are disadvantaged because data observed in a 
single animal species is not always equivalent to human outcomes, and different animal species have 
different pharmacokinetics making it difficult to extrapolate or generalise data. In vitro methods also have 
their weaknesses as homeostatic mechanisms are not present in the test, however in vitro tests are 
capable of testing specific mechanisms of action, they can be performed without the need to address 
ethical issues, can be quick and inexpensive to perform. Owing to these discrepancies in in vivo test 
methods it is desirable to consider the use of multiple models, and to study the differences and 
similarities between models and an actual tumour. When in vivo and in vitro methods correlate well they 
have the potential for predicting attributes required of the drug delivery device.  
It is important to not only to understand how the drug and DDS interact with the tumour and the 
rest of the body, but also how the drug and DDS interact with one another to provide effective treatment. 
Understanding drug-excipient interactions is essential in light of their potential to bind and release 
particular drugs in a controlled and sustained manner.  
 
1.10.1. Thermodynamics  
There has been considerable data gathered both in vivo and in vitro relating to DEBs, however presently 
no data has been generated corresponding to the thermodynamics of the beads. Isothermal titration 
calorimetry (ITC) is an established analytical technique used to study the binding interactions of 
molecules. The instrument displays a variety of thermodynamic parameters for chemical and biological 
systems. The intermolecular interactions allow determination of parameters such as binding constant 
(K), reaction stoichiometry (N), enthalpy (∆H), entropy (∆S) and Gibbs free energy (∆G) for any given 
system. From these units the number of binding sites, binding ratio, type of bonding (hydrogen, ionic 
and van der Waals), type of binding interaction (electrostatic and hydrophobic), order, spontaneity, 
conformation and aggregation state can be identified.  
Previous studies have included the use of ITC to determine the reactive sites on active ester 
surfmers nanoparticle beads with the amine containing compound remazol brilliant blue. The interaction 
between the nuclepohilic group of the dye and the activated ester was an exothermic 1:1 reaction. The 
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reaction was successfully carried out at 298 K with a buffer of pH 7.5 156. The interaction of chemically 
modified Pluronic block copolymers such as poly-acrylic acid (PAA) grafted to poly-ethylene oxide (PEO) 
with Dox has also been evaluated. 15 mM of Dox was titrated into 0.01 % wt PEO-PAA over a pH range 
of 4.3 to 7.1. It was found that exothermic peaks became broader with an increase in pH, suggesting 
that more Dox molecules were bound to the polymer chain as the pH increased 157. Figure 1.15 displays 
the main components of the ITC, in this circumstance as the syringe rotates drug is injected into beads. 
The bottom of the cell is coin shaped and there are two internally identical cells, one to hold the sample 
and the other is the reference cell. The heat difference between the two cells are measured for analysis.  
 
 
 
 
 
 
 
 
Figure 1.15: ITC cell and syringe with Dox titrated into beads.  
 
1.10.2. Drug Loading  
The amount of Dox loaded into beads can be determined by immersing a measured volume of beads 
into a Dox solution. Dox concentration can then be defined by measuring absorbance of the residual 
drug in the depleted solution and converting absorbance to concentration using a calibration plot. It has 
been publicised that >99 % of a 37.5 mg Dox solution can be loaded into DC Bead™. A maximum of 40 
mg of Dox was loaded in 1 mL of beads and the time taken for beads to load drug was dependent upon 
bead size, with smaller beads loading faster due to a larger surface area. This was also associated with 
a reduction of water contained in the bead and the effect is more pronounced in the larger bead ranges. 
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The fluorescent distribution across the surface of beads showed Dox to be homogenously dispersed, 
however cross-section analysis revealed that the internal distribution of the drug is concentrated around 
the outer 20 µm of the bead, although there was Dox present in the internal structure 47.  
 
1.10.3. Drug Elution  
High performance liquid chromatography (HPLC) has shown that Dox before and after loading does not 
change chemical structure, i.e. it does not degrade. Furthermore, Dox was found to elute in PBS and 
plasma, but did not release in water as the rate of release was dependent upon the concentration of 
salt, i.e. at higher salt concentrations a larger amount of drug was eluted from the beads 88.  
The elution of Dox in different ionic strength solutions was evaluated using the United States 
Pharmacopeia (USP) Type 2 Dissolution Apparatus (found in Chapter 711 of the USP), the paddle type 
fitting is represented in Figure 1.16 but this can be replaced with other components. The study showed 
30:70 potassium chloride in 20 % w/v ethanol to be the most suitable elution media and the drug release 
profile to follow first order kinetics. Elution increased as the diameter of the bead decreased because of 
the larger surface area, therefore the elution rate was inversely proportional to bead size 88.  
 
 
 
 
 
 
 
Figure 1.16: USP Type 2 dissolution apparatus.  
 
The USP 2 guidelines state that the in vitro release testing of implantable drug-device combination 
products may be evaluated by immersing the system, usually with a stirring element such as a paddle, 
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in a static suitable elution medium whilst heated to 310 K. The medium may be exchanged periodically 
to prevent drug saturation and is sampled intermittently for analytical determination of the elution 
kinetics. In a closed loop system the selected drug can be eluted under sink conditions, however the 
drug is released via an ion-exchange mechanism, therefore it is the presence of ions which allow the 
drug to detach from the bead. Even if there is ample medium to dissolve the drug there may not be 
enough ions for the mechanism to occur once equilibrium has been reached. Under a fixed volume of 
elution media there is limited exchange of eluent ions, it is for his reason that it is more appropriate to 
perform the elution of drug from DEBs in an open loop system.  
Nonetheless, in a high concentration of salt Hecq et al. showed that >90 % of Dox loaded in 
500-700 µm DC Bead™ eluted in less than 2 hours from a USP 2 closed loop system 158. Gonzalez et 
al. and Lewis et al. had similar observations with 100-300, 300-500, 500-700 and 700-900 µm DC 
Bead™ 88,89. The paddle suspends beads in the elution media, yet this would not be the case in a vessel 
and so the method tends to exaggerate the rate of elution. This technique is more useful for quality 
control purposes but inappropriate for in vivo correlations.  
An alternative method is the USP Type 4 Dissolution Apparatus (found in Chapter 711 of the 
USP). Figure 1.17 depicts the flow-through cell where the elution medium may be circulated around or 
through the system, depending on its configuration using flow-through apparatus. DEBs have been 
evaluated with this method, but it was unable to demonstrate complete drug elution from the systems 
under this study due to experimental conditions. Fuchs et al. suggested that 100-300 µm DC Bead™ 
loaded with Sunitinib in a flow-through cell released only 80% of the drug when microsphere were 
densely packed together, but this was using USP 4 in a closed loop system in which there was a limited 
number of ions available. The addition of a bed of glass beads to sit on top of the polymer spheres did 
not significantly change the elution profile 159. Few beads would pack together in a vessel, therefore 
dense packing may not emulate the in vivo situation and could predict lower elution rates as the medium 
fails to gain access to the entirety of each microsphere underestimating the elution of drug. Nonetheless, 
USP 4 is an improvement on USP 2 as it better predicts drug released into systemic circulation 89.  
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Figure 1.17: USP Type 4 dissolution apparatus.  
 
The T-Apparatus as seen in Figure 1.18, was designed to simulate in vivo conditions and results fitted 
a slow release model. Half-life (t1/2) was determined and was found to increase with the concentration 
of Dox loaded in the beads. t1/2 also increased with bead diameter, but the increase was not proportional 
88. The T-Apparatus was proposed as an alternative method that better emulates the embolisation 
environment by profusion of diffusion and convection zones, representing drug diffusion from the beads 
through the vessel and surrounding tissues, and then its removal in blood flowing through more distant 
patent vessels 160. This method proved useful in predicting the first 24 hours of drug release into systemic 
circulation, producing a level A in vitro:in vivo correlation (IVIVC). The technique is however 
cumbersome and not without technical limitations when forecasting elution data beyond 24 hours.  
 
 
 
 
 
 
Figure 1.18: T-Apparatus for measurement of drug elution.  
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Several attempts have been made to standardise microsphere in vitro release testing 160–162. This study 
reports the development of a new elution method for the evaluation of DEBs, which overcome some of 
the short-comings of previously reported methods and will allow a better comparison between the 
performances of different products despite their different characteristics. The aim was that the methods 
developed would distinguish between different formulations and mimic in vivo conditions, therefore 
enhancing the understanding of drug-DEB interactions.  
 
1.10.4. In Vivo Studies  
In a pharmacokinetic study Dox was detected in the plasma 24 hours longer in smaller beads and 
although the concentration of Dox was 1.5 times greater, the peak concentration was 15 times higher 
than larger bead groups, an effect of the larger surface area with smaller beads 16. Crucially, Dox was 
found to remain in 100-300 and 700-900 µm beads for at least 90 days 96. Dox loaded beads were found 
both inside and around the periphery of tumours, and an average of one bead occluded one vessel 84. 
This is useful information when designing methods and making in vivo – in vitro correlations.  
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1.11. Project Objectives  
The overarching aim of this study is to investigate drug-bead interactions, to understand how they affect 
binding and subsequent drug release phenomena using in vitro techniques to mimic in vivo scenarios.  
This aim will be achieved through the following three objectives:  
1. The application of ITC to investigate drug-bead binding interactions.  
Initially, the concept of using ITC to monitor drug-bead binding will be considered, permitting calculation 
of drug-bead binding ratios over a range of temperatures and concentrations. Subsequently, a variety 
of bead sizes, bead types and a set of drugs applicable to bead-based delivery systems will be analysed 
to determine their effect on binding ratio. It is hoped that analysing drug binding using ITC will provide a 
unique and simple way to quantify such interactions.  
2. The development of a novel method to determine the release of drug from DEBs.  
A new release method will be investigated to overcome the limitations experienced with existing 
techniques. It is to incorporate an open-loop system producing standardised, characterised and 
reproducible in vivo correlated data. Primarily, various flow rates and salt concentrations will be 
evaluated to identify suitable method parameters. Comparisons will be made between elution data using 
different bead sizes and bead types, with different drugs and drug concentrations.  
3. Confirmation of drug loading, drug elution and microscopic analysis.  
Conclusions will be drawn from data using both methods investigated in Objectives 1 and 2, along with 
quantification of residual and extracted drug from DEBs, to confirm as to whether complete drug loading 
or elution has been achieved from both ITC and elution experiments. Visual analysis of the beads will 
be conducted using microscopy before, during and after elution to support the previous results.  
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Chapter 2 : Methodology  
 
All work presented in this thesis was carried out at the University of Huddersfield. It should be noted that 
several sections of this work have been published in the well reputed International Journal of 
Pharmaceutics and European Journal of Pharmaceutical Sciences 1,2.  
 
2.1. Isothermal Titration Calorimetry (ITC)  
Isothermal titration calorimetry (ITC) measures the heat released or absorbed by an excipient as a 
consequence of injecting precise amounts of a reactant. The sample may be held at a selected 
temperature and mixed at a spin rate chosen by the user. The differential power (DP) difference between 
the reference cell and sample cell is measured from the temperature difference observed 3.  
An exothermic reaction, where heat is released from the interaction between a ligand titrated 
from the syringe into a macromolecule contained in the cell, causes a negative DP. The opposite occurs 
in an endothermic reaction, where heat is absorbed, causing a positive DP. This measure of thermal 
energy (∆H) is directly proportional to binding between the ligand and the macromolecule. At each point 
that the ligand (drug) is supplemented the heat signal decreases as the macromolecule (bead) becomes 
saturated. The signal reduces until only the background signal of dilution effects is observed 3. The 
interaction of the ligand with the macromolecule solvent can be measured and subtracted from the 
interaction with the ligand and macromolecule. The same subtraction can be made between the 
macromolecule and the ligand solvent to obtain the overall binding result, in this case the sole interaction 
of bead and drug. Figure 2.1 illustrates the main components of the ITC instrument.  
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Figure 2.1: The main components in the ITC unit 3.  
 
2.1.1. Materials  
The following drugs, beads and other materials were utilised in the ITC studies:  
Drugs:  
Doxorubicin hydrochloride (Dox) powder, >99 % purity, product code 13773, Zhejiang Hisun 
Pharmaceutical Co Ltd, Zhejiang, China.  
Mitoxantrone dihydrochloride (Mit) powder, ≥97 % purity, product code M6545, Sigma-Aldrich 
Corporation, Missouri, United States of America (USA).  
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Irinotecan hydrochloride (Iri) powder, >99 % purity, product code 218MF10990, ScinoPharm Taiwan 
Ltd, Tainan, Taiwan.  
Topotecan hydrochloride (Top) powder, >99 % purity, product code 1672257, Sigma-Aldrich 
Corporation, Missouri, USA.  
 
Beads:  
DC BeadM1™, also referred to as 70-150 µm DC Bead™ (M1), additional sizes of 100-300 µm (103), 
300-500 µm (305) and 500-700 µm (507), Biocompatibles UK Ltd, Surrey, United Kingdom (UK).  
LifePearl™, 100 µm ± 25 (100), Terumo Corporation, Tokyo, Japan.  
DC Bead LUMIM1™, also known as 70-150 µm DC Bead LUMI™ (M1), Biocompatibles UK Ltd, Surrey, 
UK.  
Tandem™, 100 µm ± 25 (110), Boston Scientific Corporation, Massachusetts, USA.  
HepaSphere™, 30-60 µm, expanding size 120-240 µm (200), Merit Medical System Inc, Roissy, France.  
 
Other materials:  
Hydrochloric acid (HCl), 37 % concentration, reagent grade, product code 435570, Sigma-Aldrich 
Corporation, Missouri, USA.  
Centrifugal filters, ultrafree-MC SV, non-sterile, 5.0 µm pore size, product code UFC30SV00, Merek 
Millipore, Massachusetts, USA.  
 
2.1.2. Instrument Preparation  
Calibration of the equipment was undertaken periodically and tests to ensure the instruments accuracy 
can be found in the Appendix ‘Isothermal Titration Calorimetry (ITC) Calibrations’ Section.  
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Before samples were placed into the ITC the equipment was cleaned thoroughly to prevent 
contamination. 10 – 20 % Decon® 90 is a dilute solution known not the damage the cells, this was 
placed in the sample cell which was heated to 60 °C and left for >60 minutes. Decon® was removed 
from the cell and replaced with deionised water, the machine was then cleaned by drawing >1 L of water 
through the apparatus using a vacuum pump. Water was also flushed through the syringe multiple times 
and could be filled with methanol, then left to dry to reduce the amount of sample required to flush 
through the system. If additional cleaning was required water was pre-heated to 60 °C to flush through 
the instrument. If other compounds had been previously used in the instrument the risk of contamination 
was greater and so strong basic chemicals such as 3 mM (12 % v/v) NaOH were used instead of 
Decon®. Excessive use of NaOH can desensitise either of the identical coin shaped sample or reference 
cell composed of Hastelloy® C 276, therefore unnecessary use was avoided. Following this the machine 
was ready to use by preparing the samples and placing them inside the instrument.  
Once an experiment was complete the sample cell and syringe contents were removed and 
replaced with deionised water if the instrument was to be left for more than 24 hours without use, as the 
contents may damage internal components of the equipment.  
 
2.1.3. Sample Preparation  
An investigation was conducted into the amount of time adequate for bead centrifugation. The purpose 
of centrifugation was to provide a mass of beads with a known solid content that could be place into the 
ITC cell. Beads unsuspended in water are also easier to place into the cell. Pre-washed beads, in either 
water or acid, were centrifuged in a 1000 µL tube with a 5.0 µm centrifugal filter unit and then weighed 
at intervals over 5 minutes. There are two known stages of water loss, in the first stage water is lost from 
outside the beads and in the second water is lost from inside the beads. For this study water must 
remain inside the beads in order to retain the beads structure, so ideally only the first stage of water loss 
would have occurred before ceasing centrifugation. When trend lines were taken from the first two and 
last two data points, it was determined that the intercept where the two sets of data points met confirmed 
that 1000 µL of beads and water required 30 seconds centrifugation at 3000 revolutions per minute 
(rpm). The results of this work are demonstrated in Figure 2.2.  
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Figure 2.2: Mass of DC BeadM1™ after centrifugation at different time points, arrow shows point of inception (n = 3, error bars = 
standard deviation).  
 
25 – 100 mg of pre-washed centrifuged beads were placed into the sample cell with a spatula. To wash 
the beads the packing solution was removed and replaced with either deionised water or 2M HCl, as 
sodium ions would interfere with bead binding properties. The beads were then shaken and left to settle 
for 1 minute to allow the ion-exchange process to take place. This washing step was repeated at least 
ten times to ensure ion-exchange equilibrium was achieved, as seen in Figure 2.3. After acid washing 
the beads were washed with deionised water to removal any residual HCl.  
To ensure all beads were inside the sample cell, the beads were periodically washed down with 
small of amounts deionised water using a syringe with a needle. Air bubbles were removed from the cell 
by inserting and removing the syringe until no bubbles could be seen. Over time beads separate from 
the water as the sample sediments, the beads were left to settle until no beads could be seen in the 
sample cell entrance, excess water was then removed. Beads with the addition of deionised water gave 
a total volume of 1.4194 mL. The syringe was filled with 1 – 43 mM of drug depending upon the type of 
experiment and drug solubility; the syringe held a volume of 290 µL.  
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Figure 2.3: Step by step bead sample preparation for ITC experiments.  
 
2.1.4. Instrument Parameters  
The majority of experiments involved a total of 14 injections, whereby each injection volume was 20 µL 
for a duration of 40 seconds. Every injection had a spacing of 600 seconds and a filter period of 2 
seconds, with the reference power set between 1 – 25 µcal/sec (depending on the experiment) and a 
stirring speed of 307 rpm. Initially, the cell temperature was set to 25 °C, with a series of temperatures 
studied from 20 – 40 °C. The instrument used in this study was a VP-ITC MicroCal™ unit manufactured 
by Malvern Instruments Inc, using Origin® 7 software for all data analysis.  
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2.2. Open-Loop Flow-Through Elution  
Ultraviolet-Visible (UV-Vis) spectrophotometry used a method incorporating a system to evaluate the 
tendency of drug to release into the systemic circulation as a function of either time or embolic load from 
drug eluting bead (DEB) products. It measures light intensity as a function of wavelength from a beam 
of light passed through a sample and compares this with the reference, which can then be converted 
into absorbance. The main components of the UV instrument are illustrated in Figure 2.4.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The main components in the UV-Vis unit 4.  
 
2.2.1. Materials  
Drugs used in the open-loop flow-through elution experiments were Dox HCl and Iri HCl as listed in 
Section 2.1.1. All beads in Section 2.1.1 were used in the elution studies, with additional bead sizes and 
other materials used in analysis as itemised below:  
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Beads:  
DC Bead LUMI™, 100-300 µm (103), Biocompatibles UK Ltd, Surrey, UK.  
Tandem™, 75 µm ± 15 (107), Boston Scientific Corporation, Massachusetts, USA.  
 
Other materials:  
Glass beads, 150-212 µm, product code G1145, Sigma-Aldrich Corporation, Missouri, USA.  
Filter membrane, polyester, pore size 27 µm, product code 07-27/19, Sefar Medifab, Heiden, 
Switzerland.  
Silicon tubing, platinum cured, 3/32 inch internal diameter, 5/32 inch external diameter, product code 
95802-03, Cole-Parmer, Illinois, USA.  
Phosphate buffered serology saline (PBSS), pH 7.0, product code 04-004, Source BioScience UK Ltd, 
Nottingham, UK.  
Helium, A Grade, product code 110745, The BOC Group plc, Guildford, UK.  
Ringer’s solution ¼ strength tablets, product code 96724, Sigma-Aldrich Corporation, Missouri, USA.  
Sodium chloride (NaCl), product code S7653, Sigma-Aldrich Corporation, Missouri, USA.  
Sodium bicarbonate (NaHCO3), product code 71631, Sigma-Aldrich Corporation, Missouri, USA.  
Potassium chloride (KCl), product code P9333, Sigma-Aldrich Corporation, Missouri, USA.  
Potassium phosphate dibasic trihydrate (K2HPO4∙3H2O), product code P5504, Sigma-Aldrich 
Corporation, Missouri, USA.  
Magnesium chloride hexahydrate (MgCl2∙6H2O), product code M2393, Sigma-Aldrich Corporation, 
Missouri, USA.  
HCl, 37 % concentration, reagent grade, product code 435570, Sigma-Aldrich Corporation, Missouri, 
USA.  
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Calcium chloride hexahydrate (CaCl2.6H2O), product code 442909, Sigma-Aldrich Corporation, 
Missouri, USA.  
Sodium sulfate (Na2SO4), product code 798592, Sigma-Aldrich Corporation, Missouri, USA.  
Tris(hydroxymethlyI)aminomethane ((CH2OH)3CNH2), product code T1378, Sigma-Aldrich Corporation, 
Missouri, USA.  
 
2.2.2. Instrument Preparation  
The overall setup as shown in Figure 2.5, consisted of an open-loop flow-through system which 
encompassed eluent solution, a peristaltic pump, a water bath with temperature controlled unit, an air 
collection unit, a flow-through cell, a Cary 60 UV-Vis spectrophotometer with an 18 cell holder accessory 
(so that samples could be tested in triplicate with standards simultaneously), quartz cuvettes, silicon 
tubing, a container to syphon water and a waste collection system.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Experiment set up of the open-loop flow-through elution.  
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Tubing inside the pump was replaced every experiment to ensure a constant flow rate. The flow rate 
was checked before and after experiments, and an average taken for the calculations. Flow rate was 
measured by pre-weighing a glass vial, filling the vial with flowing eluent for one minute and then re-
weighing the vial to give the volume per minute. The instrument has room light immunity and so can 
work with the compartment door open, allowing tubing to go to and from the flow-through cuvettes. 
Cuvettes to analyse Dox had a path length of 10 mm, whereas Iri cuvettes had a shorter path length of 
5 mm because the absorbance of this drug was >>1 under the same conditions.  
 
2.2.3. Sample Preparation  
A 25 mg/mL stock solution of Dox in deionised water was prepared. Beads were initially loaded with 
37.5 mg/mL by the addition of 1.5 mL Dox stock to 1 mL of beads, once the bead packing solution had 
been removed as demonstrated in Figure 2.6. To ensure full saturation the beads were left to load in a 
cool dark area overnight. When the bead volume was changed to 0.5 and 0.2 mL the volume of Dox 
was altered accordingly. The concentration of Dox in the beads was studied at 25, 37.5, 45, 50 and 75 
mg/mL depending on the type of bead. Further experiments were conducted using Iri at a loaded 
concentration of 50 mg/mL with a 12.5 mg/mL stock solution, i.e. 4 mL Iri stock solution in 1 mL of beads.  
 
 
 
 
 
 
 
 
Figure 2.6: Step by step bead sample preparation for elution experiments.  
 
Beads with packing solution removed were loaded with the drug of choice at the desired concentration. 
Beads were then transferred into tubes which allowed eluent through one end and out the other with the 
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eluted drug. Loaded beads were prepared with and without sand or glass beads for packing, and at 
various DEB:packing material ratios (1:0, 1:3 and 1:5).  
To insert beads into the flow-through cell deionised was water heated to 37 °C with care taken 
to avoid creating air bubbles within the sample. A ring with a filter membrane one third of the way inside 
the elution cell held beads within the plastic tube. If the experiment contained no packing material an 
adequate space was left to allow the beads to expand. A second ring and membrane resided after the 
measured space to retain the beads (e.g. for DC Bead™ this was 6 – 7 mm per mL of beads). As 
discussed, packing material was required in some cases to produce interstitial space between DEBs, 
with the aim of separating and suspending beads as well as allowing for any size changes during elution 
to be accommodated. The most suitable technique of mixing DEBs with packing material can be seen 
in Figure 2.7, which was to start with the packing substance and layer beads with packing one layer at 
a time until all the beads were in the cell. As each level was added the two were mixed to create a 
homogenous mixture. As beads were lighter than packing care was taken to avoid over-mixing as the 
beads would separate. The final layer was more packing material before the second ring and filter 
membrane was fitted on top. A third membrane was commonly used to prevent air being introduced to 
the beads, this was positioned with a space between the second filter membrane. The cell was then 
topped up with deionised water and the top of the cell fitted. The methods were initially developed using 
Dox loaded DEBs at 37 ºC with degassed eluent (physiological saline [154 mM NaCl (0.9 % w/v)]). 
However, a second drug viz. Iri, and additional eluent solutions such as various concentrations of NaCl, 
Ringer’s solution and simulated body fluid (SBF) were analysed.  
 
 
 
 
 
 
 
Figure 2.7: Step by step bead packing preparation for elution.  
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Several concentrations of NaCl solutions were prepared to identify elution behavior under different 
concentrations of salt. Table 2.1 displays the concentrations in each buffer solution.  
 
Table 2.1: NaCl buffer composition for elution studies.  
Percent of NaCl (%) 0.45 0.9 1.35 1.8 4.5 
Quantity of Salt (g/L) 4.5 9.0 13.5 18.0 45.0 
Concentration (mM) 77 154 231 308 770 
 
Ringer’s solution ¼ strength tablets were used to prepare eluent for the flow-through apparatus. The 
mixture contains several salts producing an isotonic solution related to bodily fluids. Ringer’s solution 
was created by Sydney Ringer who determined the precise concentration of salts required 5. The product 
data sheet recommends dissolving 1 tablet in 500 mL of deionised water and to adjust the pH to 7.0, 
therefore a solution of 2 tablets in 1 L was prepared to give a half-strength Ringer’s solution. A second 
Ringer’s solution was prepared by dissolving 4 tablets in 1 L of deionised water to give a full-strength 
Ringer’s solution. A third solution was prepared with 8 tablets in 1 L to give a double-strength Ringer’s 
solution. The compounds contained in Ringer’s tablets and the composition in each solution can be 
found in Tables 2.2, 2.3 and 2.4. The ionic strength of half-strength, full-strength and double-strength 
Ringer’s solution was 52.08 mM, 104.16 mM and 208.32 mM, respectively.  
 
Table 2.2: Half-strength Ringer’s solution composition 6.  
Compound 2 Tablets in 1 L (g/L) Concentration (%) Concentration (mM) 
NaCl 2.25 0.225 38.50 
KCl 0.105 0.0105 1.41 
CaCl2 0.12 0.012 1.08 
NaHCO3 0.05 0.005 0.60 
Total 2.53 0.25 41.59 
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Table 2.3: Full-strength Ringer’s solution composition 6.  
Compound 4 Tablets in 1 L (g/L) Concentration (%) Concentration (mM) 
NaCl 4.50 0.45 77.00 
KCl 0.21 0.021 2.82 
CaCl2 0.24 0.024 2.16 
NaHCO3 0.10 0.010 1.19 
Total 5.05 0.505 83.17 
 
Table 2.4: Double strength Ringer’s solution composition 6.  
Compound 8 Tablets in 1 L (g/L) Concentration (%) Concentration (mM) 
NaCl 9.00 0.900 154.00 
KCl 0.42 0.042 5.63 
CaCl2 0.48 0.048 4.33 
NaHCO3 0.20 0.020 2.39 
Total 10.10 1.010 166.34 
 
A solution of SBF was also prepared as flow-through eluent. The synthetic solution was developed by 
Kokubu et al. to imitate human blood plasma (HBP), with similar inorganic ion concentrations to human 
extracellular fluid and pH at physiological temperature 7. SBF contains the same ions as Ringer’s 
solution but with additional ions prepared in a specific way. The ion concentrations of SBF in comparison 
with HBP are detailed in Table 2.5. Each SBF reagent was placed in a 1 L volumetric with deionised 
water in the order provided by Table 2.6. The addition of reagent 9 was gradual in order to avoid local 
increase in pH of the solution. The ionic strength of SBF was 330.81 mM.  
 
Table 2.5: SBF and HBP ion concentration 8.  
Ion Concentration in SBF (mM) Concentration in HBP (mM) 
Sodium (Na+) 142.0 142.0 
Potassium (K+) 5.0 5.0 
Magnesium (Mg2+) 1.5 1.5 
Calcium (Ca2+) 2.5 2.5 
Chloride (Cl-) 147.8 103.0 
Bicarbonate (HCO3
-) 4.2 27.0 
Hydrogen phosphate (HPO4
2-) 1.0 1.0 
Sulfate (SO4
2-) 0.5 0.5 
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Table 2.6: SBF composition 8.  
Reagent Number Compound Quantity Concentration (%) Concentration (mM) 
1 NaCl 7.996 g/L 0.7996 136.82 
2 NaHCO3 0.350 g/L 0.0350 4.17 
3 KCl 0.224 g/L 0.0224 3.00 
4 K2HPO4∙3H2O 0.228 g/L 0.0228 1.00 
5 MgCl2∙6H2O 0.305 g/L 0.0305 1.50 
6 HCl (1 kmol/dm3) 40 cm3 0.1641 45 
7 CaCl2 0.278 g/L 0.0278 2.50 
8 Na2SO4 0.071 g/L 0.0071 0.50 
9 (CH2OH)3CNH2 6.057 g/L 0.6057 50.00 
10 HCl (1 kmol/dm3) 
Adjusted to pH 7.25 at 
36.5 °C 
N/A N/A 
Total 19.00 1.90 244.50 
 
2.2.4. Instrument Parameters  
A scan of the compound of interest identified the wavelength at the maximum absorbance; known as 
λmax. The UV then was set at a wavelength of 483 nm for Dox and 369 nm for Iri, readings were taken 
every minute for the first hour and every five minutes after the first hour for a maximum of 7999 minutes. 
If the experiment hadn’t completed within the allocated time frame the instrument was re-started as 
required. The software used to analyse data was Cary WinUV using the Kinetics program.  
Different parameters were analysed to optimise the method: de-gassing (to reduce air bubbles), 
packing with sand and glass beads (to eliminate swelling and flow artefacts), flow rate (to measure the 
effect on drug diffusion within DEBs), concentration of salt solution (to confirm flow rate effects), eluent 
solution (to measure the effect of different ion-exchange mechanisms) and bead volume (to measure 
the effect of packing density and bead geometry on the elution pattern).  
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2.3. Three-Dimensional Microscopy during Elution  
To identify changes in bead size during elution the flow-through method was conducted under a three-
dimensional microscope (3DM) at a magnification of x 20.  
 
2.3.1. Materials  
The drug used in this study was Dox HCl and the bead used was DC Bead™ 103, the other materials 
used were the same as described in Section 2.2.1.  
 
2.3.2. Instrument Preparation  
The microscope lens was tilted at a 90 ° angle to allow the flow-through cell to stand vertical. The 
equipment set up was similar to the open-loop flow-through elution method, but with the eluent heated 
to 70 °C rather than the flow-through cell to allow the beads to be imaged and so that beads during 
elution were 37 ° C. The DEBs were videoed and/or images were captured as depicted in Figure 2.8.  
 
 
 
 
 
 
 
 
Figure 2.8: Experiment set up of the open-loop flow-through elution with 3DM.  
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2.3.3. Sample Preparation  
Samples were prepared as in Section 2.2.3 without glass beads for packing. 0.5 mL of 100-300 µm DC 
Bead™ were used loaded with 37.5 mg/mL of Dox.  
 
2.2.4. Instrument Parameters  
The digital microscope employed for these experiments was a VHX-2000 unit using the Keyence VHX 
software program, this captured the images at magnifications of x 20 with options of: auto focus, remove 
glare, light shift, high-dynamic-range (HDR), high resolution HDR, optimize (with 9 different automatic 
settings of normal mode, normal mode + light shift, sharpening image mode, sharpening image mode + 
light shift, glare removal, glare removal + light shift, HDR (clear image), HDR (clear image) + light shift 
and high resolution HDR), image stitch, measurement, 3D (three-dimensional) display and live depth up 
used to enhance the image. The programme was set to capture images every 15 seconds over 1 day 
and 17 hours for a maximum of 9999 images. If required the timer was re-set until the experiment was 
complete. The pump was set at a flow rate of 2 mL/min with 154 mM (0.9 % w/v) NaCl.  
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2.4. Residual Solution  
UV-Vis spectrophotometry was used to determine the concentration of drug in the residual solution of 
DEBs after loading, this confirmed the loaded concentration of drug in the beads.  
 
2.4.1. Instrument Preparation  
A Cary 60 UV-Vis spectrophotometer was used to analyse the concentration of drug. The cuvette for 
both Dox and Iri had a path length of 10 mm to ensure a high signal-to-noise ratio. The software used 
for analysis was Cary WinUV using the Concentration program.  
 
2.4.2. Sample Preparation  
After beads had been saturated in a drug solution and left to sequester overnight to ensure complete 
drug loading, the residual solution was then removed using a glass pipette with glass wool in the tip to 
prevent beads from being sampled as portrayed in Figure 2.9. The residual solution was then analysed 
using UV to identify the amount of drug recovered from the sample.  
 
 
 
 
 
 
 
Figure 2.9: Collection of residual solution.  
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2.4.3. Instrument Parameters  
Dox samples were recorded at an absorbance of 483 nm and Iri samples were recorded at 369 nm. 
Absorbance was converted to concentration using a previously established calibration curve which 
included seven standards at 0.001, 0.005, 0.01, 0.02, 0.03, 0.04 and 0.05 mg/mL for Dox, and 0.01, 
0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL for Iri, standard curves can be found in the Appendix ‘Ultra-Violet 
Visible (UV-Vis) Spectrophotometry Calibrations’ Section. The concentration of drug was then converted 
to a percent of the unloaded drug to identify the drug loaded concentration of each sample, which was 
then correlated with the percent of drug eluted from the open-loop flow-through and ITC results.  
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2.5. Forced Extraction  
An established method used a solution of 1 % (w/v) NaCl in dimethyl sulfoxide (DMSO) to extract any 
unreleased drug from elution samples 2. This facilitated a calculation of the amount of drug bound to 
samples using UV-Vis spectrophotometry. Additional methods were performed using 15 % (w/v) NaCl 
in deionised water, 0.1 M HCl in deionised water and 20 % (w/v) KCl in deionised water in a 50:50 (v/v) 
ethanol (EtOH) solution to identify the most suitable chemical combination for drug extraction.  
 
2.5.1. Materials  
KCl, NaCl and HCl details are as described in Section 2.2.1. Additional materials used of DMSO 
anhydrous, ≥99.9 %, product code 276855, Sigma-Aldrich Corporation, Missouri, USA and EtOH, 
product code 459836-1L, Sigma-Aldrich Corporation, Missouri, USA.  
 
2.5.2. Instrument Preparation  
A Cary 60 UV-Vis spectrophotometer was used to analyse the concentration of drug in the samples. 
The cuvette for both Dox and Iri had a path length of 10 mm to ensure a high signal-to-noise ratio. The 
software used for analysis was a Cary WinUV using the Concentration program.  
 
2.5.3. Sample Preparation  
In Figure 2.10 eluted beads along with any packing material were washed into a separation column with 
deionised water. Any residual drug and the deionised water was drained into a waste container from the 
column. This was followed by adding an extraction solution of 10 mL 1 % NaCl/DMSO prepared by 
producing a 20 % (w/v) NaCl solution in deionised water, i.e. 10 g in 50 mL, then transferring this into 1 
L DMSO. The column was agitated to ensure that the beads were mixed in the extraction solution. 
During this procedure the solution became the colour of the loaded drug and the beads began to return 
to their original colour. The beads were left for at least 10 minutes before the solution was collected in 
a vial below the column. The addition of extraction media was repeated until drug could not be seen in 
the solution or beads. The extracted drug was analysed using UV to identify the amount of drug 
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recovered. If required the solutions were occasionally diluted by known concentrations to record a value 
within the standard range and to record an absorbance of ≤ 1. If the drug was not extractable with this 
method 15 % NaCl, 0.1 M HCl or a solution of 10 % KCl/EtOH was used. To prepare the KCl ethanol 
solution a 20 % (w/v) KCl solution in deionised water was produced, i.e. 20 g KCl in 100 mL. This solution 
was then mixed in a ratio of 80:20 or 50:50 (v/v) KCl solution:ethanol, however the 50:50 solution was 
found to be a superior mixture for drug extraction from DEBs.  
 
 
 
 
 
 
Figure 2.10: Step by step bead sample preparation for forced extraction analysis.  
 
2.5.4. Instrument Parameters  
Dox samples were recorded at an absorbance of 483 nm and Iri samples were recorded at 369 nm. 
Absorbance was converted to concentration using a previously established calibration curve which 
included seven standards at 0.001, 0.005, 0.01, 0.02, 0.03, 0.04 and 0.05 mg/mL for Dox, and 0.01, 
0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL for Iri, standard curves can be found in the Appendix ‘Ultra-Violet 
Visible (UV-Vis) Spectrophotometry Calibrations’ Section. The concentration of drug was then converted 
to a percent of the unloaded drug to identify the drug loaded concentration of each sample, which was 
then correlated with the percent of drug eluted from the open-loop flow-through and ITC results.  
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2.6. Three-Dimensional Microscopy (3DM) of Drug-Eluting Beads (DEBs)  
To identify the distribution of drug and to ascertain the extent of any aggregation and/or fragmentation 
the beads were analysed using a 3DM before loading, after loading and after the flow-through method 
was conducted. Analysis was completed at a magnification of x 250, 500, 1000 and 2500.  
 
2.6.1. Instrument Preparation  
Unlike microscopic during elution in which the microscope lens was tilted at a 90 ° angle (see method 
2.3) the lens in these experiments was left horizontal at a 180 ° angle to capture the images.  
 
2.6.2. Sample Preparation  
Samples of beads were placed in a petri dish or on a glass slide under the microscope lens. In the eluted 
bead samples glass beads were avoided in the analysis of the cross section as shown in Figure 2.11. 
Samples were removed from the flow-through cell by piercing the filter membrane and washing the 
beads into a vial. Mechanical force of removing beads out of the cell caused bead destruction.  
 
 
 
Figure 2.11: Petri dish of beads.  
 
2.6.3. Instrument Parameters  
In the ‘Optimize’ setting glare was removed in order to visualise the beads, however this gave a green 
effect to the bland samples. The microscope employed for these experiments was a VHX-2000 unit 
using the Keyence VHX software program which captured the images.  
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2.7. Hot Stage Microscopy (HSM)  
Hot stage microscopy (HSM) is a technique which combines microscopy and thermal analysis of 
samples. Samples can be heated and images can be captured with the increase in temperature over a 
period of time. Through recording images at designated time/temperature points the equipment can also 
record any corresponding changes in colour and light intensity.  
 
2.7.1. Materials  
The drug used in the HSM study was Dox HCl and the bead used was DC BeadM1™ with NaCl.  
 
2.7.2. Instrument Preparation  
The sample was heated either to room temperature (25 °C) or to average normal internal body 
temperature (37 °C) and images were captured every minute for 30 minutes.  
 
2.7.3. Sample Preparation  
10 mg of beads were placed in a crucible which was located inside the sample holder. 10 µL of 1 mM 
Dox was added to the beads for drug-bead binding studies and 10 µL of 15 mM NaCl was added to 37.5 
mg/mL drug loaded beads for elution the studies.  
 
2.7.4. Instrument Parameters  
Figure 2.12 shows the optical microscope arrangement which was an Olympus SZ11 model coupled 
with a Stanton-Redcroff hot-stage. The software was written in-house using Visual Basic.  
 
 
 
73 
  
 
 
 
 
 
 
Figure 2.12: Elements of the HSM.  
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Chapter 3 : Method Development of Drug-Bead Binding Interactions 
using Isothermal Titration Calorimetry (ITC)  
 
3.1. Introduction  
Isothermal titration calorimetry (ITC) has previously been employed to determine the saturation of 
surfactants with several drugs. A method was developed to provide data which was unusual to traditional 
practice, whereby a change in the isotherm such as an increase in the enthalpy change from a negative 
value (exothermic response) to a positive value (endothermic response) was identified as the saturation 
limit rather than diminished signals 1. Typically, the middle of the isotherm is attained as the binding ratio 
as seen in Figure 3.1, but alternatively the point of change was selected.  
 
 
Figure 3.1: Typical example of ITC data with plateau saturation point (A) 2 and alternative example of ITC data with a change in 
enthalpy from exothermic to endothermic as the point of saturation (B) 1.  
 
A 
B 
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Preliminary work for this study suggested a similar enthalpy change in the isotherm with drug eluting 
beads (DEBs). One particular bead is DC Bead™, this is a polyvinyl alcohol (PVA) hydrogel with 2-
acrylamido-2-methylpropane sulfonate sodium salt (AMPS) binding sites. This study investigates the 
binding ratio of drug to AMPS. The beads are commonly used with the chemotherapeutic agent 
doxorubicin (Dox) and this was the initial compound of interest. The beads are known to consist of 55.55 
% PVA macromer 45.45% AMPS monomer, and earlier research has shown 1 mL of beads has a 
theoretical binding capacity of 44.77 mg if 1 mole of sulfonate was to react with 1 mole of Dox. The 
actual binding capacity was found to be 37.04 mg with a standard deviation of 0.377. Considering that 
the water content of these beads is 95 % in packing solution, this equates to a ratio of 0.836:1 Dox to 
AMPS using the technique of ultraviolet-visible (UV-Vis) spectroscopy 3. ITC has the potential to produce 
accurate and precise data with further information about the binding characteristics of DEBs.  
 ITC has the ability to conduct experiments at set temperatures from 275 – 353 K. DEBs are 
loaded prior to the medical procedure at room temperature, but it was of interest to study the effects of 
temperatures outside of this range. Standard ITC experiments are run at 298 K and so four additional 
temperatures were chosen which were 293, 303, 310 and 313 K.  
 A further variable to be considered is pH as this can alter the binding interaction. Not only can 
the results be of an acid-base titration, but they can depend on the amount of ionised compound. Any 
changes must be investigated, but with careful contemplation in extremely low and high pH 
environments as unstable baselines and pH shifts are common.  
The concentration of Dox loaded into DC Bead™ prior to the medical procedure is generally 
37.5 mg in 1 mL of beads. This requires 1 mL of beads saturated in 1.5 mL of a 25 mg/mL (43 mM) Dox 
solution 4. As the ITC syringe only holds 290 µL it requires an extremely small number of beads. The 
ITC also has a maximum detection limit which is +/- 38.799 µcal/sec and a minimum of +/- 3 – 5 µcal/sec 
5, therefore an appropriate concentration of drug and mass of beads is required for analysis along with 
discovering whether any changes influenced the results.  
 The volume of injectant and the number of injections may be altered during instrumental set up. 
The instrument manual advises a volume between 3 – 15 µL and 10 – 15 injections 5, a set of 
experiments were undertaken to examine this recommendation.  
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 Finally, the saturation of beads, aggregation state of Dox and the ITC limit of Dox detection 
(LOD) was confirmed. The saturation test was completed by evaluating the residual solution collected 
from the ITC experiment for the concentration of drug unloaded, in addition to extracting the drug from 
the beads to confirm whether the concentration of drug expected to have loaded into the beads was 
achieved during analysis. Rather than Dox titrated into water, water was titrated into Dox to determine 
to self-association of the drug. Minute concentrations of Dox were titrated into the ITC, the concentration 
was reduced until the differential power (DP) was close to 0.1 µcal/sec which is the instruments LOD. 
This experiment determined the lowest concentration of Dox required for a visible interaction on the ITC.  
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3.2. Results and Discussion  
3.2.1. Effect of Temperature  
ITC was used to investigate drug-bead interactions, whereby drug was injected into the sample cell 
containing polymer beads, namely DC BeadM1™. To calculate the moles of DC BeadM1™ binding 
sites, specifically the moles of AMPS in the ITC sample cell, the solid content was first determined using 
Equation 3.1. For this calculation 1000 µL of water washed beads were placed in a pre-weighed 
centrifugal filter insert and were centrifuged for 30 seconds at 3000 rpm. The beads and the centrifugal 
filter insert were then weighed and placed in a vacuum oven for 24 hours at 313 K. After 24 hours in the 
vacuum oven the beads were allowed to cool to room temperature, then the beads and the insert were 
weighed for a second time. These weights were used to calculate the percentage solid and water content 
of beads which have been centrifuged for 30 seconds at 3000 rpm. The test was conducted in triplicate 
and the results of DC BeadM1™ are found in Table 3.1.  
 
Equation 3.1: Calculation of solid content.  
% Solid Content = 
(Weight of Dry Beads + the Insert) - (Weight of the Empty Insert)
(Weight of the Wet Beads + the Insert) - (Weight of the Empty Insert)
∙100 
 
Table 3.1: The percentage solid content of DC BeadM1™ in water prepared for the ITC (sample number = 3).  
Weight of Empty 
Insert (mg) 
Weight of Wet Beads 
+ insert (mg) 
Weight of Dry Beads 
+ Insert (mg) 
% Water Content % Solid Content 
908.90 1167.52 916.75 96.96 3.04 
908.45 1184.28 916.82 96.97 3.03 
926.52 1159.54 933.58 96.97 3.03 
 
The average percentage solid content of DC BeadM1™ in water centrifuged for 30 seconds at 3000 
rpm was 3 % to the nearest whole number. To confirm the percentage solid content the method was 
performed in packing solution and compared with results in water. The solid content of beads in packing 
solution is known to be ~5 %, and so performing the method in saline as well as in water was to confirm 
accuracy of the method. The test was executed in triplicate and the results are shown in Table 3.2.  
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Table 3.2: The percentage solid content of DC BeadM1™ in saline (sample number = 3).  
Weight of Empty 
Insert (mg) 
Weight of Wet Beads 
+ insert (mg) 
Weight of Dry Beads 
+ Insert (mg) 
% Water Content % Solid Content 
900.82 999.78 908.50 92.24 7.76 
926.45 1041.20 935.08 92.48 7.52 
891.15 1004.38 899.92 92.25 7.75 
 
The average percentage solid content of DC BeadM1™ in saline centrifuged for 30 seconds at 3000 
rpm is 7 % to the nearest whole number. Although the solid content of beads in saline was expected to 
be 5 % and this study presents a larger value, the discrepancy in the results could be caused by a 
difference in the removal of water test method. Some choose to wick the water off the beads, others 
pipette the water off and a variation in the amount of water removed from the beads would result in a 
disparity between the solid content. If the beads were centrifuged for an extended amount of time than 
required, water would then be removed from inside the bead along with outside presenting a higher solid 
content. Nevertheless, it was important to establish the solid content of beads used in the testing of 
drug-bead binding, and it does indicate that there is a difference in the solid content of beads in water 
and beads in saline which was anticipated. While there was variation between the expected value of 
beads in saline the difference is relatively small, and so long as the value used was the solid content of 
beads in the experiment it will ensure the accuracy of the results contained in this report.  
For all ITC experiments a decrease in exothermic signals was selected as the saturation of 
AMPS binding sites from the binding of Dox. The volume of Dox titrated to achieve the exothermic 
endpoint was calculated (mL) by multiplying the number of exothermic injections by the volume per 
injection (mL). The concentration of Dox (g/mL) was then multiplied by the volume of injections at the 
endpoint (mL) to equal the mass of Dox at the said endpoint (g). Since the mass of Dox used (g) and 
the relative molecular mass (RMM) was known ((C27H29NO11.HCl) 579.99 g), the number of moles was 
calculated by dividing the mass of Dox bound to AMPS by the RMM of Dox.  
The solid mass of beads in the sample cell was the weight of centrifuged beads (g) divided by 
100 and multiplied by the 3 % solid content. However, Dox binds to AMPS groups situated on DC Bead™ 
and not to the whole bead structure. DC Bead™ contains 45.45 % AMPS, therefore the mass of AMPS 
is equal to the mass of beads (g) divided by 100 and multiplied by 45.45 %. Since the mass of AMPS 
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has been calculated and the RMM is known ((C7H12NNaO4S) 229.23 g), the number of moles was 
calculated by dividing the mass of AMPS by the RMM of AMPS.  
Therefore, the moles of Dox at the endpoint divided by the moles of AMPS in the sample cell 
equalled the molar ratio of AMPS bound to Dox. The Dox-water interaction and the bead-water 
interaction were subtracted from the Dox-bead results to produce the true Dox-DC Bead™ values. A 
selection of raw ITC data is displayed in Figures 3.2, 3.3, 3.4 and 3.5.  
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Figure 3.2: 10 mM Dox into 100 mg DC BeadM1™ at 298 K 
– the syringe contained Dox, the sample cell contained 
beads with deionised water and the reference cell also 
contained deionised water.  
 
Figure 3.3: 10 mM Dox into water at 298 K – the syringe 
contained Dox, the sample cell and reference cell contained 
deionised water.  
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Figure 3.4: Water into 100 mg DC BeadM1™ at 298 K – the 
syringe contained deionised water, the sample cell 
contained beads with deionised water and the reference cell 
contained deionised water.  
Figure 3.5: Subtraction of Figures 3.3 and 3.4 from 3.2. 
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Five temperatures were selected (293, 298, 303, 310 and 313 K) to encompass typical temperatures 
encountered during sample preparation, through to those encountered by the formulated product in vivo. 
The signals for Dox-bead binding were exothermic, whereas the interaction of Dox-water was 
endothermic as this process includes the dissociation of Dox-Dox aggregates under water dilution, 
water-bead was discovered to have a negligible trace. Where the thermogram changed from exothermic 
to endothermic the beads were considered saturated with drug. It was also found that the binding ratio 
was temperature independent as presented in Figure 3.6, this was expected since there were a set 
number of binding sites on the bead for the drug to bind. 303 K has a slightly different profile to the other 
temperatures and this could be a consequence of the small number of replicates. 
 
 
 
 
 
 
 
 
Figure 3.6: The interaction of Dox-water was subtracted from Dox-beads, the top graph shows the DP of each injection (A) and 
bottom graph is the matching binding isotherms (B), with 43 mM Dox titrated into 100 mg water washed beads at 293, 298, 303, 
310 and 313 K (sample number = 3, error bars = standard deviation, time has been adjusted by two minutes so the details of each 
trace can be identified).  
293 K 298 K 303 K 310 K 313 K
A 
B 
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It was concluded that ITC was a suitable method for the investigation of drug-excipient binding 
interactions. Whilst studying the thermodynamic data of bead binding at different temperatures the 
average molar ratio (n) of Dox molecules bound to AMPS sites was 0.43:1 ± 0.02. Origin® displays 
incorrect n values as it sets the middle injection at half the molar ratio, a manual calculation of Dox to 
AMPS can be found earlier in this chapter and in a preceding paper 6. An R2 value of 0.12 demonstrated 
in Figure 3.7 suggests that there is no change in binding with a change in temperature and an ANOVA 
test provided evidence that there was no statistical significance within the population.  
 
 
Figure 3.7: Molar ratio of Dox to AMPS at temperatures of 293, 298, 303, 310 and 313 K (sample number = 3, error bars = 
standard deviation).  
 
The ratio of Dox bound to AMPS was expected to be much closer to 1:1 according to previous work 
completed by Gonzalez 3. It was suggested that as the ITC adds extremely small amounts of Dox over 
time, that Dox binds to the outside of the beads and prevents Dox from binding to the inside, which 
ultimately affects the binding ratio 6. However, on further investigation it seems that the preparation of 
beads is of immense importance, as explained in detail further in the chapter.  
Upon analysing the individual injections more closely it seems that at higher temperatures the 
reaction occurred at a faster rate, this was noted in Figure 3.8 and can be identified by the reduced time 
taken for the trace to reach the baseline after the injection. This occurs as Dox needs to diffuse into the 
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beads before interaction with the binding groups. Diffusion rate increases with temperature and this can 
only be seen in each individual injection since injected time is controlled, i.e. every 10 minutes.  
 
 
 
 
 
 
 
 
Figure 3.8: Illustration of the first injection in an ITC experiment where 20 µL of 10 mM Dox was titrated into 100 mg beads at 293 
K, unsubtracted trace (A) and Dox-water subtracted from Dox-bead (B).  
 
Note that the peak height of experiments at different temperatures varied due to the rate at which the 
experiment occurred, however peak area was comparable. At higher temperatures molecules move 
faster, the rate of diffusion is greater, the interaction occurs quicker and the peaks are more pronounced, 
but the total area at each temperature was the same as the amount of Dox bound to the beads at each 
temperature is equivalent. Occasionally Dox interacted with water more than with beads, producing a 
small initially endothermic signal before it exothermically interacted with beads, over time Dox was then 
293 K 313 K
A 
B 
84 
 
absorbed by beads switching the signal from endothermic to exothermic. This is apparent at 313 K in 
the unsubtracted trace and disappeared in the subtraction, but was evident at various temperatures in 
several runs possibly depending on the arrangement of binding sites within and on the surface of beads.  
Data in Table 3.3 indicates normal distribution and a significant difference was found using 
Minitab® software. This was used to calculate an unpaired t-test between the time taken for the reaction 
to complete in the first injection by the trace retrieving to the baseline at 293 and 313 K (p = 0.0049). At 
higher temperatures molecules move faster and an increase in collisions leads to more diffusion. This 
data shows that the reaction takes place over a shorter period of time, most likely as the drug finds 
binding sites quicker at higher temperatures within the range of 293 – 313 K.  
 
Table 3.3: Time taken for the first injection of an ITC experiment to return to the baseline at 293 and 313 K (sample number = 3, 
error = standard deviation).  
Temperature (K) Time to Reach Baseline (mins) Average Time (mins) 
293 
7.4 
8.6 ± 1.1 9.5 
9.0 
313 
4.5 
4.0 ± 0.9 4.6 
3.0 
 
Origin® calculates the thermodynamic values of stoichiometry (n), binding constant also known as the 
equilibrium constant (K (M-1)), enthalpy change (∆H (cal/mol)) and entropy change (∆S (cal/mol/deg)). 
K is associated with binding and unbinding of the receptor (R) and ligand (L) molecules in a reaction. If 
K >> 1 the product is favoured in the reaction and thus is spontaneous in the forward direction of 
Equation 3.2. If K << 1 the reactant is favoured and thus is non-spontaneous in the forward direction of 
Equation 3.2. If K ≈ 1 the system is at equilibrium and K is never a negative value for any given reaction. 
The average experimental value for K was 4.45 x 105 M-1 and in Table 3.4 there seemed to be no 
correlation between temperature and equilibria, however K is a function of temperature and the large 
error bars make this temperature effect inconclusive.  
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Equation 3.2: Binding (equilibrium) constant, where R is the receptor and L is the ligand.  
R + L ⇌ RL 
 
Table 3.4: Binding constant of Dox to AMPS at temperatures of 293, 298, 303, 310 and 313 K (sample number = 3, error = 
standard deviation).  
Temperature (K) K (x 105 M-1) 
293 0.25 ± 0.06 
298 6.43 ± 9.76 
303 0.44 ± 0.25 
310 7.29 ± 10.11 
313 7.82 ± 7.70 
 
Change in enthalpy is a measure of the heat content of a system, which can be released (exothermic) 
or absorbed (endothermic). At closer inspection of change in enthalpy there was in general a decline as 
the temperature increased in Figure 3.9 and R2 was close to 1 at 0.83. A statistical difference was noted 
between 293 and 313 K (p = 0.0016), showing that enthalpy change is temperature dependent. Binding 
was an exothermic process which became more exothermic upon an increase in temperature, as the 
change in free energy behind the partitioning phenomenon became more favourable.  
 
 
Figure 3.9: Enthalpy change of Dox to AMPS at temperatures of 293, 298, 303, 310 and 313 K (sample number = 3, error bars = 
standard deviation).  
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Entropy change is the measure of the disorder in a given system. As this was positive at each tested 
temperature with an average of 8.91 ± 4.24 kJ/mol.K in Table 3.5, entropy change thus increases as the 
reaction progresses and the change in entropy seemed not to be affected by temperature. As ∆S universe 
= ∆S system + ∆S surrounding = >0, the reactions are therefore spontaneous. If ∆S was equal to the measured 
reaction would be considered reversible at equilibrium.  
 
Table 3.5: Entropy change of Dox to AMPS at temperatures of 293, 298, 303, 310 and 313 K (sample number = 3, error = standard 
deviation).  
Temperature (K) T∆S (kJ/mol.K) 
293 6.59 ± 0.68 
298 13.53 ± 4.94 
303 4.51 ± 2.33 
310 10.40 ± 4.39 
313 9.55 ± 1.88 
 
As both change in enthalpy and change in entropy are known values as outputs from the software 
Origin®, the change in Gibbs free energy can be determined using Equation 3.3. This calculates the 
change in favourability of a reaction. Negative values in Table 3.6 with an average of -17.16 ± 4.34 
kJ/mol propose a spontaneous reaction in the forward direction of the equation, this indicates that there 
is no correlation between temperature and the change in free energy. The reactions are therefore not 
reversible in their current state, this statement is well documented as salt present in blood is required to 
release drug from the bead using an ion-exchange mechanism 7,8.  
 
Equation 3.3: Calculation of the change in Gibbs free energy, where ∆G is the change in Gibbs free energy, ∆H is the change in 
enthalpy, T is Temperature and ∆S is the change in entropy.  
ΔG = ΔH - TΔS 
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Table 3.6: Free energy change of Dox to AMPS at temperatures of 293, 298, 303, 310 and 313 K (sample number = 3, error = 
standard deviation).  
Temperature (K) ∆G (kJ/mol) 
293 -13.50 ± 0.60 
298 -20.32 ± 5.00 
303 -13.30 ± 2.39 
310 -19.07 ± 4.71 
313 -19.63 ± 2.53 
 
Spontaneity of a process can be determined when temperature and pressure are constant values using 
Table 3.7. As ∆H was negative, ∆S positive and ∆G negative for all temperatures, the reaction of Dox 
into water washed beads is always spontaneous regardless of the systems temperature.  
 
Table 3.7: Determining spontaneity of a system, colour blue corresponds to low temperature (L) and the red colour corresponds 
to high temperature (H).  
∆H ∆S T ∆G Spontaneity 
+ + L/H +/- 
Non-Spontaneous at Low 
Temperature/Spontaneous 
at High 
+ - L/H + 
 
Always Non-Spontaneous 
 
- + L/H - 
 
Always Spontaneous 
 
- - L/H -/+ 
Spontaneous at Low 
Temperature/Non-
Spontaneous at High 
 
The interaction of Dox-water has been subtracted from the interaction between Dox solubilised in water 
and titrated into beads in water. Due to unforeseen circumstances with the equipment Dox into water 
was only completed once at each temperature, however enthalpy change was plotted to ensure correct 
values were obtained. As R2 specified in Figure 3.10 is equal to 0.99 it was sufficient assurance for a 
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sample number of 1. Each signal in the thermodynamic profile for water titrated into beads in Figure 
3.11 was <0.1 µcal/sec, signifying that no binding was present.  
 
 
Figure 3.10: Enthalpy change of Dox to water at temperatures of 293, 298, 303, 310 and 313 K (sample number = 1).  
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Figure 3.11: Isotherm of water into beads at 293 (A) and 313 K (B).  
 
3.2.2. Binding Ratio Study  
The ratio of Dox molecules to SO3- groups was previously reported to be 0.42:1 with a standard deviation 
of 0.02 6, however a further study found the ratio much closer to data obtained by Gonzales using UV-
Vis where the binding ratio was quantified as 0.836:1 and a standard deviation of 0.377 3.  
A B 
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Firstly, it was ascertained that the presents of residual Decon® existed in the temperature 
experiments. The manual suggests washing the ITC cell with 200 – 400 mL of detergent and rinsing 
with 300 mL of water. By thoroughly washing the cell with at least 1 L of water and removing all traces 
of Decon® a decrease in binding was observed. Higher ratios were then obtained by washing the beads 
in hydrochloric acid (HCl). The beads arrive stored in saline and it was believed that washing the beads 
in deionised water during the first study removed free excess sodium ions from around the beads, but 
that sodium ions bound within the bead would remain and interfere with bead binding properties. 
Different washing processes were found to produce varying results. Washing the beads in acid improved 
reproducibly and led to an increased drug-bead interaction. This acid washing step does not take place 
in the clinic and yet a similar binding ratio was achieved which was demonstrated by the UV method. 
However, in the clinic Dox is loaded into beads in one simple step where a high concentration of drug is 
added in one go, whereas the ITC injects small amounts of Dox over time. The concentration of Dox in 
the one step process could drive the Dox-bead interaction. Washing the beads in 2 M HCl exchanges 
the sodium for a proton. The hydrogen bond on the protonated bead is weaker, less energy is required 
to break the bond and it is therefore easier for Dox to displace than the ionic bond on the sodium ion.  
 The water content changed when acid washed beads compared with water washed beads and 
the results can be found in Table 3.8. The new percentage solid content value of 6 % was replaced with 
3 % in the molar ratio calculations for all further analysis.  
 
Table 3.8: The percentage solid content of DC BeadM1™ in HCl prepared for the ITC (sample number = 3).  
Weight of Empty 
Insert (mg) 
Weight of Wet Beads 
+ insert (mg) 
Weight of Dry Beads 
+ Insert (mg) 
% Water Content % Solid Content 
906.97 1153.46 921.71 94.02 5.98 
887.76 1150.71 903.40 94.05 5.95 
922.57 1149.20 935.91 94.11 5.89 
 
Figure 3.12 illustrates Dox binding to sulfonic acid on the bead in contrast with a sulfonate salt. It was 
difficult to determine the endpoint of bead loading using a change in exothermic to endothermic signal 
with this new method of bead preparation. Consequently, the highest ΔH value was used as the point 
of bead saturation where there was a plateau or fall in ΔH after this point. The ratio of Dox to acid 
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washed beads was 0.81:1, whereas Dox to water washed beads with no Decon® present was 0.29:1 
(water washed beads data varied greatly but for clarity not all data is shown). Clearly there was an 
increase in activity with the elimination of ions when using the ITC.  
 
 
 
 
 
 
 
 
Figure 3.12: 43 mM Dox titrated into 100 mg water washed beads and 100 mg acid washed beads (sample number = 1, time 
has been adjusted by two minutes so the details of each trace can be identified).  
 
Binding constant is an indication of the extent of binding interaction in that the larger the K value the 
greater the binding affinity. The binding constants for both preparations of beads are given in Table 3.9. 
The affinity was much smaller in the acid washed sample, therefore the extent of binding appears to be 
greater in the water washed beads. This is a consequence of the extended binding event observed in 
the water washed sample and does not reflect the fact that acid washed beads are available for binding.  
Water Washed Acid Washed
A 
B 
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Table 3.9: Binding constant of Dox to AMPS with beads washed in either water or acid (sample number = 1).  
Bead Preparation K (M-1) 
Water Washed 7.73 x 108 
Acid Washed 1.19 x 104 
 
The thermodynamic data for the two washing preparations of beads is available in Figure 3.13. Both 
bead preparations were discovered to be exothermic, but water washed beads released a greater 
amount of heat than acid washed beads. Consequently, more energy was required to break the bonds 
in the water washed sample when sodium ions were present in comparison to hydrogen ions in the acid 
washed sample. The entropy change for water washed beads was negative and for acid washed beads 
was positive. This reveals that for the water washed sample change in entropy decreased towards the 
product, whereas entropy change of the system increased in the acid washed sample resulting in a 
much more spontaneous reaction. This is possible because more protons are released from the acid 
washed beads and hence entropy is greater. The change in free energy is negative, and so is 
spontaneous in the forward direction and subsequently non-spontaneous in the reverse.  
 
 
Figure 3.13: Thermodynamics of Dox to AMPS with beads washed in either water or acid (sample number = 1).  
 
As ∆H, ∆S and ∆G were negative for water washed beads the reaction is spontaneous at low 
temperature and non-spontaneous at high, in these experiments the temperature was relatively low and 
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so the process was spontaneous. For acid washed beads ∆H was negative, ∆S positive and ∆G 
negative, and so the reaction was always spontaneous regardless of the systems temperature. Binding 
affinity is influenced by non-covalent intermolecular interactions such as electrostatic interactions, 
hydrogen bonding, hydrophobic and Val der Waals forces between the two molecules 9. The 
thermodynamics of water washed beads indicate favourable hydrogen and hydrophobic interaction, 
whilst acid washed beads exhibit good hydrogen bonding with unfavourable conformational change. 
The reaction of water washed beads was enthalpically driven, whereas acid washed beads were both 
enthalpically and entropically driven. The enthalpy contribution is due to hydrogen bonding, electrostatic 
and van der Waals interactions. The entropy contribution is due to due to hydrophobic interactions. 
Moreover, water molecules which surround the bead binding sites are replaced by the drug and the 
bead changes conformation during binding to create binding sites which can accommodate the drug. 
This is exactly what is known to happen during the drug loading process of DEBs and is another 
indication that binding occurs as expected in the acid washed sample 10,11.  
This study was to identify the binding characteristics and provide a method whereby different 
types of bead can be distinguished. It was not to mimic the binding method produced in the clinic, and 
so this technique provides a way of understanding the drug-excipient interaction and a possibility of 
demonstrating the binding properties of different beads. It would be easier for future analysis to 
differentiate between different product and types of binding with a method that produces a higher binding 
ratio, and so the process of washing the beads with 2 M HCl was adopted as the preferred technique.  
Without washing the beads very small interactions were seen, as when sodium ions are 
replaced with hydrogen a greater amount of Dox has the potential to bind. The strong binding of the 
sodium ion with the sulfonic group may need to absorb more energy to exchange with Dox in comparison 
to hydrogen. The protonated form of the bead has a non-ionic bond, which is weaker and will need to 
absorb less energy to exchange with Dox compared with the ionic bond between sodium and the bead. 
The energy required for Dox to exchange with sodium compared with Dox to exchange with a proton is 
larger and may not be detectable in the current method. Standard enthalpy of formation for the cation 
sodium (Na+) was discovered in various literature to be -239.7 and -240.34 kJ/mol in a 1 M aqueous 
solution at 298 K, the compound sulfur trioxide (SO3) was exposes to be -395.2 and -395.7 kJ/mol under 
the same conditions and the anion hydroxide (OH-) was revealed as -229.9 and -230.015 kJ/mol 12,13. 
As values for Na+ are greater than OH- more energy is required for breaking bonds with SO3.  
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3.2.3. Effect of pH  
Dox has six pKa values of 8.1, 9.8, 11.8, 13.6, 14.2 and 15.7 as illustrated in Figure 3.14 in its protonated 
form. To confirm whether binding was a result of a change in pH of the beads, the pH of Dox was altered 
to the same pH of the acid washed beads. The pH of 43 mM Dox was 3.788, the pH of water washed 
beads in 1.4194 mL water was 5.612 and 100 mg of acid washed beads in 1.4194 mL water was pH 
1.824. At pH 3.8 and 1.8 the ionisation of the amine group on Dox theoretically corresponded to 99.99 
and 100 %, respectively. The pH of the Dox solution was consequently adjusted to 1.8 with the addition 
of HCl. The pH of the beads was not increased to 3.8 as this would have involved the addition of ionic 
compounds such as sodium hydroxide (NaOH), which would have led to the inhibition of Dox binding.  
In another experiment the pH of water washed beads was decreased to 1.8, whilst the pH of 
Dox was unchanged at 3.8. This was to reveal whether the presence of acid rather than the removal of 
sodium was the result of the exothermic response. A similar amount of Dox was bound to the beads 
when the pH of Dox was 1.8 compared with the pH of Dox remaining unchanged, as the ratio was 0.94:1 
this indicates that the results are not the effect of an acid-base titration. On the other hand, the baseline 
drifted from ~0 to ~15 µcal/sec in the raw data profile producing unreliable thermodynamic parameters 
and suspected isotherm imperfections. Less binding was observed in the experiment where the cell was 
filled with water washed beads and pH 1.8 deionised water, the ratio was reduced to 0.72:1 showing 
that the presence of HCl may have removed some but not all the ions from the beads, and therefore the 
results were not the cause of acid but the insufficient removal of ions demonstrated in Figure 3.15.  
 
       
Figure 3.14: Structure and pKa groups of Dox (left) and plot of net charge versus pH (right) 14.  
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Figure 3.15: 43 mM Dox unchanged pH (3.8) into 100 mg water washed beads altered to pH 1.8, and 43 mM Dox adjusted to pH 
1.8 into unchanged pH (1.8) 100 mg acid washed beads (sample number = 1, time has been adjusted by two minutes so the 
details of each trace can be identified).  
 
The binding constant displayed in Table 3.10 is much smaller in the sample where the pH of Dox had 
been altered to 1.8 with acid washed beads which innately had a pH of 3.8, in comparison to the pH 3.8 
Dox with water washed beads altered to pH 1.8. Combined with Table 3.9 the data revealed that the 
binding constant was reduced in the presence of a lower pH, however binding was weaker with acid 
washed beads, thought to be a consequence of the extended binding event observed in the water 
washed samples and does not reflect the fact that acid washed beads are available for binding.  
 
 
Altered pH 1.8 Dox in acid washed beads at pH 1.8
Unchanged pH 3.8 Dox in water washed beads altered to pH 1.8
A 
B 
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Table 3.10: Binding constant of Dox to AMPS at different pH values (sample number = 1).  
Drug and Bead Preparation K (M-1) 
Altered pH 1.8 Dox into acid washed beads at pH 1.8 8.62 x 102 
pH 3.8 Dox into water washed beads altered to pH 1.8 1.74 x 104 
 
Thermodynamic data of Dox at pH 3.8 into water washed beads at pH 1.8 and of Dox at pH 1.8 into acid 
washed beads at pH 1.8 is expressed in Figure 3.16. The change in enthalpy was similar at both pH’s 
and a negative value stipulates an exothermic reaction. A negative entropy change with pH 1.8 Dox 
indicates that the disorder of a system decreases as the reaction develops, a positive entropy change 
with pH 3.8 Dox illustrates the system has a more disorder spontaneous state. The change in Gibbs 
free energy with Dox at pH 1.8 is a positive value implying a non-spontaneous process in the forward 
direction and with Dox at pH 3.8 is a negative value implying a spontaneous event in the forward route.  
 
 
Figure 3.16: Thermodynamics of Dox to AMPS binding with Dox at different pH values (sample number = 1).  
 
The experiment conducted with Dox at pH 3.8 had a negative ∆H, positive ∆S and negative ∆G, thus 
the process is spontaneous at all temperatures. The experiment conducted with Dox at pH 1.8 was also 
spontaneous, but only at low temperatures as ∆H and ∆S were both negative whilst ∆G was positive. 
Dox at pH 3.8 exhibits good hydrogen bonding with unfavourable conformational change. The Dox at 
pH 3.8 experiment is both entropically and enthalpically driven, whereas Dox at pH 1.8 is entropically 
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unfavourable. This means the reaction is not spontaneous and therefore cannot occur, it is possible that 
a shift in the baseline caused by the pH being too far away from neutral has produced unreliable results.  
 
3.2.4. Effect of Concentration  
Signal size is partially related to concentration and can be modified to some extent by varying the volume 
and concentration per injection. Based on initial experiments it was difficult to identify measurable 
signals using 14 injections with each injection 20 µL of 10 mM and 43 mM Dox into water washed beads. 
However, upon reducing this to 2 injections of 10, 20, 30 and 43 mM Dox where each injection was 140 
µL, this produced signals above the equipment detection limit. The number of beads in the experiment 
was designed to form an exothermic and endothermic peak as expressed in Figure 3.17. An increase 
in signal strength was discovered as the concentration increased. The first injection generated two 
exothermic peaks, which can clearly be identified in the raw data. The first interaction shoulders a 
second, once Dox-water has been subtracted from Dox-beads. This indicates two binding events that 
could be attributed to either Dox diffusing through the bead, the collapsing of the PVA structure 
preventing some Dox from internal binding or the distance between Dox-Dox groups changing as bead 
stiffness and compressibility transform. Gonzales defined two distinctive densities of matter 
concentrated around the external and the internal structure of the bead using a scanning electron 
microscope (SEM), and the microscopic image is illustrated in Figure 3.18 3. The first peak could be Dox 
binding to the denser more crosslinked outer structure, Dox then diffuses through the concentrated layer 
of SO3- and a second peak occurs as Dox then binds to the inner less dense less crosslinked matter. 
As the outer layer is more crosslinked the binding event would be more intense than the second. The 
endothermic peak in the raw data is the interaction of Dox with water.  
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Figure 3.17: Raw ITC data (left) and subtracted ITC trace (right) of 2 injections of 10, 20, 30 and 43 mM Dox into a respective 
mass of 15, 30, 40 and 60 mg water washed beads, where each injection was 140 µL to obtain one exothermic and one 
endothermic response, inset is a rescaled graph of the shouldering peak (sample number = 1).  
 
 
Figure 3.18: SEM image displaying the internal and external structure of a bead 3.  
 
An investigation was then conducted where the injection number was increased with 10 mM Dox to 
discover the concentration required to create visible binding. Dox binding was present in Figure 3.19 
with 2 injections of 140 µL of 10 mM Dox, 4 injections of 70 µL 10 mM Dox and 7 injections of 40 µL 10 
mM Dox. Significantly less binding was observed with 14 injections of 20 µL 10 mM Dox, and so 40 µL 
of 10 mM Dox was required for binding without acid washing to protonate the beads. As analysis requires 
10 – 15 injections to define a binding isotherm the molar ratios calculated in Table 3.11 are estimations, 
however it seems that with higher concentrations of drug there is more competition of binding.  
 
External Layer 
Internal Layer 
10 mM 20 mM 30 mM 43 mM
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Figure 3.19: 2, 4, 7 and 14 injections of 10 mM Dox into water washed beads (sample number = 1, time has been adjusted by the 
addition of two minutes per injection profile so the details of each trace is displayed).  
 
Table 3.11: Estimated molar ratios of 2, 4, 7 and 14 injections of 10 mM Dox into water washed beads (sample number = 1).  
Number of Injections in 
Experiment 
Injection Volume (µL) 
Injection Number at Point 
of Bead Saturation 
Molar Ratio 
2 140 1 0.88:1 
4 70 2 0.90:1 
7 40 5 0.88:1 
14 20 6 0.21:1 
 
As Dox was injected into the beads two effects were seen; initially Dox interacted with water breaking 
Dox-Dox bonds (an endothermic event), Dox then immediately bound to beads and bonds were formed 
(an exothermic event). As the experiment continued and more Dox was bound to the beads the time 
taken for the signal to reach the baseline increased. This could be due to Dox requiring time to diffuse 
through the bead when surface binding sites are occupied. The endothermic signal increased during the 
experiment as the exothermic signals decreased, this might also be due to the occupation of beads 
sites. Eventually, as beads become saturated during the experiment only the effects of Dox interacting 
with water can be seen through endothermic signals, here the change in enthalpy decreased and this 
point was used for the calculation of Dox bound to beads. If this wasn’t seen within the 14 injections of 
the experiment the syringe was reloaded and the experiment was started again with the same sample 
2 injections 4 injections 7 injections 14 injections
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in the cell until saturation of the beads occurred. The interaction of Dox-water was subtracted from Dox-
beads, the interaction of water-beads was negligible and so was not required in the subtraction equation.  
In Figure 3.20 with an increase in beads from 25 to 50 and 100 mg a similar ratio was calculated, 
but larger heat signals were detected because there were more beads for the drug to interact with. Four 
titrations of 10 mM Dox were required for saturation of 100 mg beads, two titrations of 10 mM Dox for 
50 mg beads and one titration of 10 mM Dox for 25 mg beads. Where each titration was fit together the 
adjoining connection was visible, this could be due to experiments situated in the cell for an extensive 
period of time before another titration was initialised, the impact of which is not fully understood.   
 
 
 
 
 
 
 
 
Figure 3.20: 10 mM Dox to 25, 50 and 100 mg beads with inset graph of 25 mg exposing the time taken for each injection to return 
to the baseline (sample number = 3, error bars = standard deviation, time has been adjusted by the addition of two minutes per 
mass profile so the details of each trace is displayed).  
25 mg 50 mg 100 mg
A 
B 
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Although the ratio of Dox bound to AMPS increased with mass of beads in Figure 3.21, an increase in 
bead mass most likely improved the reproducibility of the experiment. Some beads were lost outside 
the sample cell and mass variation will contribute a larger error with a smaller number of beads, therefore 
100 mg was a preferred bead mass rather than 25 mg. An average calculated resultant ratio of 0.86:1 
is similar to the value of 0.836:1 reported by Gonzales using UV-Vis, however the standard deviation of 
0.09 was much smaller than the previous work of 0.377.  
 
 
Figure 3.21: Molar ratio of Dox to AMPS with 10 mM Dox and 25, 50 and 100 mg beads (sample number = 3, error bars = standard 
deviation).  
 
The average binding constant of 10 mM Dox into 25, 50 and 100 mg beads was 1.62 x 104, and the data 
exhibited in Table 3.12 exposes no correlation between bead mass and binding affinity.  
 
Table 3.12: Binding constant of Dox to AMPS with 10 mM Dox and 25, 50 and 100 mg beads (sample number = 3, error = standard 
deviation).  
Bead Mass (mg) K (x 104 M-1) 
25 2.53 ± 1.63 
50 1.27 ± 0.13 
100 1.07 ± 0.76 
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All integers for enthalpy change were negative and increased with bead mass, yet there are only three 
data points therefore more experimental data is required to verify this statement. Entropy change also 
increased with bead mass and a positive change in entropy shows that the reaction was spontaneous 
in the forward direction. Yet again, with three data points and larger error bars more data requires 
collection to verify this statement. The change in free energy was negative and implies a spontaneous 
system, the data infers no relationship with bead mass. Thermodynamic data for bead mass is 
expressed in Figure 3.22 and demonstrates that ∆H is negative, ∆S positive and ∆G negative in all bead 
masses, consequently the reaction is always spontaneous regardless of the systems temperature. All 
reactions were enthalpically and entropically driven, which includes hydrogen bonding, electrostatic, van 
der Waals and hydrophobic interactions resulting in conformational changes.  
 
 
Figure 3.22: Thermodynamics of 10 mM Dox to 25, 50 and 100 mg beads (sample number = 3, error bars = standard deviation).  
 
With higher concentrations of Dox such as 30 and 43 mM, two exothermic effects were recognised with 
one injection. With a more concentrated solution there was a large, sharp and rapid exothermic signal 
with a shallower, broader exothermic signal. The first exothermic signal is thought to be Dox binding to 
the surface of the bead, the second exothermic signal is then thought to be Dox penetrating the internal 
sites which was a much slower and less intense binding process. The break between these two signals 
is the time taken for the drug to diffuse through the hydrogel. As the experiment continued the two 
exothermic signals merged as there were less surface groups. Ultimately, the experiment developed in 
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a similar manner to the previously described test such as 10 and 20 mM Dox, with decreasing 
exothermic signals and emerging endothermic signals.  
With an increase in Dox from 10 to 20, 30 and 43 mM in Figure 3.23 a similar ratio was 
calculated, but larger heat signals were detected with an increase in concentration because there were 
more Dox molecules for the beads to interact with. Most binding isotherms are sigmoidal, however the 
trace for Dox into beads has a rapid uptake in the initial section of the curve. One explanation could be 
the structure of the bead and how the surface differs from the internal segment. As the external layer is 
more crosslinked Dox would bind more tightly, with greater energy and would encounter this primarily. 
As this section becomes more saturated Dox binds to the less crosslinked internal layer with less energy.  
 
 
 
 
 
 
 
 
Figure 3.23: 10, 20, 30 and 43 mM Dox to 100 mg beads with inset graph of the first injection at 43mM (sample number = 3, error 
bars = standard deviation, time has been adjusted by the addition of two minutes per concentration profile so the details of each 
trace is displayed).  
10 mM 20 mM 30 mM 43 mM
A 
B 
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The average molar ratio for Dox at different concentrations was slightly higher than beads at different 
masses, with an average ratio of 0.94:1 ± 0.06 exhibited in Figure 3.24. Nevertheless, the difference by 
conventional criteria is not considered statistically significant (p = 0.0911), and the data suggests no 
relationship between molar ratio and drug concentration.  
 
 
Figure 3.24: Molar ratio of Dox to AMPS with 100 mg beads and 10, 20, 30 and 43 mM Dox (sample number = 3, error bars = 
standard deviation).  
 
Table 3.13 presents the average binding constant of 10, 20, 30 and 43 mM Dox into 100 mg beads 
which was 8.17 x 103, and indicates no correlation between drug concentration and binding strength.  
 
Table 3.13: Binding constant of Dox to AMPS with 100 mg beads and 10, 20, 30 and 43 mM Dox (sample number = 3, error = 
standard deviation).  
Drug Concentration (mg) K (x 104 M-1) 
10 1.07 ± 0.76 
20 0.49 ± 0.24 
30 0.87 ± 0.14 
43 0.84 ± 0.51 
 
The values for enthalpy change were negative and so binding was exothermic. The data insinuates that 
the change in enthalpy increased with concentration of drug, however more data is required to validate 
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this statement. A positive change in entropy infers a spontaneous reaction as the experiment proceeds. 
The calculated change in entropy also increased as the concentration of drug increases, nevertheless 
the error bars at 43 mM are rather large and need further investigation. The values for changes in Gibbs 
free energy were negative and decreased as the concentration of drug increased, but again the errors 
bars of 43 mM were particularly large in comparison with other values for this assumption. Like the data 
for bead mass Figure 3.25 reveals ∆H is negative, ∆S is positive and ∆G is negative, the experiments 
studied were therefore spontaneous at both low and high temperatures. At each drug concentration the 
reactions were enthalpically and entropically driven, which includes hydrogen bonding, electrostatic, van 
der Waals and hydrophobic interactions resulting in conformational changes.  
 
 
Figure 3.25: Thermodynamics of 10, 20, 30 and 43 mM Dox to 100 mg beads (sample number = 3, error bars = standard deviation).  
 
Illustrated in Figure 3.26 is enthalpy change of experiments performed with Dox titrated into water 
examined against concentration to determine how precise and accurate results were gathered for 
subtraction from Dox into beads. R2 was 0.98 and so it was decided that a sample number of 1 was an 
acceptable collection of data. It is worth noting that 10 mM Dox into water includes four titrations of 280 
µL, 20 mM and 30 mM include two titrations of 280 µL and 43 mM includes one titration of 280 µL. 
Change in enthalpy decreases with an increase in drug concentration because Dox aggregates 
depending upon the concentration, which in-turn alters the thermodynamic processes. Aggregation 
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occurs to a greater extent at higher concentrations allowing Dox-Dox bonds to be broken and then 
formed, which is limited at the lower concentrations.  
 
 
Figure 3.26: Enthalpy of Dox to water at selected concentrations of 10, 20, 30 and 43 mM (sample number = 1).  
 
3.2.5. Effect of Volume and Number of Injections  
With an increase in the volume of each injection the number of injections must decrease, as the syringe 
has a set capacity. Decreasing the number of injections decreases the accuracy, as the drug-bead ratio 
can only be accurate to one injection. In other words, one more or one less injection when the total 
number of injections is reduced has a much larger effect on the binding ratio. With an increase in the 
number of injection there is less change in DP between injections and so a greater error incurs due to 
the inability to pin point the number of injection required to saturate the beads. To maintain experimental 
success there was a decrease in the amount of beads loaded into the sample cell when the volume of 
injection decreased, this could contribute to the difficulty in determining the saturation point and the error 
associated with a small sample. Malvern Instruments Inc (the manufacturer of the ITC), recommends 
that for reproducible results the total number of injections should be 10 – 15 to define a binding isotherm. 
An injection volume generally of 3 – 15 µL is required to ensure high volumetric accuracy, signals above 
the sensitivity of the VP-ITC which is 0.1 µcal/sec but preferably heat of at least 3 – 5 µcal/sec absorbed 
or evolved for precise measurements and a c value between 5 – 500 for ideal measurements of K 5.  
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Since the time between injections could not be adjusted from 600 seconds to allow the signal 
to retrieve back to the baseline, a 2 injection experiment takes 20 minutes to complete, whereas a 290 
injection experiment requires at least 48 hours 20 minutes, as illustrated in Figures 3.27 and 3.28, 
respectively. It was therefore possible to finish three experiments in one working day, including cleaning, 
preparation and equilibration time, hence for practical feasibility 14 injections were chosen as the 
appropriate length of study. To improve the accuracy of the test experiments could have been increased 
to 29 injections, which would have taken 4 hours 40 minutes for the run to terminate.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: 10 mM Dox to 25 mg beads with 2, 4, 7 and 14 injection binding isotherm (sample number = 1, time has been adjusted 
by the addition of two minutes per injection profile so the details of each trace is displayed).  
 
2 injections 4 injections 7 injections 14 injections
A 
B 
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Figure 3.28: 10 mM Dox to 25 mg beads with 29, 58, 145 and 290 injection binding isotherm (sample number = 1, time has been 
adjusted by the addition of two minutes per injection profile so the details of each trace is displayed).  
 
The data in Table 3.14 confirms that an injection volume of 1 and 2 µL is an inappropriate use of the 
instrument. An early 7 injection experiment gave a ratio 1.26:1 (data not shown) proving that too few 
injections runs a risk of over or under shooting the ratio by a large amount, as the ratio can only be 
accurate to one injection. A suitable number of injections was found to be between 14 and 58.  
 
 
 
 
29 injections 58 injections 145 injections 290 injections
A 
B 
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Table 3.14: Molar ratio of 10 mM Dox to 25 mg beads with different numbers of injections (sample number = 1).  
Number of Injections Injection Volume (µL) Ratio of Dox to AMPS Experimental Time 
2 140 0.88:1 20 min 
4 70 0.84:1 40 min 
7 40 0.71:1 1 h 10 min 
14 20 0.79:1 2 h 20 min 
29 10 0.73:1 4 h 50 min 
58 5 0.83:1 9 h 40 min 
145 2 0.49:1 24 h 10 min 
290 1 0.60:1 48 h 20 min 
 
Table 3.15 lists calculated c values, this number determines the shape of the binding isotherm using 
Equation 3.4, where K is the binding constant, Mtot is the total macromolecule concentration and n is 
stoichiometry. An ideal c value for measuring K is between 5 and 500 5. This means anything above 7 
injections provided an adequate c, however in 145 and 290 injections there were a number of 
imperfections, and it was difficult to determine the point of bead saturation. As the manual for this 
equipment suggests, this many injections cannot be recommended. The volume in 2 – 7 injections was 
too large, and so over saturation and under saturation was common (data not shown). As stated in the 
manual a preference would be to set the instrument parameters with 5 – 20 µL of reactant per injection, 
which allows for 14 – 58 injections with a one syringe loaded test.  
 
Equation 3.4: Calculation of c, where c is the shape of the binding isotherm, K is the binding constant, Mtot is the total 
macromolecule concentration and n is stoichiometry.  
c = K Mtot n 
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Table 3.15: c values of 10 mM Dox to 25 mg beads with different numbers of injections (sample number = 1).  
Number of Injections C 
2 43736 
4 8034 
7 49 
14 59 
29 39 
58 26 
145 130 
290 46 
 
3.2.6. Saturation, Aggregation and Limit of Detection (LOD) Study  
Origin® software identifies the midpoint of the sigmoidal ITC trace as n, this is used by many in literature 
at the molar ratio, as these reactions are reversible it would be correct to use the point of equilibrium. 
However, the reactions in this study were not reversible without intervention, i.e. the addition of salt 
occurring naturally in blood elutes drug from the bead. It is for this reason the point where the change 
in enthalpy decreased was believed to be where Dox interacted with water after beads were fully loaded.  
 To check whether this was indeed the case a standard experiment was conducted of 43 mM 
Dox into 100 mg DC Beads™. A deviation was made whereby the experiment was discontinued midway 
on the 7th 20 µL injection, where the Origin® molar ratio was around 0.55 (close to the point where the 
software stated was equal to n), indicated by an example ITC trace in the red boxed sections of Figure 
3.29. The residual solution, as well as beads were collected from the ITC sample cell. Dox was then 
extracted from the sample with a 20 % (w/v) potassium chloride (KCl) solution into 50:50 (v/v) ethanol 
(see Chapter 2 for extraction solution preparation). Standard samples, the ITC residual solution and 
extracted sample were analysed on the UV-Vis spectrophotometer.  
The amount of Dox calculated to have entered the cell and expected to be in the beads was 3.5 
mg/mL. The amount of Dox extracted from the beads was 3.2124 mg/mL and the amount in the residual 
solution was 0.0101 mg/mL, which equates to 92 % of the titrated solution. 8 % could have been lost 
during removal of the sample from the ITC or bound to the ITC cell. The amount of Dox was equivalent 
to 5.54 mM into 11.30 mM AMPS, a ratio of 0.49:1. Therefore, the software calculation of n at ~0.55 (the 
midpoint of the sigmoidal curve) was not the point of bead saturation as would be expected for an 
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equilibrium reaction. The endpoint was then much further on and since the absorbance matched close 
to the expected value of 0.53:1 when the concentration of Dox titrated into the cell should have been 
6.03 mM into 11.30 mM AMPS, this confirmed that the top of the sigmoidal curve (and not the middle) 
is the saturation point closer to the expected 1:1 ratio.  
A report found that dimers were formed at 0.1 mg/mL in Dox solution and 1.0 mg/mL in Dox 
loaded beads 15,16, the studies in this document contained Dox at concentrations of 58 – 580 mg/mL. 
Therefore, these concentrations of Dox in aqueous solution will self-associate to form aggregate 
structures of dimers and trimer though π-π hydrophobic stacking of the dihydroxyanthraquinone ring.  
 
 
 
 
 
 
 
 
Figure 3.29: Saturation test to determine the concentration of Dox at midpoint of experiment (sample number = 1).  
 
Actual Expected
A 
B 
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It is well known that Dox aggregates 16, a test for confirmation was conducted where water was titrated 
into 43 mM Dox. Figure 3.30 is a clear example of a non-constant monotonously decreasing heat of 
dilution without sigmoidal behaviour, suggesting Dox self-association in this solution. The absence of 
sigmoidal behaviour suggests Dox does not self-associate cooperatively.  
 
 
Figure 3.30: Aggregation test to determine the formation of Dox (sample number = 1).  
 
In Figure 3.31 1 µL of 10 mM Dox into the ITC cell initially produced a signal intensity of ~0.19 µcal/cec, 
the first injection is not included as this can be inaccurate especially as such low concentrations. The 
ITC LOD is known to be 0.1 µcal/sec, so 1 µL of 10 mM Dox is close to this limit. As the cell contained 
1.4194 mL deionised water and the mass of Dox in one injection is known to be 0.58 µg, the 
concentration in the cell was 704.41 nM. The amount of Dox could be further reduced to reach 0.1 
µcal/sec, but this experiment does show that any interaction of 0.58 µg Dox should be visible. However, 
Dox signals decrease due to aggregation and this should be considered when working at such low 
concentrations. This information will prove useful when analysing the interactions with different types of 
beads and comparisons with different types of drugs.  
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Figure 3.31: 1 mM Dox into deionised water with 290 injections and each injecton a volume of 1 µl, inset is a closer view of the 
first five injections (sample number = 1).  
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3.3. Conclusion  
Although temperature didn’t affect the binding ratio of Dox to beads it did affect the rate of reaction, 
which can be seen in each injection by the length of time taken for the reaction to complete. At higher 
temperatures there were a larger number of high energy collisions, as molecules move faster, collisions 
were more frequent and diffusion was quicker, which resulted in an increase in the rate of the reaction.  
 It was thought that the binding ratio of AMPS to Dox was 0.42:1 with a standard deviation of 
0.02, however removing the sodium ions from the beads by washing them in 2 M HCl increased the 
binding to 0.90:1 and a standard deviation of 0.09, when both bead mass and drug concentration results 
were combined. As previously explained the packing solution of the DEBs must be removed before the 
mixture of chemotherapeutic agent is loaded, this packing solution contain sodium chloride and sodium 
ions interfere with drug-bead binding. Larger concentrations of drugs achieved saturation by adding the 
drug in one stage, such as those used when preparing the device for patient use. This could drive the 
Dox-bead binding interaction without the need of acid washing, which has been reported by Gonzales 
to be 0.836:1 3. Not only has the ITC method found the binding 0.90:1 to be slightly higher than previously 
reported, but the standard deviation was much lower at 0.09 compared with the UV method of 0.377 3, 
showing that the new method is more precise and accurate in comparison with UV analysis.  
Dox at pH 4 and water washed beads adjusted to pH 2 the stoichiometry decreased in 
comparison to acid washed beads, which confirmed that the response was not an acid-base titration 
and that the presence of acid does not create the results. Altering the pH of Dox to 2, which then matched 
the pH of acid washed beads, caused a drift in the baseline which started 15 µcal/sec higher than it was 
set and continued drifting during the run. A drift larger than 1 µcal/sec is not considered suitable fitting.  
Once the binding ratio had been identified Origin software® was employed to calculate K, ΔH 
and ΔS, then from this calculate ΔG. Output values for n were not suitable for analysis, as the reactions 
in these instances without the presence of salt were not reversible. The software takes the midpoint of 
the reaction as equilibrium, but of interest in these circumstances was the endpoint, hence n was 
calculated manually. The data was analysed to determine the stoichiometry of the drug–polymer 
interaction and the highest molar ratio was reported with the beads washed in acid.  
Spontaneity is related to enthalpy change, entropy change and change in free energy of binding 
associated with the interaction. In the experiments where residual Decon® was suspected to be present 
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the reaction was considered spontaneous at all temperatures, water washed beads were spontaneous 
only at low temperatures and acid washed beads were spontaneous at both low and high temperatures.  
An increase in the molar ratio was expressed with an increase in bead mass, a correlation could 
be due to a small number of beads being lost as they were placed into the sample cell. With a small 
sample the percentage of beads lost outside of the sample port would be greater than a larger sample. 
The binding interaction was independent of concentration. 10 mM Dox to 25 mg beads and 43 mM Dox 
to 100 mg beads were preferred, as saturation occurred in one experiment without the syringe being re-
filled for additional titrations. The binding constant appeared independent of temperature, bead mass 
and drug concentration. The change in enthalpy decreased with temperature, alternatively it increased 
with both bead mass and drug concentration. While a conclusive statement cannot be made as, this 
does indicate that temperature, mass and concentration could affect enthalpy, yet this needs additional 
work as the sample number was small. An increase in the change in enthalpy during temperature could 
be connected to an increase in endothermic signals in the reaction of Dox to water. As temperature 
increased and more heat was absorbed into the system, the drug into bead reaction consequently 
became more exothermic. Correspondingly, in the mass and concentration experiments the Dox to 
water interaction became less endothermic and so the exothermic signals of Dox to bead became more 
endothermic. The change in entropy was also an independent variable for the temperature, whereas for 
beads mass and drug concentration although some relationship was possible, when the data was 
gathered together large error bars prevented stating that the change in entropy increased by the 
increase of either of these variables. Any increase in entropy change with an increase in mass and 
concentration could be attributed to an increase in the number of molecules in the system. The energy 
available in the system to do useful work seems an independent variable in the temperature study and 
in bead mass, though for an increase in drug concentration there was a decline in the Gibbs free energy 
change, nonetheless this could be due to large error bars in one of the data points. Although often 
conducted, technically three data points are not enough for an exact calculation standard deviation, 
replicating some of this work would remedy these queries.  
At least 14 injections, each 20 µL, were found mandatory to provide accurate data. Less 
injections would require an increase in volume to saturate the beads and this would dramatically shift 
the ratio. More injections than 58 would decrease the volume and in-turn decrease the signal size, 
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forcing the change in exothermic to endothermic peaks to be much more difficult to discover, and 
consequently rendering the bead saturation point and hence the ratio more inaccurate.  
Saturation is usually the midpoint of the experiment, however analysis of drug concentration 
using UV-Vis at the midpoint following collection from the ITC and extraction of the drug found that the 
endpoint is much later, as only half the concentration of drug had loaded. This is a consequence of the 
reaction being irreversible under the experimental conditions. At the experimental concentrations Dox 
forms aggregates, which explains the endothermic interaction and the decrease heat signals, as the 
drug is supplemented into the cell as Dox-Dox bonds are broken. A mass of 0.58 µg Dox from 1 µL of a 
1 mM solution titrated into the ITC cell was just over the instruments LOD. interactions between 
concentrations much lower than conducted in the LOD experiment maybe not be detected, and the 
decrease in DP as the experiment progresses during Dox dilution must also be considered. 1µL of 1 
mM Dox might be treated as an exploration into the limit of the method.  
In summary, there are multiple methods which provide the binding characteristics of drug to 
bead, this study describes a preferred method where a higher binding potential was achieved with acid 
washed beads. This study paves the way for further research into DEBs.  
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Chapter 4 : Characteristic Determination of the Effect of Bead Size, 
Bead Type and Drug Type using Isothermal Titration Calorimetry 
(ITC)  
 
4.1. Introduction  
DEBs (drug eluting beads) are available to purchase in assorted dimensions, the size range is selected 
depending upon the size of the vessel to be embolised. There are currently four sizes of DC Bead™, all 
work thus far has been completed on the smallest bead size of 70-150 µm labelled M1. The other sizes 
are 100-300, 300-500 and 500-700 µm (termed 103, 305 and 507, respectively) 1.  
These assorted sizes have been found to elute the drug differently and so it is conceivable that 
they may also bind differently 2. However, it has been well documented that each bead size is able to 
bind to the same total amount of drug and still achieve complete elution 3. Yet the pattern of elution and 
binding, in particular the length of time, differs due to smaller bead having a large surface area to volume 
ratio and therefore a faster binding and elution 4,5. Table 4.1 summarises data supplied by the 
manufacturer regarding the length of time required for beads to load doxorubicin (Dox) according to their 
size, along with Table 4.2 which displays the predicted period of time required for the concentration of 
drug in the body to be reduced by half for each size of bead. Half-life is predicted from in vitro-in vivo 
correlation and proposes that the smallest size of bead elutes the fastest into the body, and thus 
metabolises at a quicker rate. The predicted half-life data was derived from T-apparatus experiments, 
the values decrease with an increase in bead size, except for the largest bead. The data does not follow 
a trend and could be affected by many factors such as bead packing, shape of cell, flow and convection 
etc. Details of this method are given in Chapters 1 and 5.  
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Table 4.1: Manufacturer suggested loading instructions, clinical loading of 37.5 mg Dox per mL of DC Bead™ at 98 % uptake (75 
mg Dox per 2 mL vial of beads) 1.  
Bead Name Bead Size (µm) Loading Time (min) 
M1 70-150 30 
103 100-300 45 
305 300-500 90 
507 500-700 90 
 
Table 4.2: Half-life values for DC Bead™ loaded with Dox at 37.5 mg/mL 6.  
Bead Name Bead Size (µm) Predicted Half-life (t1/2) (h) 
103 100-300 1505 
305 300-500 2478 
507 500-700 3658 
709 700-900 2557 
 
There are several types of DEBs available on the market, Some from the same and alternative suppliers. 
Some DEBs are made from similar materials and behave alike whilst other are somewhat different. To 
date there are few methods to distinguish drug-binding properties from different beads, therefore in this 
work the ITC was employed to determine whether this could be used as a method to identify bead 
characteristic differences exhibited from different bead properties. This project focused on five distinctive 
bead types named DC Bead™, DC Bead LUMI™, LifePearl™, Tandem™ and HepaSphere™.  
Firstly, comparing DC Bead™ and LifePearl™, it was discovered that DC Bead™ is produced 
from a polyvinyl alcohol (PVA) crosslinked with N-acrylol-aminoacetaldehyde dimethylacetal (NAAADA) 
7, whereas LifePearl™ is made of polyethylene glycol (PEG) crosslinked with polyethylene glycol 
diacrylate (PEGDA) 8. Both products are modified with sulfonate groups the former been 2-acrylamido-
2-methylpropane sulfonate sodium salt (AMPS) 7, and the latter been 3-sulfopropyl acetate sodium salt 
(SPA) 8. Certain properties between the two are alike, for instance both are hydrophilic, compressible, 
elastic hydrogels. Furthermore, both types of beads have comparable solid and water content in saline 
solution, as discovered by Biocompatibles Ltd and summarised in Table 4.4 (data unpublished).  
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Table 4.3: Components of DC Bead™ and LifePearl™ 7,8.  
Feature DC Bead™ LifePearl™ 
Polymer 
Backbone 
PVA 
 
PEG 
 
Crosslinker 
NAAADA 
 
PEGDA 
 
Binding Site 
AMPS 
 
SPA 
 
Solid 
Content 
6.2 % 4.1 % 
Water 
Content 
93.8 % 95.9 % 
 
The third type of bead considered in this work was DC Bead LUMI™, which builds on the predicate 
device of DC Bead™. This bead uses the well-established technology with the addition of a radiopaque 
moiety, used to enhance clinical performance with the ability to visualise the procedure under x-ray 
imaging modalities. The chemistry of DC Bead LUMI™ is identical to DC Bead™, with the exception of 
a covalently bonded iodine and without the addition of blue dye. Because of this the colour, density and 
time in suspension differs, illustrated in Table 4.4 9,10.  
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Table 4.4: Attributes of DC Bead™ and DC Bead LUMI™ 9,10.  
Feature DC Bead™ DC Bead LUMI™ 
Radiopacity 
No, but contains blue dye 
 
Yes, contains iodine 
 
 
 
 
 
Colour Blue Golden 
Density 1.03 g/cm3 1.30 g/cm3 
Suspension 
Suspends more than DC Bead LUMI™ 
because it is lighter 
Suspends less than DC Bead™ 
because it is denser 
Size Change  
Shrinks up to 25 % with Dox loading 
and 30 % with Iri loading 
No change upon drug loading 
 
The fourth type of bead considered in this work was Embozene Tandem™. Referred to as Tandem™ it 
is polymethacrylate (PMA) sodium coated with Polyzene®-F (poly(bis[trifluoroethoxy]phosphazene) 11. 
Like DC Bead LUMI™, Tandem™ is a more crosslinked product (i.e. has a higher solid content and 
lower water content) which changes little in size after loading by < 5 % 12, where DC Bead™ is said to 
reduce in size by ≤ 20 % 13,14. The drug loading capacity of Tandem™ is indicated as higher than DC 
Bead™, for use with 50 mg of Dox for each mL of beads compared with 37.5 mg/mL in the equivalent 
loading period for DC Bead™ 12, however internal studies have concluded that DC Bead™ has the 
potential to load 60 mg Dox per mL of beads and DC Bead LUMI™ 178 mg per mL (data unpublished).  
The fifth and final type of bead considered in this work was HepaSphere™, made from a sodium 
acrylate alcohol (SAA) copolymer formed from the combination of two monomers, vinyl acetate and 
methyl acrylate. Hepasphere™ microspheres conform to the shape of the vessel lumen in vivo, unlike 
the other beads it is supplied dry and is alleged to expand approximately four time in diameter when 
reconstituted in saline 15. A maximum dose of 75 mg of Dox can be loaded into a 25 mg vial of 
Hepasphere™, which must be placed in either 0.9 % (w/v) sodium chloride (NaCl) or non-ionic contrast 
media before use 16. The polymeric structures of Tandem™ and HepaSphere™ are shown in Table 4.5.  
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Table 4.5: Composition of Tandem™ and HepaSphere™ 12,15.  
Feature Tandem™ HepaSphere™ 
Polymer 
PMA (core)
 
 
Polyzene-F (shell) 
 
 
SAA 
 
 
It was important to understand the binding process of DEBs to different drugs to identify specific drug-
bead interactions. The previously mentioned beads are indicated for use with both Dox and irinotecan 
(Iri), hence both these compounds were chosen for analysis. It was understood that Dox and Iri have 
one potential binding site per drug molecule. In contrast, mitoxantrone (Mit), a compound similar in 
structure to Dox and an associated topoisomerase II (TOPII) inhibitor, exhibits two potential binding sites 
and was therefore selected for investigation. It was then reasonable to compare Iri with a corresponding 
structure and an alternative topoisomerase I inhibitor (TOPI), hence topotecan (Top) was also evaluated.  
 In summary, this work investigated the ability of ITC to provide data that would allow analytical 
comparisons to be made with respect to drug-bead binding for four sizes of bead (70-150, 100-300, 300-
500 and 500-700 µm), five types of bead (DC Bead™, DC Bead LUMI™, LifePearl™ Tandem™ and 
HepaSphere™) and four drugs (Dox, Iri, Mit and Top).  
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4.2. Results and Discussion  
4.2.1. Effect of Bead Size  
During preliminary testing of the obtainable sizes of DC Bead™, it seemed that the larger beads bound 
to less drug, conversely preceding studies have opposed this statement 3. It is possible that during 
experimental bead preparation sodium ions had not been entirely removed from the larger beads, as a 
smaller surface area to volume ratio would require this process to take an increased amount of time. 
Larger beads were left to soak in acid for 1 hour and this did improve drug loading, but not to the 
expected quantity, as demonstrated in Figure 4.1. Allowing the beads to soak for even longer from 1 
hour to overnight, affected the bead structure. The beads became translucent, highly swollen and the 
loading did not improve further but diminished. The effect of leaving the beads to soak in 2 M 
hydrochloric acid (HCl) influences the bead binding properties because the structure is acid labile and 
the polymer degrades upon hydrolysis of the amide group. Optimum time for soaking in HCl could be a 
focus of investigation for future work on the use of calorimetry to analyse DEBs.  
The solid content and water content of 103, 305 and 507 beads were presumed to be the same 
as the previously tested M1 beads, since the beads are produced by the same supplier, with the same 
materials and by the same manufacturing process, with the only deviation being the beads were from a 
segment of a different sized sieve at the final stage of production. Based on experimental data presented 
in Figure 4.1 the four bead sizes achieved different final drug-bead binding ratios and displayed 
differences in the kinetic profiles, such as the rate of each injection completing the binding process. 
However, the rate of binding didn’t not correlate to bead size with the largest beads binding the slowest, 
which could indicate that either there was incomplete binding or that larger beads have more internal 
binding sites compared to smaller beads with more surface sites. The difference in the density of the 
outer and inner layer of different sized beads changes the difficulty of the penetration of Dox. Slower 
binding could lead to signals under the limit of detection.  
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Figure 4.1: Binding of different sized beads with 10 mM Dox to 25 mg beads (sample number = 3, error bars = standard deviation, 
time has been altered by two minutes for each sample for visibility). Please note that the baseline of 507 beads drifts but does not 
exceed 1 µcal/sec and is therefore valid data. Inset is a replicate of the first injection at a closer scale and all injections starting at 
the same timepoint to identify the rate at which each injection completes the binding process.  
 
Using data obtained from Figure 4.1, it was possible to calculate overall drug-bead binding ratios in 
Table 4.6. From this, 103 beads were found to have a lower average molar ratio than M1 beads, but the 
two group are not statistically different using Minitab® software to calculate the values of an unpaired t-
test (p = 0.7056). M1 is made from a similar distribution size of beads as 103, therefore similar results 
were anticipated. In contrast, the difference between M1 and 305 as well as M1 and 507 were found to 
be significantly different (p = 0.0098 and p = 0.0446, respectively).  
 
M1 103 305 507
A 
B 
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Table 4.6: Molar ratios of different sized bead with 10 mM Dox into 25 mg beads using the highest ∆H value for the calculation 
(sample number = 3, error = standard deviation).  
Bead Size Run Molar Ratio Average 
M1 
1 0.82:1 
0.79:1 ± 0.05 2 0.73:1 
3 0.83:1 
103 
1 0.78:1 
0.76:1 ± 0.13 2 0.62:1 
3 0.88:1 
305 
1 0.56:1 
0.58:1 ± 0.06 2 0.64:1 
3 0.52:1 
507 
1 0.60:1 
0.53:1 ± 0.15 2 0.63:1 
3 0.36:1 
 
The concentration of Dox was increased to observe whether binding would also increase, with the theory 
being that an increased concentration would force the removal of sodium. Interestingly, an increase in 
the molar ratio was observed in Table 4.7, but with both 10 mM and 43 mM Dox the 103, 305 and 507 
beads appeared to have a different isotherm shape compared with M1 beads, as is visible in Figure 4.2.  
Overall, the increased Dox concentration did further increase the binding ratio for all four bead 
sizes to achieve values much closer to the anticipated 1:1 ratio, but it is possible since the rate of binding 
again did not correlate with bead size, that the ratio is less than recorded and that full binding could not 
be achieved. The inset graph of Figure 4.2 displays the rate of reaction for the first injection, all four 
bead sizes reach the baseline at roughly the same time, so rate of binding was regarded as the same 
regardless of bead size. There are at least two conceivable explanations for the larger bead size results, 
one is that sodium ions were not completely removed from the larger beads. The other is that there are 
two mechanisms at play, one being initial binding on surface of the bead that the ITC picks up well, and 
a secondary mechanism as the drug skips through the bead matrix. It was plausible that larger beads 
tend to bind drug on surface and possibly build a barrier to slow down drug diffusion and binding. The 
later slow binding could generate less heat due to the low level of drug diffusion and this lower energy 
could be under the limit of detection, resulting in increased measurement error.  
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Figure 4.2: Binding of different sized beads with 43 mM Dox to 100 mg beads (sample number = 3, error bars = standard deviation, 
time has been altered by two minutes for each sample for visibility). Inset is a replicate of the first injection at a closer scale and 
all injections starting at the same timepoint to identify the rate at which each injection completes the binding process.  
 
Currently the point of saturation selected is the highest value on the enthalpy (∆H) curve, a unit which 
has until now descended at the end of the experiment, unfortunately this was not the case with the larger 
beads as ∆H levelled off. It is possible that the beginning of the plateau rather than a latter point is the 
saturation site. If a much earlier point in the experiment was chosen as the position of completely loaded 
bead, then the calculated molar ratio of the larger beads would decrease significantly. Therefore, in 
these experiments full binding may not have been achieved which would explain the change in the 
shape of the isotherm and is potentially the result of the inability to protonate the beads.  
The peaks showed that drug binding with 43 mM Dox and 507 beads did finish in 140 min 
however, further binding would indicate a 2:1 binding ratio which is known not to be the case. It would 
M1 103 305 507
A 
B 
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appear that either incomplete removal of acid, or slower binding of the drug to the surface of bead has 
extended the binding process, of which is more prominent in the larger bead size. In any case, larger 
beads were unable to achieve expected drug loading, which therefore requires further investigation.  
Residual and extracted drug analysis of the ITC samples confirmed that a significantly lower 
portion of the titrated drug had bound to the larger beads than in Table 4.7. M1 was calculated to have 
an average ratio of 0.89 (standard deviation of 0.07), any discrepancy could be drug bound to the ITC 
cell or inefficient removal of all beads. 103 was found to have a ratio of 0.86:1, 307 was 0.61:1 and 507 
at 0.59:1 (corresponding standard deviations were 0.18, 0.78 and 0.76, respectively).  
 
Table 4.7: Molar ratios of different sized bead with 43 mM Dox into 100 mg beads using the highest ∆H value for the calculation 
(sample number = 3, error = standard deviation).  
Bead Size Run Molar Ratio Average  
M1 
1 0.92:1 
0.92:1 ± 0.08 2 1.00:1 
3 0.84:1 
103 
1 0.98:1 
0.97:1 ± 0.02 2 0.95:1 
3 0.99:1 
305 
1 0.97:1 
1.00:1 ± 0.04 2 0.99:1 
3 1.04:1 
507 
1 0.93:1 
0.95:1 ± 0.02 2 0.94:1 
3 0.97:1 
 
Single injection method (SIM) experiments were then conducted to simplify the investigation with just 
one injection of drug into the various bead sizes. This would establish the time taken for each sample 
to return to the baseline, hence the loading speed. The SIM experiments equate to 1.68 mg Dox in the 
cell with ~0.13 mL beads when reconstituted in saline. When compared with clinical loading 
concentrations of 37.5 mg Dox in 1 mL beads, 4.88 mg Dox would be required to saturate the same 
volume of bead in the ITC cell. In the SIM experiments beads were under saturated to create one 
exothermic peak, however this requires much lower concentrations of Dox than in the clinical setting.  
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 The SIM experiments in Figure 4.3 signify each bead size reached the baseline at approximately 
the same time of 50 mins. It was expected that the larger beads would take longer to completely bind, 
the results may be attributed to smaller concentrations and volumes used compared with clinical loading. 
In agreement with previous data, a larger portion of the drug had bound to the M1 bead in the first ten 
minutes, and a general pattern can be seen to correlate bead size with increasingly slower binding.  
 
 
 
 
 
 
 
 
Figure 4.3: SIM experiment with 100 µL 10 mM Dox into 25 mg beads of different sizes. The bottom graph is a replication of the 
top graph exposing the baseline of each bead size (sample number = 1).  
 
Tables 4.8 and 4.9 reveal that the binding constant and free energy remained much the same with a 
change in bead size. In Figures 4.4 and 4.5 both enthalpy and entropy increased as the diameters of 
M1 103 305 507
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the bead also increased. Although the R2 values are either > 0.96 or < 0.01 for each parameter, there 
is only one replicate of each experiment and therefore definitive conclusions cannot be made. However, 
this data does permit an initial relationship to be explored.  
 
Table 4.8: Binding constant of SIM experiments with 100 µL 10 mM Dox into 25 mg M1, 103, 305 and 507 beads (sample number 
= 1).  
Bead Size K (x 105 M-1) 
M1 1.73 
103 1.74 
305 1.72 
507 1.74 
 
 
Figure 4.4: Enthalpy of SIM experiments with 100 µL 10 mM Dox into 25 mg M1, 103, 305 and 507 beads (sample number = 1).  
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Figure 4.5: Entropy of SIM experiments with 100 µL 10 mM Dox into 25 mg M1, 103, 305 and 507 beads (sample number = 1).  
 
Table 4.9: Free energy of SIM experiments with 100 µL 10 mM Dox into 25 mg M1, 103, 305 and 507 beads (sample number = 
1).  
Bead Size ∆G (kJ/mol) 
M1 -29.8 
103 -29.9 
305 -29.8 
507 -29.8 
 
If it is considered that the larger beads bound to less drug, possibly due to inefficient removal of sodium 
with the current bead washing process, then there would be a decrease in the heat released from the 
reaction as less binding transpires. Entropy can change depending on the number of molecules in a 
system, and as larger beads are thought to be bound to a greater number of sodium ions there will be 
a larger number of molecules in the system, which is likely to increase the change entropy.  
 In summary, it would appear that bead size does affect the binding process, as evidenced using 
ITC, although it concerns the kinetics of binding rather than the absolute binding ratio achieved.  
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4.2.2. Effect of Bead Type  
In this study five bead types were investigated to consider the effect of bead type on drug-bead binding, 
firstly comparing DC Bead™ and LifePearl™, the most recent DEB to be released into the market. The 
average solid content of DC Bead™ washed in 2 M HCl and centrifuged for 30 seconds at 3000 rpm 
was 6 %, and for LifePearl™ under the same experimental conditions was 5 % with no significant 
difference between the values in Table 4.10 and 4.11 (p = 0.2269). DC Bead M1™ (70-100 µm) was 
selected for analysis as it was closest in size to LifePearl™ 100 µM (75-125 µm). It’s important to think 
about this topic in terms of solid content, as water content is essentially the same (94 – 95 %), whereas 
the solid content is 5 or 6 %, i.e. DC Bead has 20% more solid present.  
 
Table 4.10: Solid content of DC Bead™ prepared for use in the ITC (sample number = 3).  
DC Bead™ Insert (mg) Wet Beads (mg) Dry Beads (mg) % Water Content % Solid Content 
Sample 1 932.38 993.90 936.25 93.71 6.29 
Sample 2 910.50 973.58 913.79 94.78 5.22 
Sample 3 910.32 983.36 914.91 93.72 6.28 
 
Table 4.11: Solid content of LifePearl™ prepared for use in the ITC (sample number = 3).  
LifePearl™ Insert (mg) Wet Beads (mg) Dry Beads (mg) % Water Content % Solid Content 
Sample 1 908.65 946.11 910.32 95.54 4.46 
Sample 2 917.66 952.66 919.40 95.03 4.97 
Sample 3 914.87 946.45 916.75 94.05 5.95 
 
It was vital to identify the number of binding sites on the beads, the DC Bead™ formulation was known 
to be 45.45 % AMPS sites from the manufactures calculations. This value was investigated by washing 
a known mass of beads in 10 mM HCl to remove sodium ions, and with deionised water to remove any 
residual acid. A salt solution consisting of NaCl was filtered through the beads and then washed with a 
known volume of deionised water to removed free NaCl, followed by an acid-base titration with the 
collected solution. This facilitated a calculation of the amount of salt bound to the beads, and the value 
equates to the total number of binding sites when subtracted from the standardisation.  
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For DC Bead™ the average titrated volume in Table 4.13 subtracted from the average 
standardisation titration in Table 4.10 and fit to 100 mg of beads was 8.17 mL, which is known to equate 
to 45.45 % AMPS sites in the 6 % solid content of DC Bead™. 8.17 mL divide by 45.45 and multiplied 
by 100 is 17.98. An identical test was then conducted for the LifePearl™ product. So, in 100 mg of 
LifePearl™ an average titrated volume in Table 4.14 subtracted from the average standardisation is 
10.33 mL and this divided 17.98 and multiplied by 100 equates to 57.44 % binding sites in the 5 % of 
solid content of LifePearl™. An attempt has been made to standardise the calculation of the number of 
binding sites on the beads, however the different configuration of binding sites within each bead make 
the uniform penetration of acid and salt problematic. Insufficient removal of sodium ions from the packing 
solution, beads sites not bound back to sodium and sodium not completely removed for a second time 
could all contribute to inaccurate results, leading to incorrect binding site and molar ratio calculations.  
 
Table 4.12: Standardisation for determining binding sites of different bead types (sample number = 3, error = standard deviation).  
Standardisation Mass of NaOH (mg) 8.38 mM HCl (mL) 
Sample 1 10.05 23.70 
Sample 2 10.15 24.20 
Sample 3 9.99 24.00 
Average Fit to 10.00 mg NaOH 23.82 ± 0.25 
 
Table 4.13: Number of binding sites on DC Bead™ prepared for use in the ITC (sample number = 3, error = standard deviation).  
DC Bead™ Mass of Beads Mass of NaOH (mg) 8.38 mM HCl (mL) 
Sample 1 100.92 10.07 15.70 
Sample 2 100.92 10.04 15.70 
Sample 3 100.92 10.27 15.90 
Average Fit to 100.00 mg Beads 10.00 mg NaOH 15.57 ± 0.07 
 
Table 4.14: Number of binding sites on LifePearl™ prepared for use in the ITC (sample number = 3, error = standard deviation).  
LifePearl™ Mass of Beads Mass of NaOH (mg) 8.38 mM HCl (mL) 
Sample 1 97.65 10.53 14.50 
Sample 2 97.65 10.15 13.90 
Sample 3 97.65 10.12 13.90 
Average fit to 100.00 mg Beads 10.00 mg NaOH 13.73 ± 0.03 
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A separate calculation was performed to compare with the titration data using element analysis and the 
solid content of beads by applying Equation 4.1. Comparisons could then be made between the binding 
site values of the two different methods of titration data and element analysis.  
 
Equation 4.1: Calculation of moles of binding sites per mL of hydrated DC Bead™.  
% of Sulfur = 
Relative Molecular Mass (RMM) of Sulfur (32.06)
RMM of AMPS (229.23)
∙100 = 13.99 
% of AMPS (w/w) = 
% Solid Content (6)
% of Sulfur (13.99) 
∙100 = 42.89 
% of PVA (w/w) = 100 - % of AMPS = 57.11 
AMPS mol/g = 
% of AMPS (42.89)
RMM of AMPS (229.23) 
/100 = 1.87 x 10-3 
PVA mol/g = 
% of PVA (57.11)
RMM of PVA (44.05) 
/100 = 1.30 x 10-2 
AMPS mol/mL = AMPS mol/g (1.87 x 10-3) ∙50 1000⁄ = 9.35 x 10-5 
PVA mol/mL = PVA mol/g (9.35 x 10-5) ∙50 1000⁄ = 6.48 x 10-4 
Capacity of Dox mg/mL = AMPS mol/mL (9.35 x 10-5) ∙579.99 ∙1000 = 54.26 
 
A calculation of the percentage binding sites of DC Bead™ was 42.89 %, the moles of sites per mL was 
9.35 x 10-5 mol/mL, which means a loading capacity of 54.24 mg/mL Dox. There is a small difference 
between these values and the manufacturers data, which may be due to different procedures to define 
the solid content. If the same equations were used with the DC Bead™ titration data, 45.45 % AMPS 
from DC Bead™ is equal to 9.91 x 10-5 mol/mL and 57.50 mg/mL Dox loading.  
LifePearl™ was calculated to 35.74 % binding sites, which is 9.20 x 10-5 mol/mL and a Dox 
loading capacity of 53.37 mg/mL, by substituting the solid content with 5 % and the RMM of AMPS with 
the RMM SPA of 194.21 g. Again, the values were substituted with the LifePearl™ titration data of 57.44 
% sites, which was calculated to be 1.48 x 10-4 mol/mL and a Dox loading capacity of 85.77 mg/mL. 
There is a vast difference between the LifePearl™ data of these two methods, the solid content to 
calculate the element analysis data could be incorrect as the ratio of Dox-AMPS was much greater than 
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1:1 and it is known that theoretically only one sulfonate group can bind to a molecule of Dox. It is for the 
reason that the titration values were used in the molar ratio calculation.  
Figure 4.6 exposes LifePearl™ to have a similar ITC profile to that of DC Bead™. The interaction 
of water with LifePearl™ was found to be negligible with each signal <0.1 µcal/sec in Figure 4.7, thus 
confirming the similarity in thermodynamic profiles of water-bead binding.  
 
 
 
 
 
 
 
 
Figure 4.6: Binding of LifePearl™ in comparison to DC Bead™ with 43 mM Dox to 100 mg beads (sample number = 3, error bars 
= standard deviation, time has been altered by two minutes for visibility).  
 
DC Bead LifePearl
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Figure 4.7: Isotherm of water into 100 mg LifePearl™.  
 
As presented in Table 4.15, the average molar ratio of 43 mM Dox to 100 mg LifePearl™ beads was 
determined to be 0.78:1, with an average (previously determined) ratio of 0.92:1 for DC Bead™. 
Statistical analysis found these two groups to be significantly different (p = 0.0221) thus, confirming that 
DC Bead™ was able to accommodate a greater drug loading. 
 
Table 4.15: Molar ratios of DC Bead™ versus LifePearl™ with 43 mM Dox into 100 mg beads (sample number = 3, error = 
standard deviation).  
Product DC Bead™ LifePearl™ 
Molar Ratio 
0.84:1 0.74:1 
1.00:1 0.70:1 
0.92:1 0.77:1 
Average 0.92:1 ± 0.08 0.74:1 ± 0.04 
 
The shape of the isotherm between the two bead types was different, the signals began with a similar 
intensity but LifePearl™ rapidly declined with smaller interactions compared with DC Bead™ after the 
first injection. The area of the combined exothermic peaks was approximately comparable, and so 
LifePearl™ in general has much shallower broader signals than DC Bead™, as seen in Figure 4.8. This 
slower binding process affects the overall shape of the binding profile.  
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Figure 4.8: A magnification of an injection of DC Bead™ and LifePearl™ binding with 43 mM Dox to 100 mg beads (sample 
number = 3).  
 
Figure 4.9 suggests both processes are exothermic as the change in enthalpy values are negative. It 
should be noted that the change in entropy are presented as TΔS, for both beads this is positive and 
therefore increases as the reaction proceeds, but the value is greater in DC Bead™ and consequently 
the system is more disordered. Since the actual size in the change in entropy is comparatively large in 
comparison with the change in enthalpy, both Dox binding to DC Bead™ and LifePearl™ are enthalpy 
driven processes. The change in the Gibbs free energy is a negative value thus is spontaneous for drug-
bead binding, but again is more so in DC Bead™. Based on these findings it is proposed that the two 
reactions are spontaneous regardless of the system temperature. Both reactions are entropy and 
enthalpy driven, from hydrogen bonding, electrostatic or van der Waals interactions, in addition to 
hydrophobic interactions resulting in conformation changes. There are greater entropic and enthalpic 
forces in Dox-DC Bead™ compared with Dox-LifePearl™, and differences are considered significant 
(∆H p = 0.0018, T∆S p = 0.0386 and ∆G p = 0.0435).  
 
DC Bead LifePearl
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Figure 4.9: Thermodynamics of Dox into DC Bead™ and LifePearl™ (sample number = 3).  
 
The third and fourth beads to be evaluated, namely DC Bead LUMI™ and Tandem™, were found to 
behave quite differently to the previously discussed beads. Tables 4.16 and 4.17 identifies these beads 
to be much denser, with solid contents of 33 % for DC Bead LUMI™ and 38 % for Tandem™. They do 
not have as substantial swelling properties during binding and elution compared with DC Bead™ and 
LifePearl™. The size of DC Bead LUMI™ under investigation was M1 (70-150 µm) and the size of 
Tandem™ selected for analysis was 100 µm (75-125 µm) to correspond with previous testing.  
 
Table 4.16: Solid content of DC Bead LUMI™ prepared for use in the ITC (sample number = 3).  
DC Bead LUMI™ Insert (mg) Wet Beads (mg) Dry Beads (mg) % Water Content % Solid Content 
Sample 1 930.80 1012.17 957.10 67.68 32.32 
Sample 2 906.13 1017.50 942.65 67.21 32.79 
Sample 3 930.76 1053.90 972.64 65.99 34.01 
 
Table 4.17: Solid content of Tandem™ prepared for use in the ITC (sample number = 3).  
Tandem™ Insert (mg) Wet Beads (mg) Dry Beads (mg) % Water Content % Solid Content 
Sample 1 906.87 964.49 982.87 61.82 38.18 
Sample 2 911.44 977.98 937.71 62.02 37.98 
Sample 3 897.58 955.50 919.22 62.64 37.36 
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The average titrated volume of DC Bead LUMI™ in Table 4.18 subtracted from the average 
standardisation titration in Table 4.10 and fit to 100 mg of beads was 4.66 mL, the percent of binding 
sites was then calculated to be 25.90 %, which is 3.39 x 10-4 mol/mL and 196.59 mg/mL Dox capacity. 
Elemental analysis values were calculated from DC Bead LUMI™ and found to be 23.59 % AMPS and 
3.09 x 10-4 mol/mL with a Dox capacity of 179.05 mg/mL. The small difference from the projected values 
could again be due to the errors in the solid content analysis or error in the volume of solution titrated, 
as it could only be precise to 0.1 mL or 0.05 mL at best.  
With 100 mg Tandem™, the average titrated volume in Table 4.19 subtracted from the average 
standardisation in Table 4.10 was 3.40 mL, and this equates to 18.49 % binding sites and 8.55 x 10-5 
mol/mL, therefore the maximum loading capacity of Dox was calculated as 49.62 mg/mL. When AMPS 
in Equation 4.1 was replaced with Polyzene-F, the percentage binding sites was calculated as 17.45 % 
and 8.07 mol/ mL, the total amount of Dox which could bind to Tandem™ was 46.81 mg/mL.  
 
Table 4.18: Number of binding sites on DC Bead LUMI™ prepared for use in the ITC (sample number = 3, error = standard 
deviation).  
DC Bead LUMI™ Mass of Beads Mass of NaOH (mg) 8.38 mM HCl (mL) 
Sample 1 102.05 10.50 19.90 
Sample 2 102.05 10.05 19.30 
Sample 3 102.05 10.12 19.20 
Average Fit to 100.00 mg Beads 10.00 mg NaOH 19.04 ± 0.11 
 
Table 4.19: Number of binding sites on Tandem™ prepared for use in the ITC (sample number = 3, error = standard deviation).  
Tandem™ Mass of Beads Mass of NaOH (mg) 8.38 mM HCl (mL) 
Sample 1 102.16 10.44 21.10 
Sample 2 102.16 10.08 20.70 
Sample 3 102.16 10.14 20.80 
Average Fit to 100.00 mg Beads 10.00 mg NaOH 20.42 ± 0.15 
 
With a known solid and salt content of DC Bead LUMI™ the ITC should have required ~25 mg of 
centrifuged beads with 43 mM Dox. Several bead masses were studied in Figure 4.10, to optimise and 
identify the method restrictions. A mass of > 5 mg beads was difficult to place into the ITC cell without 
losing beads on the outside of the sample port, thus creating caution with further data analysis.  
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Figure 4.10: Binding of DC Bead LUMI™ with 43 mM Dox to 25, 10 and 5 mg beads (sample number = 3, error bars = standard 
deviation, time has been altered by two minutes for each sample for visibility).  
 
Unexpectedly the number of injections needed for bead saturation did not coincide with the molar ratio. 
When the mass of beads decreased the molar ratio continually shifted with both water washed, and acid 
washed beads causing unreliable results, apparent in Table 4.20. Based on the comparatively small 
signals associated with this particular bead, caution should be expressed regarding this data.  
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Table 4.20: Molar ratios of DC Bead LUMI™ with 43 mM Dox into 25, 10 and 5 mg beads (sample number = 3).  
Mass of DC Bead LUMI™ 
(mg) 
Concentration of Dox (mM) 
Injection Number at Point 
of Bead Saturation 
Molar Ratio 
25 43 13 1.37:1 
10 43 11 2.34:1 
5 43 11 4.84:1 
 
Equivalent results were found with the product Tandem™, that with both water washed and acid washed 
beads many signals were too small for analysis, evident in Figure 4.11.  
 
 
 
 
 
 
 
 
Figure 4.11: Binding of Tandem™ with 43 mM Dox to 25, 10 and 5 mg beads (sample number = 3, error bars = standard deviation, 
time has been altered by two minutes for each sample for visibility).  
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With several beads masses the molar ratio was found to be inconsistent, as displayed in Table 4.21. In 
Figure 4.12 the interaction of DC Bead LUMI™ into water, along with Tandem™ into water, was 
considered negligible, thus confirming the water-bead interaction to be thermodynamically insignificant.  
 
Table 4.21: Molar ratios of Tandem™ with 43 mM Dox into 25, 10 and 5 mg beads (sample number = 3).  
Mass of Tandem™ (mg) Concentration of Dox (mM) 
Injection Number at Point 
of Bead Saturation 
Molar Ratio 
25 43 12 0.47:1 
10 43 3 1.17:1 
5 43 4 2.00:1 
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Figure 4.12: Isotherm of water into 100 mg DC Bead LUMI™ (A) and Tandem™ (B).  
 
It was thought possible that the interaction of Dox with DC Bead LUMI™ and Tandem™ was under the 
instruments limit of detection, therefore samples were collected after completion of the experiment and 
the residual, in addition to the extracted solution tested. UV analysis of the residual solution confirmed 
that there were 3.7564 mg/mL Dox present, and this equates to 91 % of the drug that entered the ITC 
cell was unbound to the beads. The concentration of drug that had bound to the beads and extracted 
from them was 0.2378 mg/mL and equates to 6 % of Dox that entered the ITC cell. The extra 3 % was 
most likely bound to the ITC cell or was lost during collection of the beads. These results imply that only 
a very small amount of drug had bound to the beads during the experiment.  
A B 
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HepaSphere™ was the fifth and final bead was selected for binding analysis. Unfortunately, no 
experimental data was obtained for this bead as it was momentarily removed from the test samples. 
This bead was not inserted into the ITC as the product formed a gel, and it wasn’t understood whether 
the microspheres could be easily removed and whether the syringe would be blocked causing damage 
to the internal components of the instrument. Preliminary testing to identify bead and instrument 
preparation is required before this bead can be thermodynamically analysed.  
Overall, it was found that bead type does play an influential role in the binding and can be a 
significant factor in controlling drug-bead binding ratios as well as the kinetic profile obtained.  
 
4.2.3. Effect of Drug Type  
In total, four drugs were analysed to investigate the effect of drug choice on binding. For comparison of 
different drugs into DEBs, 43 mM drug into 100 mg beads was initially chosen as the most suitable 
concentration and mass. This is because in initial studies it gave the largest signals and best chance to 
differentiate between similar compounds. DC M1 Bead™ was used in the evaluation of several drugs 
as this had been studied the most extensively with the ITC in previous work.  
One such structurally related drug to Dox is Mit, both contain an anthracene however Dox 
consists of a 1,4-dihydroxyanthraquinone and Mit a 1,4-dihydroxy-5,8-bisaminoanthraquinone, 
indicated in Figures 4.13 and 4.14. Mit has four potential basic binding sites, the two that are attached 
to the aromatic ring can protonate, but the charge is delocalised around the ring structure and hence it 
is not strong enough to interact with the beads. This is technically there are only 2 possible interactions 
with Mit and Dox has just the one binding site. The pH of Mit in deionised water was 3.799 and the pH 
of 100 mg acid washed beads in 1.4194 mL deinoised water was 1.824. Three of the Mit sites are ionised 
at the pH of the drug with the addition of acid washed beads of ~1.8. At pH 1.8 the ionised sites of Mit 
would include the strongest base, the group directly opposite and the adjacent basic group the number 
of ionised sites would consist of 11.57 %, then the strongest base and opposing group were ionised at 
88.43 % of formulations. Dox has just one basic site at the pH Dox combined with acid washed beads 
of ~1.8 and this is 100 % ionised. As the majority of Mit has at least two possible binding sites, only half 
the concentration of drug should, in theory, be required to create a comparable profile to Dox.  
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Figure 4.13: Dox chemical structure with ionisation sites (left) and pka graph (right) – red circles indicate an acid whilst blue is a 
base; the darker shades denote the strongest acid and base 17.  
 
       
Figure 4.14: Mit chemical structure with ionisation sites (left) and pka graph (right) – red circles indicate an acid whilst blue is a 
base; the darker shades denote the strongest acid and base 18.  
 
Calorimetric data of both Dox and Mit binding to beads can be seen in Figure 4.15. The Mit-bead graph 
implies a 0.4:1 ratio, which can also be written as 0.8:2 AMPS to drug sites as there are two Mit sites 
are involved with binding and the bead has only one site. If the data was considered as the ratio of 
AMPS to drug rather than drug sites, this could be easier compared with Dox and was calculated as 
0.8:1. The ITC results for Mit show that the two sites that are involved with binding are identical, and 
with half the concentration of drug in comparison with Dox, the isotherm fits a two-site model 19,20. With 
two identical sites engaged with binding, this must consist of the strongest base and the opposite basic 
site. The signal intensity is larger in Mit compared with Dox for the first three injections but is then roughly 
the same for the rest of the experiment. The isotherm shapes are different as Dox has two distinctive 
curves in the trace, Mit also has two curves although it is much more discrete. These finding implies 
Dox-bead binding, in addition to Mit-bead binding consist of a two-step process.  
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Figure 4.15: Binding of Mit in comparison to Dox with 43 mM Dox and 20 mM Mit to 100 mg beads (sample number = 3, error 
bars = standard deviation, time has been altered by two minutes for visibility).  
 
A calculation of Mit-AMPS binding sites was performed using the same calculation used for Dox-AMPS, 
only that the RMM of Dox HCl was substituted with the RMM of Mit HCl which was 517.404 g 
(C22H30Cl2N4O6). With half the concentration of Mit and two binding sites on the drug, a similar ratio is 
noted to that of Dox in Table 4.22, when comparing the whole Dox structure to individual Mit sites 
occupied, and this difference was not considered significant (p = 0.2149). Comparison of these two 
drugs is particularly striking, as it displays the considerable difference in binding ratios that can be 
observed when binding to beads. Furthermore, this result confirms that each Mit molecule can span 
across two AMPS molecules, therefore double binding is sterically possible.  
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Table 4.22: Molar ratios of Dox versus Mit with 43 mM Dox and 20 mM Mit into 100 mg beads (sample number = 3, error = 
standard deviation).  
Drug Dox Mit (Whole Drug) Mit (Individual Sites) 
Molar Ratio 
0.84:1 0.44:1 0.89:1 
1.00:1 0.41:1 0.83:1 
0.92:1 0.41:1 0.81:1 
Average 0.92:1 ± 0.08 0.42:1 ± 0.02 0.84:1 ± 0.04 
 
Iri is another drug licenced for use with these types of DEBs. Previous data has shown it is a drug which 
exhibits a very different elution profile to Dox and it is therefore conceivable that it has a different binding 
process. The pH of 50 mg acid washed bead in 1.4194 mL of deionised water was 2.175, and the pH of 
20 mM Iri in deionised water was 4.325. 20 mM was the chosen concentration as Iri was not soluble at 
43 mM (solubility is ~12.5 mg/mL). An experiment was conducted where the pH of acid washed beads 
was measured with irrigation and the addition of 20 µL Iri every ten minutes to a total of 14 times to 
replicate conditions inside the ITC. When investigating the pKa values of Iri using Figure 4.16, there 
were two potential basic binding sites. The results provided in Table 4.23 show that as Iri enters the ITC 
cell, the pH is forced from 4.3 to 2.0-2.2. At the average experimental pH of 2.1 with Iri in acid washed 
beads 99.33 % of both sites were ionised in the solution and 0.67 % of the strongest base individually. 
Since the vast majority of the two sites on Iri were ionised, this creates two potential binding sites.  
 
 
Figure 4.16: Iri chemical structure with ionisation sites (left) and pka graph (right) – red circles indicate an acid whilst blue is a 
base; the darker shades denote the strongest acid and base 21.  
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Table 4.23: pH of 20 µL Iri injected 14 times into 50 mg acid washed bead in 1.4194 mL deionised water (sample number = 1).  
Injection Number Volume of Iri in the Beads (µL) pH 
1 20 2.143 
2 40 2.157 
3 60 2.127 
4 80 2.116 
5 100 2.086 
6 120 2.040 
7 140 2.069 
8 160 2.022 
9 180 2.062 
10 200 2.026 
11 220 2.055 
12 240 2.128 
13 260 2.118 
14 280 2.101 
Average pH 2.089  
 
Figure 4.17 indicates that Dox and Iri are two compounds that each have a unique way of binding to 
DEBs, as the shape of the Dox isotherm is completely different to Iri. Another usual phenomenon noticed 
was the different shape of the raw data of Iri into beads without the subtraction of Iri into water, expressed 
in Figure 4.18. This is not the effect of an acid base titration, as in another experiment the pH of Iri was 
adjusted to 2.2 into pH 2.2 beads and the same effect was, displayed in Figure 4.19.  
The subtracted drug into water run was not altered in pH as previous data demonstrated an 
unstable baseline, and it is for this reason that the effect fails to exist after the subtraction. The shape is 
attributed to a two-site model 19,20, and it is the pH of 2.2 which creates an environment for two binding 
sites on Iri. It was assumed that Iri had only one binding site for the bead to attach, and this statement 
is correct in a clinical situation as the pH of beads would not altered, but a new phenomenon was 
discovered where at a pH of 2.2 the bead bound to two sites at different points of the loading process.  
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Figure 4.17: Binding of Iri in comparison to Dox with 20 mM drug to 50 mg beads (sample number = 3, error bars = standard 
deviation, time has been altered by two minutes for visibility) – following subtraction of water dilution data.  
 
The predominant piperidino Iri site is likely to interact with beads during approximately the first four 
injections, then the quinoline group is involved in roughly the next seven, at the end of the experiment 
the drug interacts with water once the beads are saturated. Possibly each group binds at different points 
in the experiment, and it is conceivable that only one drug site is occupied at any one-time because of 
size constraints. Another explanation is that bead is bound across both sights and flips to one site during 
the experiment. The switch from one binding site to another cannot be pKa related, as the pH has been 
shown to stay relatively the same throughout the experiment. The second Iri site binds to nearly twice 
as many AMPS sites than the first, yet the switch from one site to another is currently unknown.  
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Figure 4.18: Raw binding data of Iri in comparison to Dox with 20 mM drug to 50 mg beads, inset is the Iri raw data on a closer 
scale (sample number = 3, error bars = standard deviation, time has been altered by two minutes for visibility) – excluding 
subtraction of water dilution data.  
 
A calculation of Iri-AMPS binding sites was performed using the same calculation used for Dox-AMPS, 
only that the RMM of Dox HCl was substituted with the RMM of Iri HCl which was 623.147 g 
(C33H39ClN4O6). The ratio shows that AMPS are bounds only one site per Iri molecule, demonstrated in 
Table 4.24, and the ratios of Dox and Iri are not considered to be statistically significant (p = 0.1268).  
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Table 4.24: Molar ratios of Dox versus Iri with 20 mM drug into 50 mg beads (sample number = 3, error = standard deviation).  
Drug Dox Iri 
Molar Ratio 
0.82:1 0.79:1 
0.82:1 0.81:1 
0.83:1 0.73:1 
Average 0.80:1 ± 0.00 0.78:1 ± 0.04 
 
 
 
 
 
 
 
 
Figure 4.19: Binding of Iri at pH2 and raw data plot at pH 2 with 20 mM drug to 50 mg beads (sample number = 3, error bars = 
standard deviation, time has been altered by two minutes for visibility).  
 
The final drug to be evaluated was Top. This is a compound similar in nature to Iri, in that there is 
potential for two-site binding, although there is a different orientation of one of the ionisable groups both 
include camptothecin. The pH of Top in deionised water was 2.386, and so there were minor changes 
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when combined with acid washed beads to pH ~2.2. Top has two possible binding sites apparent in 
Figure 4.20, and at a pH of 2.2 66.19 % of both basic sites are ionised in the formulation, whilst the 
strongest base in the solution is additionally ionised by 33.7 %.  
 
       
Figure 4.20: Top chemical structure with ionisation sites (left) and pka graph (right) – red circles indicate an acid whilst blue is a 
base; the darker shades denote the strongest acid and base 22.  
 
Figures 4.21 and 4.22 illustrate the calorimetric data for Top-bead binding. Although the results are 
similar to Iri, there isn’t a significant pH change and so unlike Iri the two-site model is present after the 
subtraction of Top into water 19,20. Yet again, the beads bound to one site during approximately the first 
fours injections of the experiment and the other site in around the next eight injections. The tertiary 
amine is the strongest ionised group, which binds before the quinolone site. Twice as much Top bound 
with the second site than the first, and to only one site per drug prior to interaction with water.  
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Figure 4.21: Binding of Top in comparison to Dox with 20 mM drug to 50 mg beads (sample number = 3, error bars = standard 
deviation, time has been altered by two minutes for visibility) – after subtraction of water of dilution data.  
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Figure 4.22: Raw binding data of Top in comparison to Dox with 20 mM drug to 50 mg beads (sample number = 3, error bars = 
standard deviation, time has been altered by two minutes for visibility) – prior to subtraction of water dilution data.  
 
A calculation of Top-AMPS binding sites was performed using the same calculation used for Dox-AMPS, 
only that the RMM of Dox HCl was substituted with the RMM of Top HCl which was 457.911 g 
(C23H24ClN3O5 g). The molar ratio in Table 4.25 reveals that AMPS bound to only one Top site per drug 
molecule and was considered statistically different from the ratio of Iri (p = 0.0188).  
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Table 4.25: Molar ratios of Iri versus Top with 20 mM drug into 50 mg beads (sample number = 3, error = standard deviation).  
Drug Iri Top 
Molar Ratio 
0.79:1 0.97:1 
0.81:1 0.87:1 
0.73:1 0.92:1 
Average 0.78:1 ± 0.04 0.92:1 ± 0.05) 
 
In summary, it would appear that Top, even with two binding sites, was only able to bind one AMPS site 
per drug molecule, as was the case for Dox and Iri yet not for Mit. Overall, each compound expressed 
an exothermic response with a negative change in enthalpy. Dox and Top have the highest molar ratio, 
whilst Iri has the smallest. Dox, Iri and Top were identified in Figure 4.23 to be spontaneous processes 
at all temperatures, where Mit was the anomalous compound as it was discovered in Figure 4.24 to only 
be spontaneous at low temperatures. Positive values for changes in entropy with Dox, Iri and Top signify 
that entropy increases as the reaction proceeds and decreases for Mit as the system becomes more 
ordered. Iri has the greatest change in entropy and so the most disordered system. Dox-bead, Iri-bead 
and Top-bead are entropically and enthalpically driven processes, whereas Mit-bead is enthalpically 
driven. Therefore, Dox-bead, Iri-bead and Top-bead contain hydrogen bonds, electrostatic or van der 
Waals interactions with hydrophobic interactions, while in Mit-bead the driving forces are limited to 
hydrogen bonds, electrostatic or van der Waals interactions. The change in Gibbs free energy is 
negative for Dox, Iri and Top and so binding is spontaneous, yet since it is positive for Mit it appears 
non-spontaneous. This is of thermodynamically interest as Mit was the only drug capable of displaying 
a double binding phenomenon. Although this finding is unusual (and non-spontaneous reaction would 
imply binding could not occur) it can be explained by solvent effects and a comparatively small change 
in entropy and free energy where there could be erroneous measurements.  
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Figure 4.23: Thermodynamics of 43 mM Dox and 20 mM Mit into DC Bead™ (sample number = 3).  
 
 
Figure 4.24: Thermodynamics of 20 mM Dox, 20 mM Iri and 20 mM Top into DC Bead™ (sample number = 3).  
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4.3. Conclusion  
ITC data produced varying molar ratios for the different bead sizes of DC Bead™. As the shape of the 
isotherm changed for the lager beads, this could signify that the beads were unable to partake in 
complete binding. It is possible that sodium ions were not entirely removed from the larger beads, as 
this would take longer due to the surface area. Further work could be done to ascertain the level of 
sodium ions that effect drug binding. A slight improvement was observed when the beads were washed 
for longer, but the ratio diminished after a certain point. The inefficient removal of salt is well-known to 
inhibit the binding process. SIM experiments also suggested that the larger beads bound to less drug, 
as there was a decrease in the heat released with an increase in bead size, and this would coincide with 
a reduction in binding. An improved method to remove salt from the beads is crucial.  
It is possible to use the ITC and the methods of this study to differentiate between different types 
beads, such as DC Bead™ and LifePearl™. There are various similarities between PVA and PEG beads 
such hydrophilicity, compressibility and elasticity 23,24. Like DC Bead™, LifePearl™ bindings to Dox via 
a sulfonate group, except that the publicised activate site is SPA instead of AMPS. It is to no surprise 
that these two bead types behave similarly but differences could arise from the scale of hydrophilicity, 
compressibility and elasticity, including the strength and capacity of the binding site. The technology 
behind DC Bead LUMI™ and Tandem™ differs such as the iodinated group, however some physical 
properties are similar such as increased solid content and reduced compressibility. This suggests there 
may be a diffusion effect necessary for ITC methodology, and that the slow binding process to these 
beads may be outside the instruments limit of detection. It is also a possibility that sodium inhibits binding 
to Dox with water washed beads, and that acidified DC Bead LUMI™ and Tandem™ could lead to the 
formation of a hydrogen bond which cannot be substituted for Dox 25,26. Similar to DC Bead LUMI™, 
Tandem™ is a product of high solid content which changes little in size after loading by < 5 % 12, whereby 
DC Bead™ reduces in size by what is said to be ≤ 20 % 13,14. This shows that these two products have 
very different shrinking and swelling properties which match among DC Bead™ and LifePearl™, and 
amid DC Bead LUMI™ and Tandem™, perhaps grouping these devices with the ITC data.  
Four different chemotherapeutic compounds produced thermodynamic data displaying one and 
two-site binding models. Mit bound to twice as many AMPS sites compared with Dox as it has two 
loading locations. Iri and Top bound to two sites in an overall 1:1 ratio, possibly one site was involved 
with the first portion of the experiment and another in the second section. Two-site binding to non-
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identical sites occurred when the compounds were approximately pH 2. Top was originally this pH and 
Iri was altered due to pH of acid washed beads. Iri loaded beads would not bind to two different sites 
when prepared for use on a patient as the beads in this situation do not require acid washing, however 
Top loaded beads would bind using two sites even when if prepared for a patient using manufacturer 
loading instructions, as the drug is already at the pH were this binding phenomenon occurs.  
In summary, ITC has been shown to be an effective analytical technique to acquire 
thermodynamic data relating to drug-bead binding with respect to bead type and drug choice, a synopsis 
of this data can be found in Tables 4.26 and 4.27.  
 
Table 4.26: Comparison of bead type thermodynamic data and drug capacity calculated with elemental analysis equation (sample 
number = 3, error = standard deviation).  
Bead Type and Size Molar Ratio ∆H (kJ/mol) T∆S (kJ/mol.K) ∆G (kJ/mol) 
Dox Loading 
Capacity 
(mg/mL) 
DC Bead™ (70-150) 0.92:1 ± 0.08 -1.18 ± 0.08 9.36 ± 3.42 -10.54 ± 3.36 57.50 
LifePearl™ (75-125 µm) 0.74:1 ± 0.04 -1.52 ± 0.01 3.07 ± 1.08 -4.60 ± 1.08 53.37 
DC Bead LUMI™ (70-150) Insufficient Data 179.05 
Tandem™ (75-125 µm) Insufficient Data 46.81 
 
Table 4.27: Comparison of drug type thermodynamic data and DC Bead™ loading capacity calculated with elemental analysis 
equation. *Mit bound with two sites and molar ratio to individual sites was 0.84:1 ± 0.04 (sample number = 3, error = standard 
deviation).  
Drug Compound Molar Ratio ∆H (kJ/mol) T∆S (kJ/mol.K) ∆G (kJ/mol) 
DC Bead™ 
Loading 
Capacity 
(mg/mL) 
Dox (43 mM) 0.92:1 ± 0.08 -1.18 ± 0.08 9.36 ± 3.42 -10.54 ± 3.36 57.50 
Mit (20 mM)* 0.42:1 ± 0.02 -2.51 ± 0.16 -3.88 ± 1.65 1.37 ± 1.54 24.20 
Dox (20 mM) 0.82:1 ± 0.00 -3.49 ± 0.16 8.31 ± 1.39 -11.80 ± 1.24 57.50 
Iri (20 mM) 0.78:1 ± 0.04 -2.43 ± 0.22 11.57 ± 2.20 -13.91 ± 2.02 58.29 
Top (20 mM) 0.92 ± 0.05 -4.00 ± 0.36 7.99 ± 1.73 -11.98 ± 1.51 42.84 
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Chapter 5 : Method Development of Drug-Bead Elution 
Characteristics using a Method of Open-Loop Flow-Through Elution  
 
5.1. Introduction  
A method was developed for evaluating drug release behaviour of drug-eluting beads (DEBs). Previous 
methods such as United States Pharmacopeia (USP) 2, USP 4 and the T-apparatus have proved useful 
for quality control, however have limitations for method development when analysing the different 
compositions of DEBs and are inappropriate for long-term in vivo correlations 1,2.  
The improved method consisted of an open-loop flow-through system, whereby elutant was 
passed through drug loaded beads under a controlled flow rate and was able to extract drug from the 
beads, this flowed to an ultraviolet-visible (UV-Vis) detector and then was collected into waste with fresh 
elutant going through the beads. The elution medium must be replaced to prevent saturation of the drug 
and an underestimation of drug release. The majority of work thus far has been completed on DC 
Bead™, and so this device in particular size 103 (100-300 µm) as it is the most commonly use in the 
clinic, was chosen for development experiments. The binding and release of drug to and from DC 
Bead™ is through an ion-exchange mechanism, therefore in the elution experiments the medium must 
contain ions for the process to occur. The solution in the majority of these experiments was phosphate 
buffered saline (PBS), until the concentration and type of eluent was investigated. Unlike the previously 
discussed methods, beads were packed in an occlusive mass to emulate the embolisation of a vessel, 
which is closer to the in vivo situation than that of existing methods. The USP 2 instrument immerses 
the device allowing particles to float in a liquid phase usually with stirring allow particulates to circulate 
the system depending on particle size and density, resulting in an overestimation of drug release and 
compromises the reproducibility of the test method. The USP 4 type design hold the particles with a 
support matrix such as a bed of sand or glass beads, but the method led to in incomplete drug elution.  
Sand was eliminated from the selection of packing materials as it was established an unsuitable 
material for the method. Glass beads were mixed with DEBs in order to improve reproducibility by 
compensating for swelling phenomena. The effects of different glass bead ratios (1:0, 1:3 and 1:5 
DEB:glass bead), the elution flow rate (0.5, 1, 2, 5, 10, 20 and 45 mL/min), ion concentration (77, 154, 
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231, 308 and 770 mM) type of elution medium (PBS, Ringer’s solution, simulated body fluid (SBF)) and 
bead volume (0.2, 0.5 and 1 mL) was investigated to identify the most suitable method parameters.  
The following chapter establishes the method development of elution, specifically for the 
evaluation of DEBs which overcomes some of the limitations of the previously reported methods, and 
ascertains the effects of degassing with helium, glass beads, flow rate, salt concentration, eluent type 
and bead volume. The schematics of the different dissolution apparatus and the experimental set up of 
elution can be found in Chapters 1 and 2, however Figure 5.1 provides various systems used in the 
quantification of drug release with UV-Vis spectroscopic analysis.  
 
 
Figure 5.1: 7 types of dissolution apparatus previously used for DEB analysis.  
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5.2. Results and Discussion  
5.2.1. Effect of Packing Material  
To calculate the amount of doxorubicin (Dox) eluted, absorbance from each sample was converted into 
concentration, using standards analysed at the same time with a known concentration of drug. Then the 
area under the curve (AUC) and accumulative amount of drug was calculated with time and by defining 
the flow rate throughout the experiment. Three typical elution profiles can be seen in Figure 5.2.  
 Initially 1 mL of beads were loaded with 37.5 mg/mL Dox, PBS flowed through the elution system 
to facilitate ion-exchange and remove drug from the beads at a flow rate aimed for 1.3 mL/min. These 
parameters were selected from previous elution methods.  
During method development, experiments were conducted to observe the influence of the use 
of helium for degassing the eluent. At this stage optimised conditions, such as the use of helium, were 
fixed to continue evaluation of drug elution from drug eluting beads. Without helium aerated through the 
PBS solution, air collects around the beads, which eventually travels to the UV-Vis detector causing 
spikes throughout the elution trace. Another marked effect with air that existed, was that the air bubbles 
were easily trapped between beads, which cause drug release restriction and nonuniform flow rate.  
The swelling of beads produced artifacts and the constant disruption of beads under flow 
conditions caused an irregular UV-Vis profile, this is evident in Figure 5.2 particularly in sample number 
3. A void between the beads and the top filter membrane of ~6 – 7 mm was present to hold the beads 
in place but allow them to swell without restriction. The filter mesh pore size was small enough to prevent 
beads from passing through the system, but large enough for solution to flow without constraint. The 
beads sat in layers on the bottom filter membrane, as the beads eluted drug the size increased, the 
beads packed tightly against each other and the rate of elution slowed. The bead expanded until the 
capacity reached a limit, where the beads instantly rearranged into the void provided and a large amount 
of drug was released as eluent could flow more freely.  
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Figure 5.2: Examples of flow-through elution raw data during development of the method. The experiments were conducted using 
1 mL 100-300 µm DC Bead™ loaded with 37.5 mg/mL Dox mixed with no glass beads and a flow rate of 1.3 mL/min in PBS (154 
mM).  
 
The new elution method mimics embolisation more than the previously published methods, but it is not 
a replica of a blood vessel. Blood vessels are much smaller than the equipment used in this study, and 
this many beads would not be packed into one vessel, and so any swelling is reduced and 
accommodated by the compliance of the vessel, which is softer than the equipment tubing. Therefore, 
the effects of swelling were to be eliminated in the subsequent study.  
To overcome swelling artifacts and fluctuations, the effect of packing DEBs with sand and glass 
beads was observed. However, acid on the sand and glass seemed to bind some of the drug, as the 
mixture with DEBs turned them red in colour. This didn’t not occur once glass beads were thoroughly 
washed in deionised water, and so the investigation moved forwards with glass beads at various 
DEB:glass bead ratios of 1 mL DEB to 0, 3 and 5 mL glass beads. Rather than a void between the DEBs 
and top filter membrane, the samples that contained glass beads were compressed with the top filter 
membrane in order to sandwich the bead mixture. The results of packing ratio are highlighted in Figure 
5.3 at a flow rate of ~1.3 mL/min. With no glass beads imperfections were visible in the trace, with 3 and 
5 mL glass beads the elution profiles were smoother and similar enough to suggest the different amounts 
do not affect the elution of drug. Although the profiles differ and only two profiles reach ~100 % eluted, 
the other sample was still steadily increasing and was likely to completely elute. A 1:5 ratio of DEBs to 
glass beads was selected for further experiments, as this produced reproducible data and a more 
homogenous distribution of beads. To obtain an accurate calculation of flow rate throughout the 
Sample 1 Sample 2 Sample 3
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experiment, the mass of solution eluted in 1 min was collected at the beginning, middle and end of each 
experiment, then an average taken of the three results.  
 
 
Figure 5.3: Beads mixed with and without glass beads in several ratios. The experiment was conducted using 1 mL 100-300 µm 
DC Bead™, loaded with 37.5 mg/mL Dox and a flow rate of 1.3 mL/min in PBS (154 mM), inset is the data presented as percent 
drug eluted instead of concentration (sample number = 3, errors = standard deviation every 100 data points).  
 
The packing study of different DEB:glass bead ratios was repeated at an increased flow rate of 2 mL/min 
rather than 1.3 mL/min. This was to identify whether the flow rate could be increased and investigate 
the difference between 3 and 5 mL glass beads in the earlier experiments. Figure 5.4 illustrates that the 
two preparations containing glass beads elute the drug as a percent in a similar amount of time. The 
sample containing no glass beads had a slightly slower elution, but more importantly the same 
imperfections in the smoothness of the curve can be seen. The previously mentioned swelling effect 
was not visible, possibly due to the increased flow rate which sped up the swelling process. With 3 and 
5 mL glass beads and at a flow rate of 2 mL/min, the results were closer than that at 1 mL/min. This is 
probably a result of better handling experience of the method and again suggested that the two amounts 
of glass beads do not vastly affect the elution profile. Each sample eluted more than 97 % of the drug.  
 
No Glass Beads 3mL Glass Beads 5 mL Glass Beads
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Figure 5.4: Beads mixed with and without glass beads in several ratios. The experiment was conducted using 1 mL 100-300 µm 
DC Bead™, loaded with 37.5 mg/mL Dox and a flow rate of 2 mL/min in PBS (154 mM) inset is the data presented as percent 
drug eluted instead of concentration (sample number = 3, errors = standard deviation every 100 data points).  
 
5.2.2. Effect of Flow Rate  
The rate of Dox elution from DEBs was determined by eluent flow rate, demonstrated in  
Figure 5.5 5.5. A flow rate of 2 mL/min was selected for further studies as it correlated with in vitro study 
data 3. It was also an advantage to prepare and run an experiment in one day, with 2 mL/min the 
experiment could be prepared at the start of the working day, initiated with the pump and UV towards 
the end of the day and the results would be ready at the start of the next morning. At 2 mL/min the trace 
was not too fast to give a full and complete profile, as the flow rate increased the time for 100 % of the 
drug to elute decreased, however after 2 mL/min the next result to complete was 45 mL/min. With an 
increased flow rate, more ions reached the beads quicker and were able to remove the drug from the 
beads at a faster rate, until an increase in flow rate could not match the rate of diffusion at >5 mL/min. 
The 5 – 45 mL/min flow rates group together and also required a considerable amount of medium which 
can be problematic when needing to refill the equipment with an adequate amount of fluid that will last 
overnight. For a 45 mL/min flow rate that lasted for 500 min, the experiment required at least 22.5 L 
PBS.  
At lower flow rates there was a larger concentration and a slower decrease of drug detected as 
the samples were less diluted than the faster flows which decreased rapidly in concentration, however 
No Glass Beads 3mL Glass Beads 5 mL Glass Beads
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the cumulative amount of drug eluted was smaller at lower flow rates as flow is taken into consideration. 
The 0.5 mL/min flow rate was run until just over 6800 min where it eluted slightly over 97 % of the drug 
(data not shown). Each experiment achieved complete or very nearly complete elution of >97 %.  
 
 
 
Figure 5.5: Effect of flow rate on Dox elution. The experiments were conducted at 310 K using 1 mL 100-300 µm DC Bead™, 
loaded with 37.5 mg/mL Dox, mixed with 5 mL glass beads and in PBS (154 mM). Inset is the data presented as the percent of 
Dox eluted. *Repeat experiment of the 5 mL/min flow rate (sample number = 3, error bars = standard deviation every 100 data 
points).  
 
Table 5.1 specifies the “pseudo pharmacokinetic” measurements for the flow kinetics such as, Cmax 
which is the maximum (peak) concentration, tmax which is the time that Cmax is observed and t50 % which 
is the time taken for 50 % of the drug to be eluted. Cmax decreased with an increase in flow rate, but 
reached tmax and t50 % in a shorter period. At a flow rate of 0.5 mL/min the average highest concentration 
was 48.33 µg/mL which was achieved at an average of 47.67 min and took an average of 1108.33 min 
for 50 % of the loaded drug to elute from the beads, whereas at 45 mL/min the highest concentration 
was 14.92 µg/mL achieved at 3.36 min and took 56.02 min for 50 % to elute. The elution kinetics of flow 
rate fitted a first order rate law using Equation 5.1, where k is the rate constant and t is the time.  
 
Equation 5.1: Rate law, where MDrug Eluted is the concentration of drug eluted and MDrug Loaded is the concentration of drug loaded.  
0.5 mL/min 1 mL/min 2 mL/min 5 mL/min
5 mL/min* 10 mL/min 20 mL/min 45 mL/min
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MDrug Eluted
MDrug Loaded
= 1 - e-kt 
Table 5.1: Elution concentration and timings with flow rate. The experiments were conducted at 310 K using 1 mL 100-300 µm 
DC Bead™, loaded with 37.5 mg/mL Dox, mixed with 5 mL glass beads and in PBS (154 mM) (sample number = 3, error = 
standard deviation).  
Eluent Type 
Flow Rate 
(mL/min) 
Salt 
Concentration 
(mM) 
Cmax (µg/mL) tmax (min) t50 % (min) k (x 10
-3 min-1) 
PBS 0.5 154 48.33 ± 2.36 47.67 ± 11.02 1108.33 ± 34.04 0.66 ± 0.02 
PBS 1 154 49.85 ± 6.50 18.00 ± 6.08 500.33 ± 43.68 1.49 ± 0.16 
PBS 2 154 50.78 ± 8.94 11.33 ± 5.77 258.67 ± 12.58 2.78 ± 0.06 
PBS 5 154 40.11 ± 3.11 5.34 ± 2.31 131.67 ± 2.89 5.79 ± 0.05 
PBS 10 154 32.01 ± 2.11 2.67 ± 0.58 94.00 ± 5.00 7.35 ± 0.66 
PBS 20 154 28.77 ± 2.86 3.67 ± 2.08 66.34 ± 8.08 10.52 ± 0.48 
PBS 45 154 14.93 ± 0.72 3.36 ± 1.12 56.02 ± 16.55 12.74 ± 1.32 
 
5.2.3. Effect of Salt Concentration  
To understand the influence of saline concentration on elution, five specific concentrations of sodium 
chloride (NaCl) were considered, namely 77 mM (0.45 % w/v), 154 mM (0.9 % w/v), 231 mM (1.35 % 
w/v), 308 mM (1.8 % w/v) and 770 mM (4.5 % w/v), and release profiles were generated in Figure 5.6. 
Once more, the 77 mM NaCl experiment lasted until just over 3700 min where it eluted slightly >99 % 
of the drug (data not shown). Each experiment displayed complete or very nearly complete elution of 
>97 %. As the concentration of salt increased, more ions exchanged with drug quicker, removing the 
drug at a faster rate. This occurred until 308 mM where an increase in concentration could no longer 
impact the diffusion rate. The mass of beads in the experiment was reduced from 1 mL to 0.5 mL to 
conserve beads, drug and decrease the experimental time with the hope to still produce valid data.  
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Figure 5.6: Effect of saline concentration on Dox elution. The experiments were conducted at 310 K using 0.5 mL 100-300 µm DC 
Bead™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL of glass beads and at a flow rate of 2 mL/min. Inset is the data presented 
as the percent of Dox eluted (sample number = 3, error bars = standard deviation every 100 data points).  
 
Figure 5.7 was created to compare data in Figure 5.5 and Figure 5.6 of flow rate with fixed salt 
concentration of 154 mM and salt concentration at a fixed flow rate of 2 mL/min. 77 mM NaCl at a flow 
rate of 2 mL/min was the closer result to 1 mL/min in PBS (154 mM). 154 and 231 mM at 2 mL/min were 
most similar to 5 mL/min in PBS (154 mM). 308 and 770 mM at 2 mL/min were closer to the higher flow 
rates of 10, 20 and 45 mL/min in PBS (154 mM). The two studies followed the same trend, as the 
samples which completely eluted in ~500 min (5 mL/min, 10 mL/min, 20 mL/min, 45 mL/min, 308 mM 
and 770 mM) reached a limit in the rate of diffusion. Therefore, it would be advantageous to perform 
comparative experiments below a flow rate of 5 mL/min and a salt concentration of 308 mM.  
 
77 mM 154 mM 231 mM 308 mM 770 mM
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Figure 5.7: Effects of flow rate and saline concentration Vs. time on Dox elution. The flow rate experiments were conducted at 
310 K using 1 mL 100-300 µm DC Bead™, loaded with 37.5 mg/mL Dox, mixed with 5 mL glass beads and in PBS (154 mM). 
*Repeat experiment of the 5 mL/min flow rate. The saline experiments were conducted using 0.5 mL 100-300 µm DC Bead™, 
loaded with 37.5 mg/mL Dox, mixed with 2.5 mL of glass beads and at a flow rate of 2 mL/min (sample number = 3, error bars = 
standard deviation every 100 data points). This graph uses data from Figure 5.5 and Figure 5.6.  
 
Although the flow rate study used 1 mL of beads and the salt study used 0.5 mL, the two were analysed 
as a percent of the eluted drug and are therefore comparable. As hypothesised, an increase in flow rate 
is equivalent to an increase in salt concentration in this particular elution method and suggests that the 
same ion-exchange mechanism is in operation. Table 5.2 is a direct comparison of salt levels in the flow 
rate and salt study, which suggests flow rates of 0.5, 1, 2 and 5 mL/min should respectively correspond 
to 77, 154, 308 and 770 mM in the salt concentration study. The difference between these two 
parameters could be attributed to flow rate not being consistent throughout the experiment.  
 
 
 
 
 
 
0.5 mL/min 1 mL/min 2 mL/min 5 mL/min
10 mL/min 20 mL/min 45 mL/min 77 mM
154 mM 231 mM 308 mM 770 mM
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Table 5.2: Comparison of salt levels in the flow rate and salt concentration study.  
Flow Rate (mL/min) 
Salt Concentration in  
Flow rate Study (mM/min) 
Salt Concentration in  
Salt Study (mM/min) 
0.5 77 77 
1 154 154 
 231 
2 308 308 
5 770 770 
10 1540 
 20 3080 
45 6930 
 
The pharmacokinetic measurements for salt concentration in Table 5.3 confirms that Cmax increased 
with an increase in salt concentration and reached t50 % in a shorter period. tmax was independent of salt, 
as more salt eluted the drug from the beads quicker providing higher concentration readings, but the 
flow rate of each experiment was the same and thus was achieved at approximately the same time. At 
an NaCl concentration of 77 mM the average highest concentration was 66.74 µg/mL which took an 
average of 500.22 min for 50 % of the loaded drug to elute from the beads, whereas at 770 mM the 
highest concentration was 85.70 µg/mL and took 77.65 min for 50 % to elute. 154 mM NaCl correlates 
well with PBS at the same flow rate, as the two elution solutions have an identical amount of salt. Like 
flow rate, the effect of salt on the elution kinetics also fitted a first order profile.  
 
Table 5.3: Elution concentration and timings with salt concentration. The experiments were conducted at 310 K using 0.5 mL 100-
300 µm DC Bead™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL glass beads and in PBS (154 mM) (sample number = 3, 
error = standard deviation).  
Eluent Type 
Flow Rate 
(mL/min) 
NaCl 
Concentration 
(mM) 
Cmax (µg/mL) tmax (min) t50 % (min) k (x 10
-3 min-1) 
PBS 2 77 16.74 ± 2.28 6.67 ± 3.05 500.22 ± 52.68 1.18 ± 0.07 
PBS 2 154 51.76 ± 1.25 4.33 ± 1.15 148.33 ± 2.89 4.75 ± 0.09 
PBS 2 231 51.38 ± 1.34 8.00 ± 0.00 127.67 ± 7.64 5.26 ± 0.52 
PBS 2 308 65.40 ± 3.94 9.00 ± 1.73 85.00 ± 5.00 7.71 ± 0.46 
PBS 2 770 85.70 ± 4.84 6.00 ± 2.65 77.65 ± 5.77 8.51 ± 0.34 
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5.2.4. Effect of Eluent Type  
Different types of salt solutions were analysed under elution to identify variations and discover which 
was most comparable with in vivo data. The solutions evaluated in Figure 5.8 were PBS (154 mM [0.9 
% salt w/v]), half strength Ringer’s solution (42 mM [0.25 % salt w/v]), full strength Ringer’s solution (83 
mM [0.51 % salt w/v]), double strength Ringer’s solution (166 mM [1.01 % salt w/v]), SBF (295 mM [1.9 
% salt w/v] adjusted to pH 7.25) and 0.9 % salt w/v SBF (154 mM adjusted to pH 7.25). Composition 
and preparation of the eluent solutions can be found in Chapter 2.  
PBS and 0.9 % SBF have similar elution profiles. This is to no surprise as they both contain the 
same salt concentration of 154 mM. Interestingly, with double the number of tablets in the Ringer’s 
solution (accordingly to the preparation instructions), there is a decrease in total amount of drug eluted. 
Neither of the Ringer’s solution experiments completely eluted the drug, even when the experiments 
were extended for ~2000 min (data not shown). The total percent of eluted drug from half strength, full 
strength and double strength Ringer’s solution was 72, 74, and 56 %, respectively. Double strength 
Ringer’s solution contains a similar amount of salts to PBS and 0.9 % SBF, clearly something inhibited 
the elution process, however this is not yet fully understood. Future work could be completed on 
individual ions contained in Ringer’s solution. Ringer’s solution was prepared from Ringer’s tablets, 
which contained sodium chloride, potassium chloride, calcium chloride and sodium bicarbonate. These 
same components of NaCl, potassium chloride (KCl), calcium chloride (CaCl2) and sodium bicarbonate 
(NaHCO3) are found in SBF and in similar concentrations in either the full strength or double strength 
Ringer’s solutions, however SBF contains extra chemical elements of potassium phosphate dibasic 
trihydrate (K2HPO4∙3H2O), magnesium chloride hexahydrate (MgCl2∙6H2O), hydrochloric acid (HCl), 
sodium sulfate (Na2SO4) and tris(hydroxymethyl)aminomethane ((CH2OH)3CNH2). It is possible that 
there is competition for certain ions, particularly an affinity for either monovalent, divalent, trivalent or 
tetravalent ions. PBS and SBF both eluted >99 % of the drug, whilst 0.9 % SBF eluted >91 % but an 
increase in the elution curve was still visible, therefore it is expected that this sample would have fully 
eluted if the experiment had not been stopped prematurely.  
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Figure 5.8: Effect of eluent on Dox elution. The experiments were conducted at 310 K using 0.5 mL 100-300 µm DC Bead™, 
loaded with 37.5 mg/mL Dox, mixed with a 1:5 ratio of DEBs to glass beads and a flow rate 2 mL/min. Inset is the data presented 
as the percent of Dox eluted (sample number = 3, error bars = standard deviation every 100 data points).  
 
Figure 5.9 was created to compare data in Figure 5.6 and Figure 5.8 of salt concentration and eluent 
type. 154 mM NaCl was found equivalent to the experiment conducted in PBS, PBS also contains 154 
mM salts and so comparable results were expected. The SBF results were similar to 308 and 770 mM 
NaCl, displaying that the concentration of SBF, as with 308 and 770 mM NaCl, produced a higher rate 
of diffusion. 77 mM NaCl corresponds closely to the concentration of salt in the half strength Ringer’s 
solution at 42 mM, however the results were vastly different. This is further evidence that a component 
of the Ringer’s solution was preventing elution of drug from the beads.  
 
PBS Half Strength Ringer's Solution
Full Strength Ringer's Solution Double Strength Ringer's Solution
SBF 0.9 % SBF
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Figure 5.9: Eluent solution comparison. The experiments were conducted at 310 K using 0.5 mL 100-300 µm DC Bead™, loaded 
with 37.5 mg/mL Dox, mixed with a 1:5 ratio of DEBs to glass beads and a flow rate 2 mL/min (sample number = 3, error bars = 
standard deviation every 100 data points). This graph uses data from Figure 5.6 and Figure 5.8.  
 
It is possible that calcium in Ringer’s solution interacts with Dox, as Dox complexes with alkaline earth 
metals like calcium (Ca2+), magnesium (Mg2+), poor metals like zinc (Zn2+) 4 and transition metals like 
manganese (Mn2+) and iron (Fe2+) 5. An experiment was conducted were a UV-Vis scan of 0.5 mg/mL 
Dox in deionised water was obtained and compared with 0.5 mg/mL Dox in 0.9% (w/v) calcium chloride 
hexahydrate (CaCl2.6H2O). The absorbance of Dox was greater with calcium ions than without, 
suggesting that upon intercalation a hyperchromic effect and bathochromic shift occurred due to calcium 
complexation with Dox, causing structural changes as proposed in Figure 5.10 6, which could limit Dox 
elution with Ringer’s solution. In Figure 5.11 absorbance increased from ~0.6 to ~0.8 AU and λmax shifted 
from ~480 to ~500 nm with the addition of CaCl2.6H2O, perhaps an extra component of SBF prevents 
Ca2+ binding to Dox as complete elution was achieved with this type of eluent solution.  
 
77 mM NaCl 154 mM NaCl 231 mM NaCl
308 mM NaCl 770 mM NaCl PBS
1/2 Ringer's Solution Full Ringer's Solution x2 Ringer's Solution
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Figure 5.10: Predicted bidentate chelation structure form between Ca2+ and Dox.  
 
 
Figure 5.11: UV-Vis scan of Dox compared with Dox and calcium hexahydrate.  
 
The pharmacokinetic measurements for eluent type in Table 5.4 demonstrates that Cmax increased with 
an increase in salt concentration, as was seen with the data at different concentrations of NaCl. Again, 
Dox Solution Dox + Calcium Chloride Hexahydrate Solution
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tmax was independent of eluent. Ringer’s solution at a salt concentration of 83 mM had an average Cmax 
of 34.12 µg/mL, which took an average of 274.35 min for 50 % of the loaded drug to elute from the 
beads. The salt concentration of Ringer’s solution was similar to the 77 mM NaCl solution, however the 
average Cmax was much lower at 16.74 µg/mL and t50 % took longer with an average 500.22 min. 154 
mM NaCl, PBS and 0.9 % SBF all contained 154 mM salts and had similar Cmax and t50 % values, whereas 
full strength Ringer’s solution contained similar salt levels of 166 mM but took much longer for 50 % of 
the drug to elute. Natural SBF solution includes 295 mM salts which matches closely with 308 mM NaCl, 
Cmax for 308 mM NaCl was 65.40 µg/mL which took 85.00 min for 50 % to elute, and for SBF was 70.73 
µg/mL which took 91.00 min for t50 %. The results for SBF and 308 mM are so similar they could be 
considered equivalent. From the elution curve it can be seen that Ringer’s solution does not correlate 
with the other solutions and indicates an initial fast release of drug with a later inhibitory effect as the 
double strength solution took more than 70 min to elute 50 %.  
 
Table 5.4: Elution concentration and timings with eluent type. The experiments were conducted at 310 K using 0.5 mL 100-300 
µm DC Bead™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL glass beads and in PBS (154 mM) (sample number = 3, error = 
standard deviation).  
Eluent Type 
Flow Rate 
(mL/min) 
Salt 
Concentration 
(mM) 
Cmax (µg/mL) tmax (min) t50 % (min) k (x 10
-3 min-1) 
PBS 2 154 46.73 ± 3.18 3.67 ± 0.58 155.00 ± 5.00 4.81 ± 0.67 
1/2 Ringer’s  2 42 27.43 ± 2.36 2.67 ± 0.58 450.00 ± 31.22 2.56 ± 0.42 
Full Ringer’s  2 83 34.12 ± 0.14 6.68 ± 0.56 274.35 ± 7.64 3.95 ± 0.00 
x2 Ringer’s 2 166 45.18 ± 0.96 4.67 ± 2.08 255.00 ± 13.23 9.14 ± 0.24 
SBF 2 295 70.73 ± 4.43 7.67 ± 1.53 91.00 ± 0.00 7.83 ± 0.25 
0.9 % SBF 2 154 32.19 ± 0.95 16.33 ± 2.08 184.33 ± 2.89 3.76 ± 0.18 
 
Note that as Ringer’s solution did not show complete elution, k could only be calculated when the 
culminated concentration was also considered the loaded concentration. These results may not 
necessarily be comparable to the other elution solutions.  
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5.2.5. Effect of Bead Volume  
To conserve the bead samples, it was necessary to establish the most suitable total bead volume 
required for elution. Figure 5.12 displays flow through experiments with 0.2, 0.5 and 1 mL beads.  
A bead volume of around 0.5 mL was considered the most appropriate amount for further 
experimentation in the elution test method as both 0.5 and 1 mL eluted >97 % of the drug. 0.2 mL beads 
did not completely elute the drug, possibly because smaller volumes incur greater error.  
 
 
Figure 5.12: Effect of bead volume on Dox elution. The experiments were conducted at 310 K using 100-300 µm DC Bead™, 
loaded with 37.5 mg/mL Dox, mixed with a 1:5 ratio of DEBs to glass beads, in PBS (154 mM) and a flow rate 2 mL/min. Inset is 
the data presented as the percent of Dox eluted (sample number = 3, error bars = standard deviation every 100 data points).  
 
5.2.6. Difference and Similarity Factors  
For dissolution profile comparisons, FDA guidelines suggest a model independent approach using a 
difference factor (f1) and similarity factor (f2) 7. f1 calculates the percentage difference between two 
curves at each time point and is a measurement of the relative error between the two curves using 
Equation 5.2, where n is the number of time points, R is the dissolution value of one sample at time t, 
and T is the dissolution value of a second sample at time t. f2 is a logarithmic reciprocal square root 
transformation of the sum of squared error and is a measurement of the similarity in the percentage 
dissolution between two curves using Equation 5.3. For curves to be considered similar, f1 values should 
0.2 mL 0.5 mL 1 mL
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be close to 0, and f2 values should be close to 100. In general, f1 values <15 and f2 values >50 ensures 
the equivalence of two curves. f1 and f2 values for glass beads, flow rate, salt concentration, eluent type, 
and bead volume can be found in Table 5.5. Figure 5.2 is the standard for similarity and difference 
calculations, and is therefore not included in the statistical analysis.  
 
Equation 5.2: Difference factor (f1) calculation, where R is the dissolution value of one sample at time t and T is the dissolution 
value of a second sample at time t.  
f1= {[∑t=1
n
|Rt-Tt|]/[∑t=1
n
Rt]∙100} 
 
Equation 5.3: Similarity factor (f2) calculation, where R is the dissolution value of one sample at time t and T is the dissolution 
value of a second sample at time.  
f2= 50∙ log {[1+(1/n)∑t=1
n(Rt-Tt)
2]
0.5
∙100} 
 
The data concludes that with the exception of the experiment conducted without glass beads and at a 
flow rate of 1 mL/min, as well as the 45 mL/min flow rate, there was no significant difference between 
replicate curves, as the average f1 values were >15 and the average f2 values were <50 for all other 
samples, and hence the method is robust and able to be used to investigate experimental differences 
in the method. Without the use of glass beads the curves are not uniform and samples tested together 
do not run parallel to each other, this was less visible at a flow rate of 2 mL/min as imperfections and 
swelling effects between curve are not as extended at faster flows. The 45 mL/min flow rate was possibly 
too fast for precise and accurate results of drug elution.  
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Table 5.5: Difference and similarity calculations between elution curves. Highlighted red are f1 values greater than 15 and f2 values 
less than 50 (sample number = 3, error = standard deviation).  
Figure Number 
Figure 
Name 
Data Label f1 Value  f2 Value  
Figure 5.3 
Effects of Glass 
Beads at 1 mL/min 
No Glass 22.99 ± 11.97 39.85 ± 11.96 
3 mL Glass 2.25 ± 1.21 83.95 ± 9.47 
5 mL Glass 7.90 ± 2.68 70.32 ± 5.08 
Figure 5.4 
Effects of Glass 
Beads at 2 mL/min 
No Glass 6.45 ± 2.11 80.29 ± 5.92 
3 mL Glass 8.75 ± 4.14 74.06 ± 8.61 
5 mL Glass 4.29 ± 1.36 87.86 ± 5.23 
Figure 5.5 Effects of Flow Rate 
0.5 mL/min 1.80 ± 0.35 89.60 ± 2.57 
1 mL/min 7.90 ± 2.68 70.32 ± 5.08 
2 mL/min 4.29 ± 1.36 87.86 ± 5.23 
5 mL/min 2.53 ± 0.24 97.39 ± 0.45 
*5 mL/min 1.17 ± 0.19 99.02 ± 0.40 
10 mL/min 5.61 ± 2.83 88.05 ± 6.95 
20 mL/min 8.54 ± 4.16 82.12 ± 9.15 
45 mL/min 19.93 ± 14.77 71.28 ± 21.37 
Figure 5.6 
Effect of Salt 
Concentration 
77 mM 4.28 ± 1.64 79.68 ± 6.47 
154 mM 1.40 ± 0.75 98.54 ± 1.13 
231 mM 5.69 ± 2.62 86.75 ± 8.56 
308 mM 4.29 ± 0.44 92.34 ± 2.93 
770 mM 4.10 ± 2.99 92.56 ± 6.23 
Figure 5.8 Effects of Eluent Type 
PBS 5.48 ± 3.96 85.07 ± 12.68 
½ Ringer’s 9.89 ± 5.12 54.96 ± 16.01 
Full Ringer’s 4.92 ± 5.72 68.21 ± 32.75 
x2 Ringer’s 1.86 ± 0.72 95.05 ± 3.30 
SBF 3.54 ± 1.58 94.81 ± 3.02 
0.9 % SBF 2.52 ± 0.91 93.68 ± 2.62 
Figure 5.12 
Effect of Bead Volume 
on Dox elution 
0.2 mL 14.29 ± 9.20 61.39 ± 19.31 
0.5 mL 5.48 ± 3.96 85.07 ± 12.68 
1 mL 4.29 ± 1.36 87.86 ± 5.23 
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5.3. Conclusion  
In summary, sand and glass beads were evaluated for their suitability as packing material. Dox bound 
to the sand and glass particles rendering it an inappropriate material for packing, however washing the 
glass bead with deionised water produced an inert material. When testing the most suitable bead 
packing configuration it was found that the addition of glass beads mixed with DEBs generated more 
reproducible and consistent results. Various volume ratios of DEBs to glass beads were included in the 
experimental test design, although the elution profile did not markedly change with different volumes of 
glass beads, a ratio of 1:5 was a more convenient volume for the practicality of producing an even 
mixture of beads. Glass beads allowed DEBs to expand without being compressed. Certain DEBs 
increase in size as the drug is eluted and water is drawn in. When DEBs are restricted from swelling the 
flow rate will alter as the beads become tightly packed. Glass beads allow PBS to travel around DEB no 
matter whether the beads are prone to expansion. The introduction of helium de-gassed the eluent, 
removed dissolved air and in-turn reduced air bubbles in the system which improved the flow of medium.  
During each experiment there was an initial steep increase in the elution profile, followed by a 
sharp drop in concentration and a period of slow release. As the elution of drug from DC Bead™ is an 
ion-exchange process 7,1, the drug elution rate depends upon the cation present in the eluent. The flow 
of eluent was found to be proportional to the availability of sodium ions, the higher the flow rate the faster 
the rate of elution. Higher flow rates eluted the drug faster and so would increase the number of 
experiments which could be completed in a set amount of time. However, much larger volumes of PBS 
were required for each test, this created a greater risk running out of elutant and made each experiment 
more expensive. Lower flow rates used much smaller amounts of PBS, but the experiments took much 
longer to complete. Various flow rates have been used by a number of people with different methods, 
and it was important to select the best parameter for this particular method. Therefore, the chosen flow 
rate of 2 mL/min was not only better for comparative analysis, but had a balance of retrieving the data 
in a suitable amount of time with regards the practicality of equipment setup and completing a test within 
24 hours, whilst using a suitable amount of material. A flow rate of 2 mL/min could also correlate well 
with in vivo data; nonetheless higher flow rates could be acceptable for other types of comparative 
analysis for instance bead type, bead size and type of drug.  
Concentrations of NaCl were investigated to confirm flow rate effects. If at higher flow rates 
more sodium ions pass by the beads and so the drug can elute quicker, then varying the concentration 
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of NaCl should have the same influence. Altering the concentration of NaCl confirmed that elution is 
proportional to the availability of sodium ions. The composition of the release medium influenced the 
release kinetics, and this drug ion-exchange as a mechanism of loading and release has been previously 
demonstrated by Gonzalez et al, Jordon et al and Biondi et al 1,2,8. Both flow rate and salt concentration 
followed a similar trend and increased the elution rate up to a point where rate of diffusion becomes the 
controlling factor, this appeared to be above 5 mL/min and 308 mM NaCl, as these curves are similar 
to 10 mL/min and 770 mM NaCl. An increase of more than 308 mM NaCl or a flow rate higher than 5 
mL/min does not seem to increase the rate of elution.  
Different eluents eluted different concentrations of drug, SBF was selected as this has similar 
ion concentrations as those found in HBP (human blood plasma). SBF contains 295 mM salts, the data 
appears comparable to the 308 mM NaCl elution. However, this is at a point whereby an increase of salt 
no longer increases the rate of elution. Ringers solution has previously demonstrated the ability to elute 
drugs, however in this case a maximum of 74 % of the drug was eluted and this decreased to 56 % 
when the concentration of Ringer’s solution was doubled. In Ringer’s solution the different elution 
profiles where complete elution of the drug was not achieved could be due to Dox-Ca2+ binding.  
Owing to a limited availability of certain beads, bead volume was studied to evaluate the lowest 
amount of beads which could be employed for elution experiments. To conserve the bead samples, 0.5 
mL was found an adequate quantity, which gave precise and accurate results, as 0.2 mL did not display 
a 100 % elution. This could be down to a larger error in loading with a smaller volume of beads.  
Packing material, flow rate, salt concentration, eluent type, and bead volume each confirmed 
that elution was dependent on diffusion which in turn affected the rate that drug eluted. These 
parameters can now be used to evaluate the elution profile of different beads, bead sizes, drugs and 
drug concentrations. The new elution method overcomes limitations of the previous ones and mimics 
embolisation, this would be useful for the comparisons of bead technology and the development of new 
bead devices, in addition to in vivo correlated studies. A calculation of f1 and f2 values shows that there 
is large similarity between most of the elution curves using this elution method.  
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Chapter 6 : Determination of the Effect of Bead Size, Bead Type, Drug 
Type and Drug Concentration using a Method of Open-Loop Flow-
Through Elution  
 
6.1. Introduction  
Chapter 6 confirmed suitable elution parameters to be: a drug eluting bead (DEB) to glass bead ratio of 
1:5, an elution flow rate of 2 mL/min, a bead volume of 0.5 mL and an ion concentration of 154 mM 
phosphate buffer saline (PBS) an as appropriate elution medium. Bead size has been a well investigated 
characteristic with the calorimetric method of earlier chapters, and so the evaluation of four sizes of DC 
Bead™ (70-150, 100-300, 300-500 and 500-700 µL) and the comparison with binding data is of interest.  
The elution of drug from four bead types (DC Bead™, DC Bead LUMI™, Tandem™ and 
HepaSphere™) has been well documented using methods such as USP II and USP IV, however there 
has been some indication that Tandem™, in particular, may not completely elute the loaded drug under 
these conditions. The aim of this work was to establish whether beads can fully elute a drug using an 
alternative system and differentiate patterns of elution from different beads.  
Doxorubicin (Dox) was analysed at loading concentration of 25, 37.5 and 45 mg/mL with DC 
Bead™ and Bead LUMI™, then at 25, 50 and 75 mg/mL with Tandem™ because of the differing loading 
instructions. To create comparable data, DC Bead™ and DC Bead LUMI™ experiments contained 0.5 
mL of beads, whereas Tandem™ experiments contained ~0.4 mL of beads. This meant that 0.75 mL of 
a 25 mg/mL Dox solution would be required in all three bead types regardless of the bead chemistry.  
Drug type was evaluated to identify whether the composition of different chemical compounds 
impact the drug eluting capabilities of DEBs. Most DEBs are licenced for use with both Dox and 
Irinotecan (Iri), and so it is important to understand how these two drugs elute.  
Although 2 mL/min was selected as a practical flow rate for elution, this does not correlate to 
the flow rate of an embolised blood vessel at 0.01 mL/min 1. The aim was to reduce the flow rate to 0.1 
mL/min and identify the feasibility of elution at a flow rate closer to that of an occluded vessel. The 
rationale behind a flow rate of 0.1 mL/min, is to first attempt a slow flow rate that would not challenge 
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the equipment and detection limits. The slow flow experiments were conducted with the various 
combinations of the parameters tested such as bead size (70-150 and 100-300 µm), bead type (DC 
Bead™, DC Bead LUMI™, Tandem™ and LifePearl™) and drug concentration (37.5 and 75 mg/mL).  
The open-loop flow-through method was used to allow a better comparison between the 
performances of different DEB sizes, different DEB products despite their differing characteristics, with 
different drug concentrations, different drugs and at slower flow rates.  
  
185 
 
6.2. Results and Discussion  
6.2.1. Effect of Bead Size  
The previous chapter described an adequate method for the elution of drug from DEBs. DEBs are 
available in a range of sizes, as was detailed in Chapter 4 for the binding of drug to beads using 
isothermal titration calorimetry (ITC). For the first study of this section the same bead sizes M1 (70-150 
µm), 103 (100-300 µm), 305 (300-500 µm) and 507 (500-700 µm) were evaluated for drug elution, 
illustrated in Figure 6.1. Smaller beads bind to the drug faster than larger beads due to the larger surface 
area to volume ratio 2,3, and it was hypothesised that this may also affect subsequent drug elution. Based 
upon the elution data, at 500 min M1 beads had released ~95 % of Dox, 103 beads ~92 %, 305 beads 
~65 %, whereas 507 beads only ~50 %. At the end of the experiments, when the absorbance readings 
of all bead sizes were close to zero, each had eluted >99% of Dox.  
 
 
 
Figure 6.1: Effect of bead size on Dox elution. The experiment was conducted using 0.5 mL of 70-150, 100-300, 300-500 and 
500-700 µm DC Bead™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 
mL/min. Inset is the data presented as the percent of Dox eluted. *Repeat experiment of DC BeadM1™ (sample number = 3, error 
bars = standard deviation every 100 data points).  
 
Interestingly the shape of the 70-150 µm (M1) sample bares some similarity to the inverted ITC profile. 
The comparison of elution data with ITC binding data is displayed in Figure 6.2 for M1 beads. This non-
DC Bead M1 DC Bead M1* DC Bead 103
DC Bead 305 DC Bead 507
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linear shape is not replicated in the larger beads of 103, 305 and 507 either in the elution or binding 
experiments, however the other beads do match in shape with a conventional release profile between 
binding and elution. The similarity between binding and elution could be because the mechanistics of 
the interaction are the same as both drug binding and drug release is of an ion-exchange mechanism 
which happens near the surface of the bead. As the two are reversed processes, the initial burst in 
elution be correlated with the large heat released in the beginning of titration.  
 
 
 
Figure 6.2: Comparison of open-loop flow-through elution data (0.5 mL 70-150 µm DC Bead™, loaded with 37.5 mg/mL Dox, 
mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 mL/min) and inverted binding results from ITC (43 mM Dox 
into 100 mg 70-150 µm DC Bead™) (sample number = 3, error bars = standard deviation every 100 data points). There are no 
units as one experiment measures concentration and the other power, time is partially controlled by either flow rate or injection 
time in each experiment and so is irrelevant for comparison.  
 
Although elution data has confirmed that each bead size is ultimately capable of eluting the total amount 
of loaded drug, the ITC results differed as they did not consistently show that same amount of drug 
binding, however this is thought to be a limitation of the method. Elution was able to prove that surface 
area is crucial to the rate of elution, but this was not observed in the binding data and was thought to be 
the result of the amounts of Dox added to the beads being too small to make a significant difference.  
 
Elution Data Binding Data
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6.2.2. Effect of Bead Type  
Secondly, different types of beads were the subject of investigation (DC Bead LUMIM1™ (70-150 µm), 
DC Bead LUMI™ 103 (100-300 µm), Tandem™ 107 (60-90 µm) and Tandem™ 110 (75-125 µm)). The 
sizes of bead evaluated were comparable to the previously tested DC BeadM1™ (70-150 µm) and 103 
DC Bead™ (100-300 µm), represented in Figure 6.3.  
 
 
 
Figure 6.3: Effect of bead type on Dox elution. The experiment was conducted using 0.5 mL of 70-150 and 100-300 µm DC 
Bead™, 0.5 mL of 70-150 and 100-300 µm DC Bead LUMI™, 0.4 mL 75 and 100 µm Tandem™, loaded with 37.5 mg/mL Dox 
for DC Bead™ and DC Bead LUMI™ but 50 mg/mL for Tandem™, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow 
rate of 2 mL/min. Inset is the data presented as the percent of Dox eluted. *Repeat experiment of DC BeadM1™ (sample number 
= 3, error bars = standard deviation every 100 data points).  
 
Each bead was loaded with the same concentration of Dox, however both sizes of Tandem™ only 
achieved an 80 % elution. Each size of Tandem™ held onto 20 % of loaded Dox and this could not be 
extracted using the traditional method of forced extraction. DC Bead™ and DC Bead LUMI™ are 
composed of a similar bead chemistry and both completely eluted, although it should be noted that a 
larger concentration of Dox was initially released from DC Bead™ compared with DC Bead LUMI™, 
which had a longer slower release of drug. These results can be considered clinically relevant, for 
example it is possible that in some circumstances a condition would benefit from an initial high 
concentrated of drug 4, whilst others would benefit from a slower more controlled sustained release 5.  
DC Bead M1 DC Bead 103 DC Bead LUMI M1
DC Bead LUMI 103 Tandem 107 Tandem 110
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 Each size range in this study overlaps with the smaller or larger section of beads. The smaller 
beads did not necessarily elute faster in the case of DC Bead LUMI™, yet it must be taken into 
consideration that error bars and size range overlapped in this bead type.  
The next product considered in this work was HepaSphere™. This device was found to gel and 
block the filter membrane, this stopped the flow of PBS, and it was not possible to produce elution data. 
Pressure built up in the elution cell and forced small fragments of the embolic to pass through the 
membrane, these travelled to the UV detector, which distorted the UV readings (data not shown). 
Smaller pore sized filter membrane did not prevent the fragments passing through, therefore 
HepaSphere™ was eliminated from further analysis with this type of elution.  
Overall, it would appear that bead type can be an influential factor. It should be noted that 
Tandem™ was loaded with a different concentration of drug compared with the amount of bead, this is 
because the manufacturer guidelines are to load 1 mL of bead with 50 mg/mL of Dox 6, slightly greater 
than DC Bead™ and DC Bead LUMI™ loading of 37.5 mg/mL Dox per 1 mL of beads 7. In order to 
compare the different types of bead the experiment would require the same concentration of drug, 
therefore the mass of Tandem™ bead was reduced to 0.4 mL in contrast to 0.5 mL of DC Bead™ and 
DC Bead LUMI™. This allowed loading of the same concentration of Dox across all bead types.  
According to Boston Scientific Inc., Tandem™ can load 98 ± 2 % of 50 mg Dox or Iri per mL of 
microspheres, and that Tandem™ releases Iri 5 – 8 times slower than DC BeadM1™ (70-150 µm) and 
DC Bead™ (100-300 µm) 8. Yet in this elution method Tandem™, DC Bead™ and DC Bead LUMI™ 
eluted at similar rates, although this comparison was with Dox and not Iri, it is difficult to conceive this 
level of difference between these bead types. It is stated that the elution of Iri is a slower more controlled 
and more sustained from DC Bead LUMI™ than DC Bead™, but the curves are clinically proven to fall 
within specification of each other 9. It would be of particular interest to further test these statements 
because the mechanism of elution may well be very different for Iri.  
 
6.2.3. Effect of Drug Concentration  
The third investigation evaluated the effects of drug loading concentration on elution. Various sizes of 
DC Bead™, DC Bead LUMI™ and Tandem™ that had already been tested during the bead size or bead 
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type study, were dosed with different concentrations of Dox, illustrated in Figure 6.4 (DC Bead™ M1, 
103, 305 and 507 – 25, 37.5 and 45 mg/mL), Figure 6.5 (DC Bead LUMI™ M1 and 103 – 25, 37.5 and 
45 mg/mL) and Figure 6.6 (Tandem™ 107 and 110 – 25, 50 and 75 mg/mL).  
 
 
 
 
 
Figure 6.4: Effect of Dox concentration on elution. The experiment was conducted using 0.5 mL of 70-150 µm, 100-300 µm, 300-
500 and 500-700 µm DC Bead™, loaded with 25, 37.5 and 45 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and 
a flow rate of 2 mL/min. Inset is the data presented as the percent of Dox eluted (sample number = 1 and 2).  
 
 
DC Bead M1 (25 mg/mL) DC Bead M1 (37.5 mg/mL)
DC Bead M1 (45 mg/mL) DC Bead 103 (25 mg/mL)
DC Bead 103 (37.5 mg/mL) DC Bead 103 (45 mg/mL)
DC Bead 305 (25 mg/mL) DC Bead 305 (37.5 mg/mL)
DC Bead 305 (45 mg/mL) DC Bead 507 (25 mg/mL)
DC Bead 507 (37.5 mg/mL) DC Bead 507 (45 mg/mL)
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Tandem 107 (25 mg/mL) Tandem 107 (50 mg/mL)
Tandem 107 (75 mg/mL) Tandem 110 (25 mg/mL)
Tandem 110 (50 mg/mL) Tandem 110 (75 mg/mL)
 
 
Figure 6.5: Effect of Dox concentration on elution. The experiment was conducted using 0.5 mL of 100-300 µm DC Bead LUMI™, 
loaded with 25, 37.5 and 45 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 mL/min. Inset is 
the data presented as the percent of Dox eluted (sample number = 1 and 2).  
 
 
 
 
Figure 6.6: Effect of Dox concentration on elution. The experiment was conducted using 0.4 mL of 75 and 100 µm Tandem™, 
loaded with 25, 50 and 75 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 mL/min. Inset is the 
data presented as the percent of Dox eluted (sample number = 1 and 2).  
 
DC Bead LUMI M1 (37.5 mg/mL) DC Bead LUMI 103 (25 mg/mL)
DC Bead LUMI 103 (37.5 mg/mL) DC Bead LUMI 103 (45 mg/mL)
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An increase in drug concentration increases the time required for elution of drug in all bead types. 
Tandem™ was loaded with different concentrations because the loading instructions differed. 75 µm 
Tandem™ loaded at 25 mg/mL came the closest to complete elution, this sample was the smallest 
investigated bead size, loaded with the lowest evaluated drug concentration, however there were no 
replicates of this experiment due to a lack of sample, and so it could have been an anomalous result.  
Since the other curves eluted only 79 – 86 %, all sample from all beads types were tested for 
drug loading by removing the residual solution from loaded beads and analysing the concentration of 
drug unbound to the beads. The results were that all bead sizes, bead types and later drug types bound 
to more than 99 % of the drug. After each elution experiment beads were collected and the drug 
extracted from the beads using solutions of 1% sodium chloride (NaCl)/dimethyl sulfoxide (DMSO), 15 
% NaCl, 0.1 M hydrochloric acid (HCl) or 10 % KCl/ethanol (for preparation of extraction solutions see 
Chapter 2). The small concentrations of drug remaining in DC Bead™ and DC Bead LUMI™ were 
extracted, confirming that these beads can completely elute but that a small percentage remained in the 
beads because the experiments were stopped prematurely. The Tandem™ extractions did not contain 
any drug which leads to the belief that Tandem™ is not capable of completely eluting the remaining 
loaded drug. The structure of Tandem™ was later found to a have different surface and core, Dox could 
be held inside this structure and will be discussed in more detail in Chapter 7.  
 
6.2.4. Effect of Drug Type  
Embolic beads are indicated for use with a wide range of drugs. It was of particular interest to compare 
Dox and Iri elutions for the fourth investigation, as they are both indicated for use with DC Bead™, DC 
Bead LUMI™, Tandem™ and HepaSphere™. The ITC determined that Iri has much weaker drug-
polymer interactions than Dox, as Dox-Dox interactions are another contribution for the strong binding 
observed in Dox loading, and the maximum capacity of Iri is also greater than that of Dox. As Iri will 
elute much faster than some other drugs, it is a good indication that open-loop flow-through elution will 
be suitable under the same conditions for drugs with different physical properties. Because of the high 
concentration readings and subsequently high absorbance of Iri, a cuvette with a smaller path length of 
0.5 cm was employed, rather than the 1 cm cuvette for Dox experiments. Iri was loaded at 50 mg/mL, 
where Dox was loaded at 37.5 mg/mL because of the manufacturer’s instructions for use of loaded Iri 
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into DC Bead™. Iri was measured at an absorbance of 369 nm, whereas Dox was measured at 483 nm, 
based on the observed values of λmax. Figure 6.7 illustrates the Iri elution with DC Bead™, and Figure 
6.8 demonstrates a comparison of the two drugs Dox and Iri.  
 
 
Figure 6.7: Iri elution. The experiment was conducted using 0.5 mL of 100-300 µm DC Bead™, loaded with 50 mg/mL Iri, mixed 
with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 mL/min. Inset is the data presented as the percent of Iri eluted 
(sample number = 3, error bars = standard deviation every 50 data points).  
 
 
Figure 6.8: Comparison of Dox and Iri elutions. The experiment was conducted using 0.5 mL of 100-300 µm DC Bead™, loaded 
with either 37.5 mg/mL Dox or 50 mg/mL Iri, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 2 mL/min. Inset 
is the data presented as the percent of drug eluted (sample number = 3, error bars = standard deviation every 100 data points for 
Dox and every 50 data points for Iri as the elution was much quicker).  
Dox (37.5 mg/mL) Iri (50 mg/mL)
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The elution of Iri was, as expected, much quicker than Dox, and the results prove that two very different 
drugs can be evaluated using this method showing two distinctive elution patterns. The Iri profile 
increased rapidly in the first 2 mins which slowed for the same amount of time and then increased again. 
This could have occurred from residual drug unbound to the beads and immediately detected upon 
beginning the experiment. Both drugs fully eluted showing a robust and reproducible method.  
 
6.2.5. Effect of Slow Flow  
Flow rate was reduced in the final investigation, to create a mimic closer to that of an embolised vessel. 
The majority of experiments prior to this study were conducted at a flow rate of 2 mL/min, as this was 
deemed the most suitable test parameter. However, in this portion of the work experiments were 
conducted at 0.1 mL/min, only 10 times fasters than a reported occluded vessel 1.  
Originally slow flow experiments seemed to display some unusual characteristics, demonstrated 
in Figure 6.9. At particular timepoints there were dips in the elution curve, these coincided with sunrise 
until sunset on particularly clear forecasts. It was known that Dox is degraded by light, but the extent 
was unknown, and this had never before interfered with the results. This led to a degradation experiment 
of Dox, which tested the stability of the drug in direct light, whereby Dox standards left on a windowsill 
were analysed before and after 8 hours, one was in direct sunlight and other wrapped in foil. UV analysis 
showed the Dox standard unprotected by sunlight decreased significantly in concentration from an 
average of 50.17 mg/mL to an average of 42.28 mg/mL, which was a reduction of 15.73 %. It was 
thought that previous results had not illustrated a dip in concentration because they were conducted at 
faster flow rates, which meant that experiments, usually prepared during the day and initiated in the late 
afternoon/evening, were not exposed to light. At 2 mL/min the majority of the drug eluted in hours, so 
any decrease would have been less noticeable and have had a much smaller effect than at 0.1 mL/min.  
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Figure 6.9: Degradation of Dox with exposure to sunlight. The experiment was conducted using 0.5 mL of 100-300 µm DC Bead 
LUMI™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 0.1 mL/min (sample 
number = 3, error bars = standard deviation every 100 data points for Dox).  
 
To rectify this situation the water bath, which was a Perspex box and contained the beads in a 
transparent plastic tube, was covered in tin foil to minimise exposure to light. The silicone tubing, which 
carried the drug into the UV detector, also had a layer of foil to block out the light. The cover of the UV 
machine could not be closed to allow the cells to receive and discard the elution medium, this should 
not interfere with measurement readings according to the manufacturer, therefore a piece of foil was 
placed over the compartment to shade the flow-through extraction cell. The cell contained the drug for 
the shortest amount of time, so the effects were not as important in this position as in the occluded tube.  
As can be seen in Figure 6.10, with a flow rate of 0.1 mL/min the maximum length of experiment 
was just over 7 days with DC Bead LUMI™ 103 (100-300 µm) loaded at 37.5 mg/mL Dox, where test 
had been stopped early and the amount of Dox eluted from that sample was slightly more than 81 %. 
The products DC BeadM1™ (70-150 µm) and LifePearl™ 100 (75-125 µm) had particularly similar 
elution profiles, and this resemblance was also expressed in the ITC binding data between these two 
bead types. As expected, Tandem™ eluted much less than the other beads.  
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Figure 6.10: Slow flow elutions. The experiments were conducted using 0.5 mL of 70-150 µm DC Bead™, 70-150 µm DC Bead 
LUMI™, 100-300 µm DC Bead LUMI™ and 100 µm LifePearl, and 0.4 mL of 100 µm Tandem™, loaded with either 37.5, 50 or 
75 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 0.1 mL/min. Inset is the data presented as 
the percent of drug eluted (sample number = 3, error bars = standard deviation every 100 data points for Dox).  
 
It is proposed in Figure 6.11 that the entire elution of drug would take 14 – 16 days, if the elution path 
stayed on the same trajectory. It would be of interest to reduce the flow rate further, perhaps by removing 
the pump and allowing the eluent to pass to and from the beads using gravity. At a flow rate 0.1 mL/min 
an extrapolation completes the elution in 5 – 6 months, close to that of in vivo studies which identified 
residual drug (89 % eluted) in a porcine hepatic artery, 90 days after implantation of 100-300 and 700-
900 µm DC Bead™ loaded at 37.5 mg/mL. It is worth mentioning that this model was generated with a 
slightly different bead, which is known to have faster release kinetics 4.  
 
DC Bead M1 (37.5 mg/mL) DC Bead LUMI M1 (37.5 mg/mL)
DC Bead LUMI M1 (75 mg/mL) DC Bead LUMI 103 (37.5 mg/mL)
Tandem 110 (50 mg/mL) LifePearl 100 (37.5 mg/mL)
196 
 
 
Figure 6.11: Forecast of slow flow elution. Data is from Figure 6.10, the experiment was conducted using 0.5 mL of 100-300 µm 
DC Bead LUMI™, loaded with 37.5 mg/mL Dox, mixed with 2.5 mL glass beads, in PBS (154 mM) and a flow rate of 0.1 mL/min 
(sample number = 3).  
 
6.2.6. Difference and Similarity Factors  
Difference factor (f1) and similarity factor (f2) were calculated for dissolution comparisons 10. f1 and f2 
values were not collected for the drug concentration data in section 6.2.3, as most curves had only one 
or two replicates. The Tandem™ 107 (60-90 µm) sample in the effect of bead type data has an f1 value 
>15, and the DC Bead LUMIM1™ (70-150 µm) 37.5 mg/mL Dox loaded slow flow experiment has an f2 
value of <50, which shows the elution curves are comparatively different. During these experiments a 
kink occurred in the tubing of one of the samples, this altered the flow rate and affected the results. It 
was immediately amended and only affected a small portion of the data, but the difference affected the 
f1 and f2 values. There was no significant difference between any other replicate curves, as the average 
f1 values were >15 and the average f2 values were <50 for all other samples. This shows that all other 
work had a degree of similarity between each sample of the same experiment.  
 
 
 
 
Values Forecast
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Table 6.1: Difference and similarity calculations between elution curves. Highlighted red are f1 values greater than 15 and f2 values 
less than 50 (sample number = 3, error = standard deviation).  
Figure Number 
Figure 
Name 
Data Label f1 Value f2 Value 
Figure 6.1 
Effect of bead size on 
Dox elution 
DC Bead M1 7.78 ± 3.39 87.00 ± 6.42 
DC Bead M1* 4.58 ± 2.91 92.11 ± 5.50 
DC Bead 103 5.47 ± 3.92 85.11 ± 12.57 
DC Bead 305 9.73 ± 6.33 70.90 ± 18.43 
DC Bead 507 2.87 ± 1.34 85.72 ± 6.75 
Figure 6.3 
Effect of bead type on 
Dox elution 
DC Bead M1 7.78 ± 3.39 87.00 ± 6.42 
DC Bead 103 5.47 ± 3.92 85.11 ± 12.57 
DC Bead LUMI M1 5.01 ± 3.17 88.88 ± 8.72 
DC Bead LUMI 103 1.84 ± 1.25 93.91 ± 3.41 
Tandem 107 19.00 ± 15.30 52.36 ± 25.97 
Tandem 110 3.64 ± 0.84 82.00 ± 4.94 
Figure 6.8 
Comparison for Dox 
and Iri elutions 
Dox (37.5 mg/mL) 5.47 ± 3.92 85.11 ± 12.57 
Iri (50 mg/mL) 2.29 ± 1.66 97.63 ± 1.11 
Figure 6.10 Slow flow elutions  
DC Bead M1  
(37.5 mg/mL) 
3.06 ± 2.53 58.03 ± 10.86 
DC Bead LUMI M1 
(37.5 mg/mL) 
3.47 ± 3.33 49.34 ± 18.09 
DC Bead LUMI M1  
(75 mg/mL) 
1.00 ± 0.94 82.52 ± 12.37 
DC Bead LUMI 103 
(37.5 mg/mL) 
1.78 ± 1.46 71.90 ± 8.44 
Tandem 110  
(37.5 mg/mL) 
12.70 ± 11.47 52.71 ± 9.75 
LifePearl 100  
(37.5 mg/mL) 
0.58 ± 0.48 80.84 ± 7.49 
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6.3. Conclusion  
The study confirmed that each bead size of DC Bead™ is capable of loading the same amount of drug 
and achieving complete elution, however binding and elution patterns differ. Larger beads take a 
proportionally longer time to elute Dox, as smaller beads have a larger surface area to volume ratio. DC 
BeadM1™ demonstrated a particular elution profile shape comparable to the inverted ITC binding data. 
When evaluating the different sizes of DC Bead™, 70-150 µm reaches a plateau displaying complete 
elution earliest, with 100-300 µm next, followed by 300-500 µm and finally 500-700 µm. Each bead size 
demonstrated a slightly different elution profile, but with the same total amount of Dox eluted. DC Bead™ 
70-150 and 100-300 µm displayed a similar elution profile as their bead diameters overlap, but 70-150 
µm beads do show a higher accumulated elution profile over the first 500 minutes compared with the 
larger sized 100-300 µm beads. A larger surface area will have more contact with sodium ions and so 
a faster elution. Both sizes of Tandem™ bead (75 ± 25 and 100 ± 25 µm) and DC Bead LUMI™ (70-
150 and 100-300 µm) have similar elution profiles as again there is an overlap in bead size.  
The comparative bead study identified that each type of beads behaved in very different ways 
within this test. Each bead showed a capability to elute the full concentration of loaded drug, except for 
Tandem™. It seemed that a considerable proportion of Dox did not elute from Tandem™ beads, but 
was held within the structure. Whilst DC Bead™ and DC Bead LUMI™ eluted ~100 % of the loaded 
drug, Tandem™ under the same conditions eluted only ~80 %, which could not then be extracted from 
the beads using a variety of solutions that had worked well on DC Bead™ and DC Bead LUMI™. The 
inability of Tandem™ to freely elute all the drug across two separate testing methods suggests, that 
some permanent attachment to the bead polymer matrix had occurred. Tandem™ contains carboxylic 
acid (found in the bead), and this along with amines (from the drug) are well-known to react to form 
stable amides under appropriate conditions. Binding of high drug concentrations within the bead matrix 
brings these functional groups within close proximity of one another, potentially facilitating a templating 
reaction, as proposed in the mechanism presented in Figure 6.12.  
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Figure 6.12: Proposed reaction of Tandem™ binding to Dox.  
 
Tandem™ is indicated for loading with 50 mg/mL of Dox, where DC Bead™ and DC Bead LUMI™ is 
37.5 mg/mL. To make comparisons between DC Bead™, DC Bead LUMI™ and Tandem™, the same 
loading concentration of 37.5 mg/mL Dox was used, however for Tandem™ the volume of beads was 
decreased to 0.4 mL to give a 50 mg/mL load. Although Tandem™ beads are in general loaded with 
more drug, 150 mg/mL is the maximum concentration of Dox which can be delivered to a patient. 
Therefore a person may receive 3 mL of Tandem™ or 4 mL of DC Bead™, but in both circumstances 
would be receiving 150 mg Dox. The report indicates that a patient treated with drug loaded DC Bead™ 
would receive 100 % of the chemotherapeutic drug, whereas another patient administered drug loaded 
Tandem™ would receive 80 % of the drug. This could ultimately not only effect recovery but survival 
rates. Dox release occurred over a similar time frame with the different bead types, however DC Bead™ 
had a significantly higher burst of drug release than DC Bead LUMI™ and Tandem™ over the first 200 
minutes. It is possible that different modalities of the disease state could benefit from different release 
profiles, such as an initial high impact of drug to the tumour which dissipates over time as the disease 
reverts or a more constant release of drug with a steadier control of drug release over time. One type of 
patient may be able to withstand side effects of the initial higher dose and a decrease in side effects 
thereafter, whilst another person may be more tolerant to the same effects over the course of the 
treatment, but at this point it is difficult to endorse what implications any of this has in a clinical setting. 
HepaSphere™ was not compatible with this method, as the bead gelled and blocked flow of eluent.  
Beads were loaded with the clinical concentration of Dox, along with a lower and higher 
concentration. It was observed that drug loading dose is proportional to elution rate, a higher dose 
showed a higher release of Dox and required a proportionally longer time to elute. The investigation 
confirmed that 100 % of the drug (25, 37.5 and 45 mg/mL Dox) loaded into DC Bead™ could be eluted 
from all sizes. It appeared that 20 % of each concentration of drug (25, 50, 75 mg/mL Dox) loaded in 
Tandem™ beads was irreversibly bound to the structure. This representative method of elution 
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introduced fresh media to the beads, the elutant was not recirculated and therefore it is reasonable to 
suggest that there were plenty of sodium ions to extract the Dox from the drug delivery system. Further 
work is required to fully understand these findings.  
Iri eluted at a much greater rate than Dox as expected since Iri had shown much weaker 
interactions than Dox through the ITC, the work presented confirms the new elution method was capable 
of generating a reproducible elution profile with the same experimental conditions as Dox.  
Slow flow rates of 0.1 mL/min were achieved with the open-loop flow-through elution method. 
The experiments were terminated before the beads had fully eluted, however the results expressed 
similar profiles to the experiments conducted at 2 mL/min. This confirms that the method developed was 
suitably performed at faster flow rates that can represent elution from an embolised vessel.  
The f1 and f2 values confirmed that there was similarity between the majority of the elution 
curves. In summary, the development of a novel elution method led to better comparison with beads of 
different sizes, different types of bead, different drug loading concentrations, different types of drug and 
flow rates more comparable with embolised blood vessels.  
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Chapter 7 : Microscopic Analysis of Drug Eluting Beads (DEBs) and 
Related Techniques  
 
7.1. Introduction  
Some of the beads used in this study are known to swell, shrink or rearrange under certain conditions 
and it was therefore hypothesised that these phenomena may have affected drug elution, such as the 
studies presented in Chapters 5 and 6. For example, Figure 7.1 illustrates the possibility that the change 
in the elution profile observed without glass beads was a result of bead swelling and bead 
rearrangement within the cell. During preparation of the experiment a 6 – 7 mm space was left in the 
flow-through cells for the beads to expand into during each elution without the presence of packing 
material. It is a well-established concept that as drug is released from drug eluting beads (DEBs) they 
increase in size. It is thought that once the beads became tightly packed the flow rate slowed, eventually 
the beads increased in size by such an extent that they moved into the space provided and the flow rate 
returned to ‘normal’. To confirm whether swelling had affected elution, three-dimensional microscopy 
(3DM) was employed to visualise the swelling process during this method of elution.  
 
 
 
 
 
 
 
 
 
Figure 7.1: Bead size change in an open-loop flow-through cell without packaging material.  
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Secondly, 3DM was also used to create static images of the different bead types successfully studied 
in Chapters 4 and 6 (DC Bead™, DC Bead LUMI™, LifePearl™ and Tandem™), under different 
conditions of unloaded, loaded and eluted drug from the beads, with the most commonly used drug 
(doxorubicin (Dox)) and at the most appropriate concentration (37.5 mg/mL).  
Thirdly, hot stage microscopy (HSM) was employed to investigate bead behaviour at room and 
body temperatures. HSM is a technique which combines microscopy and thermal analysis of samples, 
recording visual changes as images at a set temperature or over a range of temperatures with time. The 
importance in this study is the fact that the equipment can also record changes in colour and light 
intensity over time. It was theorised that at extremely elevated temperatures the bead structure could 
become deformed, resulting in less drug binding to the bead. Therefore, the controlled heating capability 
of the equipment was not necessary in this study, other than to maintain samples at one of two specified 
temperatures: room temperature to replicate bead loading in a clinic and body temperature to mimic 
drug release within a patient. Morphology, particle size, and colour intensity are of particular interest, as 
the instrument can capture these events during loading by the addition of drug to the beads under the 
lens, or during elution by the addition of salt solution to drug loaded beads. Experiments were conducted 
with DC BeadM1™, Dox and phosphate buffer saline (PBS).  
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7.2. Results and Discussion  
7.2.1. Effects of Bead Swelling Properties  
Images were taken at set intervals over the course of drug elution and bespoke software converted the 
images into a video. A typical open-loop flow-through elution was conducted at a flow rate of 2 mL/min 
as this ensured the full elution could be capture over ~16 hours. DC Bead™ 100-300 µm loaded at 37.5 
mg/mL Dox was selected for microscopic analysis as this was a bead type well known to swell by ~20 
% of the loaded diameter and had been well evaluated during elution 1,2. The points where there was a 
change in bead size were noted and Figure 7.2 displays the images at these timepoints.  
 
 
  
Figure 7.2: Bead changes captured using 3DM at a magnification of x20. The experiment was conducted using 0.5 mL of 100-
300 µm DC Bead™, loaded with 37.5 mg/mL Dox and in PBS.  
 
A change in bead size started at 101.16 minutes and ended at 221.05 minutes. The information was 
compared with changes perceived in a similar experiment demonstrated in Figure 7.3, of drug elution 
using the open-loop flow-through method with ultra-violet (UV) spectroscopic analysis.  
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Figure 7.3: The experiment was conducted using 0.5 mL of 100-300 µm DC Bead™, loaded with 37.5 mg/mL Dox, with no packing 
material, in PBS (154 mM) and a flow rate of 2 mL/min. The red lines indicate the start and end of volume change identified using 
3DM data.  
 
Through analysing the data presented in Figure 7.3, it can be seen that 3DM analysis identified a change 
in bead size during the elution. These changes occurred at a similar time in which changes arose in the 
UV elution profile. When beads began to swell the flow rate reduced, as the beads packed more tightly 
against each other and this temporarily decreased the rate of elution. Once the beads had fully 
expanded they moved into the space provided, settling back to the original flow rate and increasing the 
rate of elution. It can be concluded that beads with swelling properties, such as those used in this work, 
will have an altered elution profile due to a change in bead packing, and so it is for this reason that DEBs 
are rightly packed with glass beads to avoid this issue.  
 
7.2.2. Microscopy of Unloaded, Drug Loaded and Eluted Beads  
Beads were analysed using microscopy before loading, after loading (which is also before elution) and 
after elution, to indicate homogeneous or heterogenous drug loading, and to ascertain the extent of any 
aggregation and/or fragmentation of the bead. Table 7.1 displays images of a similar bead size for DC 
BeadM1™ (100-300 µm), DC Bead LUMIM1™ (100-300 µm), Tandem™ (100 ± 25 µm) and LifePearl™ 
(100 ± 25 µm) in each of the three scenarios with a 3DM.  
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Table 7.1: Beads before loading (bland bead), after loading/before elution (loaded bead) and after elution (eluted bead). DC 
Bead™, DC Bead LUMI™ and LifePearl™ images at a magnification of x250, Tandem™ at a magnification of x500. Beads were 
loaded with the clinically recommended loading concentrations, i.e. 37.5 mg/mL Dox for DC Bead™, DC Bead LUMI™ and 
LifePearl™, but 50 mg/mL Dox for Tandem™. Note that the LifePearl™ eluted sample was not continued till complete drug 
release.  
Bead Type 
and Bead 
Size (µm) 
Bland Bead Dox Loaded Bead Dox Eluted Bead 
DC Bead™ 
103 
   
DC Bead 
LUMI™  
103 
   
LifePearl™ 
100 
   
Tandem™ 
110 
   
 
When DEBs are loaded with drug, they commonly transform from the original bead colour to the colour 
of the loaded drug, in the case of Dox loaded beads they become red. The drug was uniformly dispersed 
across loaded DC Bead™, DC Bead LUMI™ and LifePearl™, evident from the even colour, however 
the same cannot be said for Tandem™. There was a range of colour across Tandem™ beads, which 
could only suggest a range of highly concentrated and less concentrated beads within the sample.  
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 After elution of the drug, the beads should revert to the original bead colour. DC Bead™ and 
DC Bead LUMI™ released the majority of the drug and so lost most of the red colour. Tandem™ seemed 
to retain some of the drug and a substantial portion of the beads remained red. In addition to this, a 
substantial number of beads were highly concentrated with Dox whilst others had eluted a considerable 
portion, indicating possible further drug loading in addition to drug elution. The uneven loading and 
elution supports the theory that Tandem™ is a heterogenous bead, whilst the uniform nature of DC 
Bead™, DC Bead LUMI™ and LifePearl™ supports a homogenous bead across the vial or syringe 
sample. The LifePearl™ sample was not completely eluted as the experiment was stopped prematurely, 
therefore the beads have not lost a considerable amount of the red colour. Since some LifePearl™ 
beads have completely eluted by the loss of red, and as drug was entirely extracted from the beads, it 
is suggested that this bead is capable of returning to the original bead colour.  
 Furthermore, LifePearl™ and Tandem™ do have tighter calibrated bead sizes and although this 
is only a small snapshot of the samples it is noticeable in the images. Bland DC Bead™ was blue, DC 
Bead LUMI™ yellow, LifePearl™ green and Tandem white, though the pictures show a green tinge this 
is because of the filter and light mode selected on the microscope. It was not possible to create three-
dimensional (3D) images on the instrument because the samples were contained within water but 
interestingly, certain structures were observed that hadn’t been seen on a standard optical microscope. 
Table 7.2 presents further images of bland beads to identify the key structure of the different products.  
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Table 7.2: Different magnifications of bland DC Bead™, DC Bead LUMI™, LifePearl™ and Tandem™.  
Bead Type and 
Bead Size (µm) 
Magnification 
x500 x1000 x2500 
DC Bead™  
103 
   
DC Bead LUMI™ 
103 
   
LifePearl™  
100 
   
Tandem™  
110 
   
 
Different magnifications were applied to beads to ascertain particular internal features of interest. DC 
Bead™ had an extremely smooth uniform appearance. DC Bead LUMI™ was also quite smooth with 
very small indentations across the surface. Most LifePearl™ beads had a smooth exterior, but some 
were covered with dark marks. It was unclear from the images whether these were foreign objects or a 
part of the beads themselves. Tandem™ has an unusual appearance with three distinctive segments. 
These consist of an outer ring, a dense middle section and separate core. This is a structure inside the 
beads and not on the surface, as the focus plane is in the middle of the beads and not the external layer. 
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On close inspection of Tandem™, the surface comprised of small irregular shaped structures. It would 
be of interest to see how the drug concentration varies across the segments of Tandem™ bead.  
 
7.2.3. Size and Colour Change During Bead Loading  
Images obtained using the HSM were taken over time and converted into videos. The images in Figure 
7.4 indicate Dox absorbing into the DC BeadM1™ at room temperature over 30 minutes. It can be seen 
that the intense red solution was depleted and became transparent. It is visually possible to see that the 
beads have changed size, although the equipment was unable to quantify this change, this particular 
bead is known to decrease in size with drug binding 1,2.  
 
 
  
Figure 7.4: Images of 1 mM Dox into 10 mg DC BeadM1™ with insert of zoomed image, at 1 minute and 30 minutes after the 
addition of 10 µL of the drug.  
 
An additional experiment was conducted at 37 °C to mimic body temperature, whereby salt solution was 
added to Dox loaded beads to observe the release of drug over 30 minutes, in the reverse of the previous 
test. Just as salts from blood in the body would facilitate an ion-exchange process, the red drug was 
removed from the beads, the solution turned from transparent back to red and the beads transformed 
back to blue, as shown in Figure 7.5. It may be difficult to see the blue beads under the red solution, but 
a darker colour can be seen at 30 minutes in comparison to the earlier image. Supporting earlier findings, 
beads seemed to increase in size with the elution of drug as water was drawn into the bead structure.  
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Figure 7.5: Images of 10 mg DC BeadM1™ loaded with 1 mM Dox with insert of zoomed image, at 1 minute and 30 minutes after 
adding 10 µL 15 mM PBS.  
 
HSM can detect the change in colour of a sample, but since the solution and bead interchange colour 
this was problematic. The instrument uses a small window which can be placed within the microscopic 
image by the user, during the experiment the pixels within the area are detected for changes in red, 
green and blue (RGB). The RGB and light intensity data could be plotted in a graph, and compared to 
different beads or different drugs indicating the extent of drug bound or eluted from the beads. Because 
the solution covered the beads, it would have been difficult to identify a colour change. This is because 
the window of colour detection must be placed where there was solution with no beads, as this would 
readily change depending from red (in the case of Dox) to transparent. The problem occurred in 
foreseeing where the solution will lay and where beads will not before the addition of drug or salt, as the 
window must be set before the experiment was initiated. This could be thought-provoking further work.  
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7.3. Conclusion  
Elution viewed under the 3DM showed a clear volume change which matched the profile artifacts seen 
with UV spectrophotometric data. This confirms that the swelling effect of certain beads altered the 
elution profile and justifies the used of glass beads to eliminate these effects.  
 Microscopic images displayed DC Bead™, DC Bead LUMI™ and LifePearl™ to homogenously 
load the drug and was capable of achieving complete elution. Images indicate a large portion of Dox 
was present in Tandem™ after elution. It also demonstrated that Tandem™ had heterogenous loading, 
the red colour of Dox indicating significant variability, it is as yet unknown what potential implications 
this may have on a patient. HepaSphere™ had extensive evidence of aggregation and fragmentation, 
as it was unsuitable for the elution method it was excluded from further microscopic analysis.  
 HSM has thereby confirmed its suitability for bead-drug analysis under controlled temperature 
conditions. The method developed could be used for further bead type and drug type comparison.  
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Chapter 8 : Conclusion and Future Work  
 
8.1. Conclusions  
A novel set of in vitro methods have been developed to standardise and characterise the binding and 
release of selected drugs from different types of drug eluting bead (DEB), as described in the objectives 
of the thesis and stated in Chapter 1. These methods were created to overcome the limitations 
experienced with existing techniques by mimicking the in vivo environment and providing reproducible 
and in vivo correlated data. In vitro test methods with strong correlation to in vivo behavior are key in 
the development of a DEB, including material choice and drug selection to offer efficacious and 
predictable clinical solutions. In order to effectively characterise DEB products it was important to 
understand the rate and extent of drug binding and release in vivo. Comparative analysis between 
different DEB is challenging because of their variable physicochemical properties, such as bead size, 
bead density, drug dose, drug type and swelling. As the methods reported in literature were inadequate 
to generate comparative data, new methods were investigated.  
 
The achievements of each objective are as follows:  
 
8.1.1. Chapter 3  
1. The application of isothermal titration calorimetry (ITC) to investigate drug-bead binding 
interactions.  
The first portion of this objective was the development of an ITC method capable of identifying the 
number of binding sites occupied by the drug on the bead. This was achieved as the binding ratio was 
initially found to be 0.43:1 1, which later increased to 0.90:1 2-acrylamido-2-methylpropane sulfonate 
sodium salt (AMPS):doxorubicin (Dox) upon acid washed the beads. It was deemed necessary to wash 
the beads in acid to increase the initial binding due to the nature of the method. Temperature had no 
effect on the binding ratio but did increase the rate of binding. The change in pH caused by acid washing 
the beads was not the reason for the drug-bead interaction. An increase in the bead mass increased 
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the moles of drug bound to the beads possibly as result of a decline in experimental error. An increase 
in the drug concentration had no effect on the binding ratio. A dramatic increase or decrease in the 
recommended number of injections proved to reduce the accuracy of the experiments. The 
thermodynamic system of the selected experimental parameters included hydrogen bonding, 
electrostatic, van der Waals and hydrophobic interactions resulting in conformational changes, 
consequently the reactions were both enthalpically and entropically driven, and spontaneous regardless 
of the systems temperature. Using a method of drug extraction and quantifying residual drug, the 
saturation point was determined to be the position whereby enthalpy decreased. In addition, Dox was 
found to aggregate under the experimental concentrations used in this study.  
 
8.1.2. Chapter 4   
The second portion of the first objective was to compare different sized beads, different bead types, and 
different drugs. It was difficult to determine the binding interaction of larger beads in the DC Bead™ type 
than 70-150 µm, although with small additions of drug the rate of binding was comparable. LifePearl™ 
bound to less drug than DC Bead™, 0.74:1 compared with 0.92:1. DC Bead LUMI™, Tandem™ and 
HepaSphere™ were not compatible for the developed calorimetric method. In addition to Dox, 
Mitoxantrone (Mit), Irinotecan (Iri) and Topotecan (Top) were well-suited drugs which bound with DC 
Bead™ through the titration technique. Dox bound to one AMPS site per drug molecule, whereas Mit 
bound to two sites per drug molecule with a ratio 0.42:1 or 0.84:1 if individual drug binding site are 
considered. Iri and Top both bound to one site per drug molecule corresponding to 0.78:1 and 0.92:1, 
but possibly to two different sites in the first and second portion of the experiment. In the case of Iri this 
was attributable to two ionised sites at the pH of the acid washed beads and drug mixture, but naturally 
occurred in Top because of the ordinarily two ionised sites at the acidic pH of the drug.  
 
8.1.3. Chapter 5  
2. The development of a novel method to determine the release of drug from DEBs.  
The second objective was accomplished through an elution method which mimicked an embolised 
vessel and addressed the limitations of the previous methods. For the new method of elution tested 
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parameters were: DEB packing configuration, geometry and volume, eluent flow rate, drug loading and 
eluent concentration. A single pass eluent flow through system was used to mimic in vivo depletion, 
which overcame issues associated with self-aggregation and low extractability of certain drugs. The first 
set of experiments identified the need to degas the eluent using helium through an aerator. This not only 
reduced the formation of air bubbles in the sample and prevented them from travelling to the UV 
detector, but it also improved the reproducibility of the data and minimised elution profile artifacts. Sand 
was discovered not to be an appropriate packing material, but glass beads improved the reproducibility 
of the elution curve, eliminating imperfections and the swelling impact. A 1:5 ratio provided a uniform 
mixture of DEB:glass bead at both flow rates of 1 and 2 mL/min. A flow rate of 2 mL/min worked well for 
practicality with reliable results. To conserve the bead samples, 0.5 mL was found to be a suitable 
volume which gave precise and accurate results. Increasing the flow rate and increasing the 
concentration of sodium chloride (NaCl) was noticed to increase the rate of elution. Elution was 
proportional to the availability of sodium ions up to a certain concentration (308 mM) and flow (5 mL/min). 
The composition of medium influenced the release kinetics, sometimes this was dependent upon the 
concentration of salt such as in simulated body fluid (SBF) which closely matched the results of 
phosphate buffer saline (PBS) and NaCl. In Ringer’s solution complete elution of the drug was not 
achieved and other factors must have influenced the ion-exchange mechanism.  
 
8.1.4. Chapter 6  
Once again, an additional part of the second objective was to use the representative method of elution 
to compare bead size, bead type, drug concentration, drug type and slow flow rates. An increase in 
bead size increased the rate of elution, as the surface area to volume ratio decreased. Different types 
of beads provided different elution profiles, DC Bead LUMI™ had a slower release profile than DC 
Bead™ as DC Bead™ had a higher initial burst of Dox than DC Bead LUMI™. DC Bead™ and DC Bead 
LUMI™ fully loaded and eluted each concentration of drug, where Tandem™ held onto ~20 % of the 
loaded drug. Traditional, as well as innovative methods of forced extraction could not completely remove 
the drug from Tandem™, suggesting some permanent attachment of the drug to the bead. 
HepaSphere™ had to be excluded from the test samples as the product gelled, blocking the flow of 
eluent and an abundance of smaller fragments suspended in solution passed through the cell filters, 
generating falsely high spectrophotometry measurements. Beads were loaded with various clinical 
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concentrations of Dox and it was found that an increased drug loading dose decreased the rate of 
elution. Iri eluted at a much greater rate than Dox, with complete elution of 50 mg/mL Iri in just 100 
minutes compared with 37.5 mg/mL Dox in 1000 minutes for DC Bead™. The data from slow flow rates 
of 0.1 mL/min were representative of the faster flow rates and indicate that the method may be suitable 
for even slower flow rates of 0.01 mL/min that can represent elution from an embolised vessel. Even 
though experiments were terminated early and samples had not completely eluted, LifePearl™ showed 
similar results to that of DC Bead™ which correlates well with the ITC data.  
 
8.1.5. Chapter 7  
3. Confirmation of drug loading, drug elution and microscopic analysis.  
The final objective identified swelling effects, along with visual characteristics of bland beads, loaded 
beads and eluted beads. Three-dimensional microscopy (3DM) allowed for visual analysis of changes 
in the open-loop flow-through elution. These results showed that bead swelling properties may have 
impacted the elution profile. Microscopic analysis indicated homogenous loading and near complete 
elution from DC Bead™, DC Bead LUMI™ and Lifepearl™, but heterogenous loading and incomplete 
elution from Tandem™. The loading and elution of beads under the hot stage microscopy (HSM) had 
magnified visual advantages that the open-loop flow-through elution method did not have.  
 
In summary, this thesis proposed successful alternative methods of DEB evaluation. They not only 
address conventional test method limitations, but gather additional knowledge of drug-bead interactions 
which will undoubtable assist in the development of the best treatment options and paves the way further 
for research in treatment of inoperable cancers.  
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8.2. Future work  
Further work could be carried out in several areas, these potential research opportunities include:  
 
8.2.1. Isothermal Titration Calorimetry (ITC)  
1. Optimisation of the ITC technique for the analysis of dense DEBs such as DC Bead LUMI™ 
and Tandem™. Discover a suitable cleaning method and removal of samples from the ITC cell, 
in particular for the analysis of HepaSphere™ which gels when reconstituted in liquid 2.  
2. Perfect the method for analysing larger beads, for example DC Bead™ 100-300, 300-500 and 
500-700 µm. Identify the distribution of the drug during the titration using a method of either 
cryostat to distinguish loading characteristics across segments of the beads 3, fluorescence or 
the green values throughout the distance of the beads 3.  
3. Measure beads before, during and after calorimetry to determine shrinking effects 3,4.  
4. Additional drug analysis of such chemotherapeutics agents as Daunorubicin, Epirubicin, 
Idarubicin and Vandetanib 5. As well as combination drug mixtures potentially loading multiple 
drugs into one bead or mixing a variety of drug loaded beads. Dox-Rapamycin has shown 
synergistic activity with equivariant clinical results but reduced toxicity 6, binding and elution 
profiles could be of interest. Dox-Iri combinations could determine how they compete and 
interact with one another, as Iri can penetrate deep into the beads 7 and Dox can displace the 
outer section of drug on the surface of beads 3.  
5. Drug binding to DEBs has been evaluated using ITC and drug elution could also investigated 
using ITC with a method of salt titrated into drug loaded beads, to identify any correlation with 
the open-loop flow-through elution technique 8.  
6. The interaction of an imaging agent during the elution of drug loaded beads could be studied, 
to ascertain whether this hinders elution and what effect this has on different types of beads 9,10.  
7. Use of the MicroCal PEAQ-ITC for greater sensitivity, more reliable results, less instrument 
preparation, reduced sample size and a shorter experimental time.  
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8.2.2. Open-Loop Flow-Through Elution  
1. Analysis of Tandem™ particularly with Iri, to confirm the manufacturer’s statement that this bead 
elutes 5 – 8 times slower than DC Bead™ 11. Assessment of the claim that DC Bead™ has a 
more controlled and sustained released of Iri than DC Bead LUMI™ 12. Further evaluation of 
other drugs that have been studied on the ITC, specifically Mit and Top as some drugs are 
possibly more potent than the currently indicated drug loading compounds 13.  
2. Elution rate of individual components of Ringer’s solution. To establish any competition for 
certain ions in comparison with NaCl, such as potassium chloride (KCl), calcium chloride (CaCl2) 
and sodium bicarbonate (NaHCO3) due to the valency of ions.  
3. Reduction in the flow rate from 0.1 to 0.01 mL/min, to mimic the occlusion of an embolised 
vessel 8. If possible, experiments could be continued until samples have completely eluted, 
perhaps without a peristaltic pump and flow maintained by gravity with data collected each day 
or even each week over the course of a month or several months.  
 
8.2.3. Extraction of Drug  
1. Verification of the drug left in Tandem™ after elution, possibly through differential scanning 
calorimetry (DSC) or thermogravimetric analysis (TGA).  
 
8.2.4. Hot Stage Microscopy (HSM)  
1. Use of the red green blue (RGB) detection to correlate drug binding and drug elution data.  
 
8.2.5. Surface Dissolution Imaging (SDI)  
Another instrument of interest is the Sirius™ SDi2 for surface dissolution imaging (SDI). This piece of 
equipment can detect and quantify drug elution through UV absorbance, is temperature controlled, can 
be operated in an open-loop and generate images of the sample at set intervals. It could be possible to 
compare SDI to the developed method of elution and confirm the interference of bead swelling effects. 
Figure 8.1 shows the SDi2 instrument developed by Sirius Analytical Ltd.  
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Figure 8.1: Surface dissolution imager 14.  
 
A research group at Biocompatibles Ltd were tasked with the development of a method utilising a gel 
matrix as a tissue surrogate with a variable cylindrical channel geometry to simulate an embolised 
arterial vessel. This new assay allowed the evaluation of drug release via convection and diffusion from 
the DEB into the surrounding environment, illustrated in Figure 8.2. A predetermined extraction was 
followed by sectioning the arrangement into four equal quarters followed by the quantification of Dox to 
understand the effect on ‘freed’ Dox in different DEB formulations 8.  
 
 
 
 
 
Figure 8.2: Flow-through tissue diffusion model 8.  
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The cylindrical geometry test has provided evidence of differences in rate of Dox 
desorption/reabsorption for different DEB formulations. There were Dox concentration changes within 
the cylindrical column of DC Bead™, whereby the front exposed to a supply of sodium ions was depleted 
and the distal end accumulated drug exceeding the original loading reaching a maximum load of 45 
mg/mL. The diffusion of drug from DEBs into gel could be a method imitated with DSI and could perhaps 
be a simpler replacement as sectioning and extraction of drug would not be required.  
SDI is regularly used for intrinsic dissolution rate (IDR) measurements of the active 
pharmaceutical ingredient (API), measuring swelling rates for controlled release dosage forms and 
measuring drug release from compact or whole dosage forms 14. Figure 8.3 gives an idea of the types 
of images designed around Nelson and Shah flow cell for dissolution under laminar flow 15 and the USP 
4 apparatus cell (flow-through dissolution) 16 that could be produced for DEBs.  
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Figure 8.3: Examples of SDI images from Sirius Analytical using the compact or whole dosage flow cell, the top image shows IDR 
using the compact flow cell, the middle image demonstrates swelling and the bottom image displays drug release from a whole 
dosage form 14.  
 
1. The study of Sirius™ SDi2 to generate images of the beads during elution with a method similar 
to that of open-loop flow-through elution. To correlate with elution data, but to identify any key 
visual difference between this and other methods, such as bead swelling effects 14.  
2. Biocompatibles UK Ltd have developed a method for the detection of convection and diffusion 
of drug from DEBs into gel to simulate convection and diffusion into a blood vessel, a similar 
method could be developed with imaging instrumentation to compare the two methods 8.  
 
In summary, this thesis has delivered valuable techniques for the evaluation of DEBs, however there 
were challenges and further work could be conducted to fully explore ten key areas of expansion 
identified with ITC, elution and microscopic applications for the analysis of drug-bead interactions.  
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Appendix  
 
Isothermal Titration Calorimetry (ITC) Calibrations  
Isothermal titration calorimetry (ITC) calibration instructions were obtained from Malvern Instruments 
Inc, Massachusetts, United States of America (USA).  
 
Noise Test  
 
Criteria = Root mean squared (RMS) <0.5 µcal/sec. Water in the reference cell, sample cell and syringe. Injection number = 0. 
Cell temperature (°C) = 30. Reference power (µCal/sec) = 10. Initial delay (sec) = 3600. Syringe concentration (mM) = 0. Cell 
concentration (mM) = 0. Stir Speed = 307. Filter period (sec) = 2. Feedback mode/gain = High. ITC equilibration options = Fast 
equil; auto.  
RMS = 0.257.  
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Water-Water  
 
Water in the reference cell, sample cell and syringe. Injection number = 30. Cell temperature (°C) = 30. Reference power 
(µCal/sec) = 5. Initial delay (sec) = 60. Syringe concentration (mM) = 0. Cell concentration (mM) = 0. Stir Speed = 307. Volume 
(µL) = 10. Duration (sec) = 20. Spacing (sec) = 120. Filter Period (sec) = 2. Feedback mode/gain = High. ITC equilibration options 
= Fast equil; auto. Please note the water test can be performed in conjunction with the noise test.  
Peaks of similar shape and size.  
 
Differential Power (DP)/Y-Axis Test  
Criteria = Error <1 %. Experimental temp = 30. Number of pulses = 6. Reference power = 10. Filter period = 2. Stiring speed = 
300. Feedback mode/gain = High. Calibration power (µCal/sec) = 1. Pulse duration (sec) = 300. Pulse spacing (sec) = 600.  
Errors = all <1 %, data appeared similar that of the manual.  
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Calcium Chloride (CaCl2)-Ethylenediaminetetraacetic acid (EDTA)  
 
 
 
 
 
 
 
Criteria = N (stoichiometry) 0.969 ± 5 % Sites (0.921 ≤ N ≥ 1.017), K (binding constant) 2.09 x 106 ± 20 % M-1 (1.67 x 106 ≤ K ≥ 
2.51 x 106), ∆H (enthalpy) -4259 ± 10 % cal/mol (-4685 ≤ ∆H ≥ -3833). 0.1 mM EDTA in the reference cell, sample cell and 1.0 
mM CaCl2 in the syringe. Injection number = 29. Cell temperature (°C) = 25. Reference power (µCal/sec) = 10. Initial delay (sec) 
= 60. Syringe concentration (mM) = 1.0. Cell concentration (mM) = 0.1. Stir Speed = 307. Volume of 1st injection (µL) = 2. Duration 
of 1st injection (sec) = 4. Volume after 1st injection (µL) = 10. Duration after 1st injection (sec) = 20. Spacing (sec) = 210. Filter 
Period (sec) = 2. Feedback mode/gain = High. ITC equilibration options = Fast equil; auto. Please note CaCl2-EDTA test kit and 
instructions were supplied by Malvern Instruments Inc, Massachusetts, USA.  
N = 0.982 ± 0.00113 Sites, K = 2.17 x 106 ± 3.96 x 105 M-1, ∆H = -4025 ± 7.128 cal/mol, ∆S (entropy) = 
14.9 cal/mol/deg.  
  
8
8.2
8.4
8.6
8.8
9
9.2
9.4
9.6
9.8
0 20 40 60 80 100
µ
C
a
l/
s
e
c
Time (min)
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0 0.5 1 1.5 2 2.5
k
c
a
l 
m
o
l-
1
o
f 
In
je
c
ta
n
t
Molar Ratio
228 
 
Ultra-Violet Visible (UV-Vis) Spectrophotometry Calibrations  
Doxorubicin (Dox) Standards  
 
 
Irinotecan (Iri) Standards  
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